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Chapter 1 
INTRODUCTION 
1.1. Research Purpose 
Since its first introduction in the U.S. market in the 1980s, direct-to-consumer advertising 
(DTCA) of prescription drugs has become one of the main methods of pharmaceutical 
marketing. In 2010, the DTCA share of overall pharmaceutical marketing expenditure 
reached 40% (Liu and Gupta 2014). With the growing prevalence of DTCA, heated 
debates have been continuing about the potential positive and negative effects of DTCA. 
The debates have revolved around the potential effects of DTCA on individuals and 
society. DTCA supporters contend that DTCA functions as an health information source 
to patients for their medication-related decision-making, leads consumers to visit their 
doctors to discuss about their health conditions and medications, which increases the 
chance of getting an early and appropriate diagnosis and seeking necessary medical 
treatments, and leads to better adherence to medication regimens, which in turn, would 
reduce the overall healthcare costs. On the other hand, DTCA opponents argue that it 
provides inaccurate information to patients, leads patients to demand unnecessary 
prescriptions from their doctors, which can cause their relationship with doctors to 
deteriorate, and increases misuse and overuse of patients’ prescription medications, 
which would result in increased healthcare costs (Auton 2006; DeLorme, Huh, Reid, and 
An 2011; Huh 2014). 
Against the backdrop of this controversy, the vast majority of DTCA studies have 
focused on examining the effects of DTCA, some from an economic perspective and 
many others from a behavioral perspective. From the economic perspective, previous 
    
 
2 
studies have focused on how DTCA is associated with prescription drug sales and 
healthcare costs, and how it influences the pharmaceutical market. Previous studies have 
suggested a significant relationship between DTCA expenditure and overall prescription 
medication spending (Dave and Saffer 2012; Law, Soumerai, Adams, and Majumdar 
2009; Rosenthal et al. 2003). In terms of its impact on the pharmaceutical market, 
researchers have investigated the relationship between DTCA and medication prices 
(e.g., Calfee 1997 as cited in Calfee 2002), sales (e.g., Calfee, Winston, and Stempski 
2002; Donohue and Berndt 2004; National Institute for Health Care Management 
Research and Educational Foundation 2001), and market expansion (e.g., Hansen, 
Shaheen, and Schommer 2005; Iisuka 2004). From the behavioral perspective, the 
research focus has been on how DTCA affects patients’ perceptions, attitudes, and 
behaviors related to prescription medications, with the results revealing both positive and 
negative effects on patients. 
Previous studies have shown that, in general, many patients perceive DTCA as a 
useful information source (e.g., Deshpande, Menon, Perri III, & Zinkhan, 2004; Perez et 
al., 2011). This tendency is stronger among patients of low socioeconomic status (Chaar 
and Lee 2012; Liu and Gupta 2011) and among racial/ethnic minorities (DeLorme, Huh, 
and Reid 2010; Lee and Begley 2010). In addition, previous studies have shown that 
patients who have seen DTCA tend to seek more information about their condition or 
treatment options, including the advertised medication (e.g., U.S. Food and Drug 
Administration 1999; Huh and Becker 2005). However, some studies have suggested that 
DTCA may not be a comprehensible information source and that it can influence patients 
to have inaccurate perceptions about medical issues and medications. For example, one 
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study reported that African American adolescents did not fully understand DTCA 
information concerning the HPV vaccine (Leader et al. 2011). Another study 
demonstrated that depression patients who judged the prevalence of depression in the 
United States based on advertising tended to believe that it was higher than it was in 
reality (An 2008). 
Researchers have also investigated the effects of DTCA on patients’ interaction 
with their doctors. In particular, they have examined how patients’ exposure to DTCA or 
DTCA expenditures are related to the frequency of patients’ visits to doctors and 
discussions of their conditions and treatment options, requests for prescriptions for the 
advertised medications, and actual prescriptions. In general, previous studies have shown 
a positive correlation between DTCA expenditure and patients’ visits to their doctors 
(Hosken and Wendling 2013; Izuka and Jin 2005). Previous studies have also suggested 
that DTCA promotes patient-doctor discussion about health conditions and advertised 
medications (e.g., Weissman et al. 2003). DTCA has also been found associated with an 
increase in diagnosis of diseases such as high cholesterol conditions (e.g., Niederdeppe et 
al. 2013), further treatment seeking (e.g., Donohue and Berndt 2004), requests for 
prescriptions of the advertised medications (e.g., An 2007; DeLorme, Huh, and Reid  
2007; Mintzes et al. 2002), and actual prescriptions of the advertised medications (e.g., 
Donohue, Berndt, Rosenthal, Epstein, and Frank 2004; Spence, Teleki, Cheetham, 
Schweitzer, and Millares 2005). In terms of DTCA’s association with inappropriate 
prescriptions or overprescription, there has been mixed results. One study found no direct 
relationship between DTCA and inappropriate prescription of medications (e.g., Calfee 
al. 2002), while another study demonstrated that DTCA was positively associated with 
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patients’ advertised medication intake even when there were alternative medication 
options (e.g., Spence et al. 2005). 
 Compared to the large volume of research on the aforementioned issues 
commonly raised by supporters and opponents of DTCA, very little systematic research 
has been conducted about the potential effects of DTCA on patient medication adherence. 
The lack of research on the relationship between DTCA and patient medication 
adherence is somewhat surprising given that the potential positive effects of DTCA 
improving patients’ medication adherence has been one of the most common arguments 
made by DTCA supporters.  
As lack of information and negative perceptions about medications are among the 
factors that influence patients’ medication non-adherence (Gellad, Grenard, and 
McGlynn 2009), DTCA has potential to improve patients’ adherence to their prescription 
drug regimen by reminding them of the seriousness of their health problems and the 
benefits of their drugs for managing them. On the other hand, it is also possible that 
DTCA might have detrimental effects on medication adherence because the ads might 
remind patients about side effects and other risks involved in taking medications 
(Wosinska 2005). There are some survey results that suggest the potential for DTCA’s 
positive influence on patient medication adherence. In a survey conducted by the U.S. 
Food and Drug Administration (FDA) in 2002, physicians reported that DTCA improved 
their patients’ medication adherence (U.S. Food and Drug Administration 2003, as cited 
in Auton 2004). A consumer survey also showed a similar result. In a survey conducted 
by Prevention magazine in 1999, patients reported that DTCA influenced them to be 
    
 
5 
more likely to take their medication (20% of the respondents) and to fill their prescription 
regularly (33% of respondents) (Slaughter and Schumacher 2001).  
Some studies have examined the relationship between DTCA spending and 
patient medication adherence by comparing DTCA expenditure data with patients’ 
medication claim data from health insurance companies and medical records from 
hospitals. However, the findings have revealed only a weak correlation. More research is, 
therefore, needed to fully understand the relationship between DTCA and patient 
medication adherence, particularly at the individual level.  
To address this paucity in the research literature, this study investigates DTCA 
effects on patient medication adherence at the individual level. More specifically, this 
study examines the effects of DTCA on patient medication adherence as a type of media 
priming effect—a short-term media exposure effect on the audience’s thoughts, beliefs, 
judgments, and behaviors (Roskos-Ewoldsen, Klinger, and Roskos-Ewoldsen, 2007). 
According to media priming effect theory, frequent and recent exposures to certain media 
contents can affect individuals’ behaviors and evaluations relating to the object or idea 
presented in the media contents for a limited time (Roskos-Ewoldsen, Klinger et al. 2007; 
Roskos-Ewoldsen, Roskos-Ewoldsen, and Carpentier 2009).  
The predicted priming effect of DTCA on patients is not likely to be confined to 
exposure to advertisements for the particular drugs or brands that they use. It is more 
likely to be a result of general exposure to all DTC advertisements in the mass media. 
Due to the rather standardized nature of DTCA content, patients are likely to be presented 
with similar types of health information repeatedly through cumulative and constant 
exposure. Thus, the main research questions addressed in this study are whether higher 
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exposure to DTCA generates priming effects of making certain beliefs related to common 
DTCA content elements (e.g., the seriousness of medical conditions and the benefits and 
risks of the drugs) more accessible in patients’ minds and whether such priming 
influences their medication adherence behavior. This study will investigate these 
questions by applying media priming effect as a theoretical framework. Empirical 
examination of the potential effects of DTCA on patients’ medication adherence behavior 
is important both for advancing the literature on DTCA and for providing practical 
implications for addressing the medication non-adherence issues (Wosinska 2005).  
 
1.2. Background about the Medication Non-Adherence Problem 
As chronic diseases have become the primary cause of morbidity and mortality in the 
United States, the management of chronic diseases has become an important public 
health issue. According to the 2012 National Health Interview, approximately half of 
Americans have at least one chronic disease (Ward, Schiller and Goodman 2014). The 
2011 National Vital Statistics Report also revealed that chronic diseases accounted for 
seven of the top ten causes of death in the United States (Hoyert and Xu 2012).  
Since a long-term commitment to a drug regimen is the primary treatment option 
for chronic disease patients, patients’ medication non-adherence has risen as an important 
public health problem and a great challenge for healthcare practitioners (Braithwaite, 
Shirkhorshidian, Jones, and Johnsrud 2013). A recent meta-analyses of 20 studies on 
American patients’ medication non-adherence from 2002 to 2010 showed that the non-
adherence rate across all drug categories was 46% (Naderi, Bestwick, and Wald 2012). 
Another study investigating  elderly patients’ medical record from 1994 to 1998, reported 
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that about 80% of coronary artery patients stopped taking their medications within the 
first three months, and about 43% of the remaining patients stopped taking theirs within 
six months (Jackevicius, Mamdani and Tu  2002). 
Improving patients’ medication adherence is an important issue both at the 
individual and societal levels. At the societal level, approximately $290 billion or 13% of 
annual total healthcare expenditures in the U.S. was related to medication non-adherence 
issues in 2009 (New England Healthcare Institute 2009). Osterberg and Balscheke (2005) 
also reported that 33% to 69% of hospital admissions per year in the U.S. are related to 
medication non-adherence.  
At the individual level, medication non-adherence is not only correlated with 
deterioration of patients’ health, but it also increases individual patients’ healthcare 
spending. Patients who poorly adhere to their medication regimens have higher rates of 
hospitalization, higher mortality, and more frequent emergency room visits than do 
adherent patients across many chronic diseases, including diabetes and heart disease (Ho, 
Magid, Masoudi, McClure and Rumsfeld 2006; Matsui 2013). For example, myocardial 
infarction patients who poorly adhere to their statin regimen are found to be at a 25% 
higher risk of mortality than those who adhere to their regimen (Rasmussen, Chong and 
Alter 2007). Prior studies have specifically demonstrated that medication non-adherence 
increases healthcare costs for diabetic, high cholesterol and hypertensive patients 
(Shenolikar, Balkrishnan, Camacho, Whitmire, and Anderson 2006; Sokol, McGuigan, 
Verbrugge, and Epstein 2005).   
Because of the critical societal and individual implications of the medication non-
adherence problem, many public health researchers and health-related organizations have 
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examined patients’ medication adherence behavior and influencing factors (e.g., 
Christensen and Johnson 2002; Gellad et al. 2009; Kronish and Ye 2013). Most of these 
studies agree that medication adherence is a multifaceted, dynamic process with a host of 
different influencing factors, including: 1) the healthcare system factors, 2) the 
medication regimen factors, 3) the patient factors, and 4) the environmental factors. 
DTCA is a part of the broader environmental factor surrounding patients, which shapes 
the manner in which patients get information about their medication regimen and act on it 
(Kronish and Ye 2013). 
 
1.3. Chapters and Organization 
This dissertation is organized as follows: Chapter 2 discusses the concept and 
phenomenon of medication adherence and non-adherence, reviews research literature on 
medication adherence and influencing factors, and discusses media priming effect as the 
theoretical framework of this study. The first part of Chapter 2 presents an overview of 
how patients’ medication adherence and non-adherence have been conceptualized, and 
discusses medication adherence as a sequence of stages based on the stages of health 
behavior change models. Previous empirical studies on influencing factors of medication 
adherence are also reviewed. In the second part of Chapter 2, previous research 
examining the relationship between DTCA and medication adherence is reviewed. In the 
third part of Chapter 2, media priming effect theory is introduced as the theoretical 
framework of this study, followed by detailed discussion of characteristics of media 
priming effect and a review of empirical research relevant to explaining potential effects 
of frequent exposure to DTCA on patients’ medication adherence. Chapter 3 presents this 
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study’s hypotheses and research questions, which are developed based on the literature 
review.  
Chapter 4 presents a preliminary qualitative study that was conducted prior to the 
main quantitative survey study. This chapter explains the purpose and main questions 
addressed by the preliminary study, followed by presentation of key findings and 
discussion of how the findings were used for the measurement development in the main 
study. Chapter 5 describes the method of the main survey study, including the study 
context and sample, measurements, and data collection procedure. Chapter 6 presents the 
survey data analysis results. Finally, Chapter 7 summarizes and discusses the key 
findings from both the preliminary and main studies, and presents theoretical and 
practical implications of the findings. The limitations of this study are also discussed, 
followed by specific suggestions for future research directions.  
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Chapter 2 
LITERATURE REVIEW 
2.1. Medication Adherence and Relevant Research 
2.1.1. Conceptual definitions of medication adherence and non-adherence 
Medication adherence, also known as medication compliance, is a type of health 
behavior in which patients follow the medication regimen prescribed or advised by their 
healthcare providers to control their health conditions. Commonly, it is defined as “the 
extent to which a person’s behavior – taking medication… corresponds with agreed 
recommendations from a health care provider” (Sabatâe 2003, p. 3). It is a process 
concerning how patients evaluate their health conditions and the benefits and risks of 
their medications, in order to decide whether or not to follow their prescription regimen 
regarding the time, quantity, and frequency of taking medications. The process starts with 
filling a medication prescription at a pharmacy and eventually ends with the formation of 
a habit (Cramer et al. 2008). Previous research has used the terms “adherence” and 
“compliance” interchangeably, but this study uses the term adherence, because many 
healthcare providers prefer it (Osterberg and Blaschke 2005), and it reflects a more active 
role on the part of patients in the treatment process.  
Conceptually, medication adherence is considered a health behavior as well as a 
consumer behavior. As a health behavior, medication adherence is a patient’s effort to 
control his/her health condition that has deteriorated due to an illness. It is a continued 
behavior, initiated by a healthcare provider’s prescription of a medication regimen, and 
the patient’s task is to follow the instructions continuously until the healthcare provider 
confirms that the condition is fully controlled.  
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As a consumer behavior, on the other hand, medication adherence is a continuous 
decision-making process to stay on the prescribed drug regimen until it becomes a 
habitual behavior. Unlike other medical procedures performed by healthcare providers, 
medication adherence is a behavior performed by patients. In other words, patients have 
control over whether or not to take their prescribed medications and whether or not to 
follow their medication regimen. For patients who are not in the habit stage and still 
consciously appraise the value of their medication regimen, continuing the regimen 
requires a certain degree of self-regulation and control. 
Medication adherence and non-adherence is not conceptualized as a clear-cut 
dichotomy. Researchers who study medication adherence have agreed that medication 
non-adherence takes many different forms along the continuum, with one end being 
complete adherence and the other end being complete non-adherence (e.g., Gellad et al. 
2009; Park and Jones 1997). Previous research has identified and investigated three types 
of medication non-adherence behavior: 1) nonfulfillment; 2) nonpersistent adherence; 
and 3) nonconforming adherence (Gellad et al. 2009).  
 Nonfulfillment, which is known as primary non-adherence, occurs when patients 
do not initiate their prescribed medication regimen in the first place. Patients who do not 
fill their first prescription or those who filled the first prescription but never take the new 
drug are categorized as nonfullifiller. In the context of myocardial infraction (MI), one 
study reported 18% of MI patients were nonfullifillers, based on its investigation of the 
patient records from 1994 to 1998 (Jackevicius, Li, and Tu 2008).  
Nonpersistent adherence refers to when patients stop taking their medications 
after initiation. This is the most common type of medication non-adherence behavior. 
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One study compared medication claim data from 2005 for six drug categories and found 
that 55% of patients taking statins (i.e., cholesterol medication) and 47% of those taking 
diabetic medications stopped taking their medications within six months (Yeaw et al. 
2009). Another study showed that 80% of coronary artery patients stopped taking their 
medications within the first three months, between 1994 and 1998 (Jackevicius, 
Mamdani, and Tu 2002).  
Lastly, nonconforming adherence is when patients take their medications but do 
not follow the regimen as instructed by healthcare providers (Berg, Dischler, Wagner, 
Raia, and Palmer-Shevlin 1993; Gellad et al. 2009). Skipping doses and taking drugs not 
at the prescribed time or not in the prescribed doses are examples of nonconforming 
adherence. Typically, two types of measures are used to determine nonconforming 
adherence: 1) the percentage of pills that patents take as prescribed (80% is usually used 
as a point of adherence); and 2) the duration of patients’ medication adherence (Krosnish 
and Ye 2013). Nonconforming adherence is relatively less studied, but it has significant 
impact on patients’ health. For example, taking medication incorrectly can immediately 
deteriorate patients’ condition in certain disease types (e.g., Gellad et al., 2009). 
2.1.2. Medication adherence stages 
Medication adherence behavior changes over time (Park and Jones 1997) and 
these changes occur in a multistep process (Gellad et al. 2009). Various health behavior 
stage models have been employed as a theoretical framework for understanding 
medication adherence behavior stages and to design an effective intervention program to 
increase patients’ medication adherence (Sabatâe 2003). 
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The main ideas of health behavior stage models include: (1) health behavior 
changes can be understood as a process involving several stages; (2) each stage requires 
patients to make unique decisions; and (3) a certain set time period between stages is 
commonly shared by individuals (e.g., Prochaska and DiClemente 1992; Rothman, 
Baldwin, Hertel, and Fuglestad 2011). For example, Rothman and colleagues’ model of 
health behavior change proposed that a health behavior change begins with an initial 
response, such as making a decision to try a new health behavior, followed by continued 
response, maintenance, and habit stages (Rothman et al. 2011). Similarly, Prochaska and 
DiClemete (1992) identified five stages (i.e., precontemplation, contemplation, 
preparation, action, and maintenance) and argued that patients’ health behavior changes 
or health behavior adoption would undergo the five stages sequentially. Regarding the 
time taken to move from one stage to the next, they proposed a time period of six months 
between each stage transition in the context of smoking cessation.  
Among various health behavior stage models, this study adopts and modifies 
Rothman et al.’s model, because this model is conceptually better applicable to the 
medication adherence context than other models. It views forming a habit as the ultimate 
final stage of the health behavior adoption process, which is conceptually equivalent to 
the final desired stage of medication adherence. According to Rothman et al. (2011), 
changing one’s behavior or adopting a new health behavior consists of four stages or 
phases: 1) the initial response stage is the first step where individuals decide whether or 
not to try a new recommended health behavior; 2) the continued response stage is the 
second step of this process, where individuals decide whether or not to establish the 
changed or newly adopted behavioral pattern; 3) the maintenance stage is the third stage 
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where individuals decide to continue the newly adopted behavioral pattern; and 4) the 
habit stage is the final stage, in which individuals no longer consciously evaluate the 
newly adopted behavior but automatically continue the behavior. In the habit stage, the 
main predictor of the behavior is individuals’ past behavior.  
 Applying Rothman et al.’s health behavior stage model to patients’ medication 
adherence behavior, this study proposes three stages: 1) the initiation stage, 2) the 
maintenance stage, and 3) the habit stage. In the initiation stage, a patient decides 
whether or not to fill the prescription received from his/her healthcare provider and 
whether or not to take the drug. If the patients fill the first prescription and begin their 
medication regimen, they move on to the maintenance stage. The maintenance stage is 
not a mere continuation of taking the prescription drug, but rather a conscious and 
continuous decision-making process to appraise the value of outcome from continuing 
the newly adopted behavior (in medication adherence context, taking the prescription 
medication). Patients in the maintenance stage continually assess if following the 
medication regimen can improve their health and decide whether or not to adhere to the 
regimen. When patients no longer consciously assess the value of their medication 
regimen but automatically take the drugs, they are considered to have arrived at the habit 
stage. In the habit stage, patients form a routine around the newly adopted behavioral 
pattern (Rothman et al. 2011) and automatically adhere to it without conscious thoughts 
about the behavior. Figure 1 summarizes the three stages of patients’ medication regimen 
adherence. 
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Figure 1. Stages of Patient Medication Regimen Adherence 
 
2.1.3. Factors influencing medication adherence behavior 
Previous studies on medication adherence from pharmacy and public health 
examined various influential factors for improving patients’ medication adherence (e.g., 
Gellad et al. 2009; Kronish and Ye 2013; Park and Jones 1997; Sabatâe 2003). The 
influencing factors can be classified into four broad categories: 1) the healthcare system 
factors (financial factors, distribution channel factor, and healthcare provider factors); 2) 
the medication regimen factors (medication-related factors such as the complexity of 
medication regimens and side effect experiences); 3) the patient factors (demographic 
factors, condition-related factors and beliefs about their illnesses and drugs).; and 4) the 
environmental factors.  
 Healthcare system factors 
 Financial factors. The financial factors, particularly about patients’ cost-sharing, 
include medication cost and patients’ health insurance status (Kronish and Ye 2013). 
Because patients’ health insurance status and insurance coverage of prescription 
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medication costs are directly related to the costs of medications that patients have to 
cover, health insurance status has been studied frequently as a predictor of patients’ 
medication adherence.  
Previous research has consistently shown a negative association between 
medication cost and patient medication adherence (Balkrishnan 1998; Sabatâe 2003). For 
example, one study based on secondary analysis of the National Health and Nutrition 
Examination Surveys (NHNES) showed that having no health insurance increased the 
chance of patients’ medication non-adherence by 88% (Baustista 2007). Other studies 
also found that patients were less likely to adhere to their medications when the out-of-
pocket cost of medications increased (Bowman, Heilman, and Seetharaman 2004; 
Goldman, Joyce, and Zheng 2007). 
Distribution channel factors. Compared to other healthcare system factors, 
medication distribution channels have been studied less. Distribution channels can 
influence patient medication adherence because they can consistently remind patients to 
refill their prescription and to take their drugs (Bowman et al., 2004). One study tested 
the relationship between the type of distribution channels and patients’ medication 
adherence using an economic modeling approach, and found that direct channels, such as 
an online or catalog order system, were more positively related to patient medication 
adherence than other distribution channels such as pharmacies at the grocery stores 
(Bowman et al., 2004). 
 Healthcare provider factors. Frequency and the quality of communication 
between patients and their healthcare providers have been frequently examined as another 
important factor influencing patients’ medication adherence (Baustista 2007; Gellad et al. 
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2009; Hyre et al. 2007; Nguyen et al. 2009; Sabatâe 2003; Schoenthaler et al. 2009;Wu, 
Moser, Chung, and Lennie 2008). The number of patients’ visits with healthcare 
providers during a certain time period is commonly used as an indicator of frequency of 
communication with healthcare providers. One study found that patients who visited their 
healthcare providers at least once a year were more likely to adhere to their medication 
regimen than those who never visited during the same time period (Baustista 2007).  
In terms of the quality of communication, the amount of information provided by 
healthcare providers, the degree of comfort that patients felt during the conversation with 
their healthcare providers, and healthcare providers’ communication style have been 
examined in connection to patient medication adherence. A report from the World Health 
Organization (WHO) on patients’ treatment adherence showed that patients who adhere 
to their medication regimen tended to be those who received more information about 
their medication from healthcare providers and actively participated in the prescription 
process (Sabatâe 2003). Another study demonstrated that patients who felt more 
comfortable asking questions to their physicians tended to adhere more to their 
medication regimen (Hyre et al. 2007). Healthcare providers’ collaborative 
communication style has also been found positively related to patients’ medication 
adherence. One study found that patients who reported that their healthcare provider had 
a friendly communication style adhered more to their medication regimen (Schoenthaler 
et al. 2009).  
 The influences of patients’ satisfaction with and trust in healthcare providers on 
medication adherence have been also frequently studied. Generally, patients who are 
more satisfied with their healthcare providers and who trust in them are more likely to 
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adhere to their medication regimen (Gellad et al. 2009). For example, a survey of 
inflammatory bowel disease (IBD) patients demonstrated that patients with greater trust 
in their physicians adhered more to their treatment regimen (Nguyen et al. 2009). 
Another survey with a sample of heart failure patients also showed that patients who 
highly trusted their physicians were more likely to adhere to their medication regimen 
(Wu et al. 2008).  
Medication regimen factors  
 Complexity of medication regimens and side effect experiences have been 
frequently studied as medication regimen-related factors influencing medication 
adherence. Complexity of medication regimen is commonly operationalized by the 
frequency of medication use, the number of doses, and the number of other prescription 
medications taken concurrently. Previous studies have shown that patients are more likely 
to adhere to their medication regimens when the drugs are taken less frequently (Saini, 
Schoenfeld, Kaulback, and Dubinsky 2009), and when a smaller number of pills are taken 
at once (Phatak and Thomas 2006; Wu et al. 2008).  
However, the association between the number of other medications taken and 
medication adherence is unclear. Some studies revealed that patients who were taking 
more numbers of medications tended to adhere more to their regimen (Bilups, Malone, 
and Carter 2000; Burge et al 2005), while other studies found a negative association 
between the two (Bowman et al. 2004; Chapman et al. 2005; Gazmararian et al. 2006).  
 When it comes to the relationship between patients’ side effect experience and 
their medication adherence, previous studies have shown a negative association between 
them (Sabatâe 2003). A recent survey by the National Community Pharmacist 
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Association revealed that patients who experienced side effects from their medications 
were less likely to adhere to the medication regimen (National Community Pharmacist 
Association 2014). Another study also found that high cholesterol patients who 
experienced side effects from their cholesterol medications tended to be more non-
adherent to the medication regimen (Kaplan et al. 2004). 
Patient factors 
Patient factors are the most frequently examined factors influencing patients’ 
medication adherence, based on the assumption that medication non-adherence is an 
abnormal patient behavior that should be fixed by understanding patients’ individual 
characteristics (Berg et al., 1993). Patient factors can be categorized into patient 
demographic attributes, their condition-related factors and psychological factors.  
 Patients’ demographic attributes. Demographic attributes have been studied most 
frequently; however the results have been inconsistent, even within the context of 
treatment for the same illness. For example, some studies showed that, in the context of 
hypertension medication regimens, older patients tended to better adhere to their 
medication regimen (Bautista 2008; Schoenthaler et al. 2009), while another study on the 
same topic found younger patients were more likely to adhere to their medication 
regimen (Krousel-Wood, Muntner, Islam, Morisky, and Webber 2009).  
Overall, previous studies on patient demographic factors have shown no 
consistent evidence of significant relationships between patient medication adherence and 
demographic characteristics, such as age, sex, education, income, race and ethnic 
background (Haynes 1979; Kaplan and Simon 1990). Moreover, even when significant 
relationships were found between some demographic characteristics and medication 
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adherence, no meaningful theoretical discussions were offered about the findings. 
Instead, most of the previous studies simply described the demographic characteristics of 
medication adherers or non-adherers. 
Patients’ condition-related factors. Patients’ health condition-related factors, such 
as symptom severity, have been studied as potential influences on medication adherence 
(Sabatâe 2003). Particularly, whether the illness is symptomatic or asymptomatic, and 
whether the consequences of non-adherence are severe or not severe have been studied 
frequently. Generally, patients who take prescription drugs for controlling asymptomatic 
illnesses tend to be more non-adherent to their medication regimen than those with 
symptomatic illnesses (Sabatâe 2003). One study revealed that high cholesterol and 
hypertension patients were less adherent to their medication regimen than diabetic 
patients, whose condition was more symptomatic and consequences of non-adherent were 
more severe (Bowman et al. 2005).  
Patients’ psychological factors. The psychological factors can be divided into 
individual personality factors and beliefs about medications and illnesses. Previous 
studies have found no significant influence of patients’ personality factors on their 
medication adherence (Sabatâe 2003). On the other hand, patients’ beliefs about their 
illnesses and medications have been proposed as an important factor in medication 
adherence, both theoretically and empirically (e.g., Christensen and Johnson 2002; 
McHorney et al. 2007; Park and Jones 1997).  
Beliefs are a psychological representation about some objects. Commonly, 
individuals’ thoughts or knowledge about an object are considered their beliefs about the 
object (Fannis and Stroebe 2010), which are the basis of attitude toward the object (Ajzen 
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and Fishbein 1980). According to Rokeach (1968), there are three types of beliefs: 1) 
descriptive beliefs, 2) prescriptive beliefs, and 3) evaluative beliefs. Descriptive beliefs 
are represented as factual statements in our mind and they can be determined to be 
accurate or inaccurate. Prescriptive beliefs about an object are the desirability of the 
object. Evaluative beliefs reflect one’s assessment of the object, which are commonly 
represented as good or bad. Previous studies examining the role of beliefs on patients’ 
medication adherence have focused on the role of the accuracy of descriptive beliefs (or 
knowledge) and the effects of evaluative beliefs about the medication and illness. 
Patients’ descriptive beliefs about their illnesses and medications. Previous 
studies measured descriptive beliefs by assessing how accurately patients answered a 
series of knowledge questions about their illnesses and medications. Therefore, many 
studies used the term, knowledge, to describe descriptive beliefs about illnesses and 
drugs. The research findings have generally demonstrated a positive association between 
accuracy of patients’ knowledge about their illnesses and medication adherence (Sabatâe 
2003). For example, a study of type 2 diabetes patients found that the patients who had 
incorrect beliefs about their disease were less likely to adhere to their medication 
regimens (Mann, Ponieman, Leventhal, and Halm 2009). Results from a survey of 
Korean American high blood pressure patients also showed that patients with inaccurate 
knowledge of high blood pressure were less likely to adhere to their medication regimen 
(Kim et al. 2007). 
Regarding patients’ beliefs about their medications as well, research has 
demonstrated generally positive relationship between accuracy of descriptive beliefs 
about medications and patient medication adherence. A cohort study of asthma patients 
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revealed that patients who had more accurate knowledge about their treatment tended to 
better adhere to their medication regimen (Apter et al. 2003). A survey conducted in the 
same disease context also showed the same relationship between accuracy of the asthma 
treatment knowledge and patients’ medication adherence (Wells et al. 2008). Another 
study with glaucoma patients found that patients who had inaccurate beliefs about the 
consequences of glaucoma medication regimen non-adherence (i.e. reduced vision) were 
less likely to adhere to their medication regimen (Friedman et al. 2008). 
While the previous research results have demonstrated a significant and consistent 
effect of patients’ descriptive beliefs about their medications on medication adherence, 
the research has limitation in that all of the measured beliefs were beliefs about 
medication benefits. The effects of descriptive beliefs about medication risks have not 
been directly tested. 
Patients’ evaluative beliefs about their illness and medication. Evaluative beliefs 
about the illness and the drug in patients’ mind have been proposed as a strong predictor 
of patient medication adherence (e.g., Gellad et al. 2009; Park and Jones 1997). 
Particularly, patients’ evaluative beliefs about the severity of their illness have been 
frequently studied. In terms of evaluative beliefs about medications, evaluative beliefs 
about the drug itself, about the drug benefits and the drug risks have been studied. 
Generally, most of the studies testing the effects of evaluative beliefs about the 
illness severity on patients’ medication adherence have shown that patients who perceive 
their illnesses more severely tend to adhere to their medication regimen more. In the 
context of asthma, a couple of studies demonstrated that asthma patients adhered to their 
regimen better when they perceived their condition as more severe (De Smet, Erickson, 
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and Kirking 2006; Janson, Earnest, Wong, and Blanc 2008). Other studies with high 
cholesterol patients (Mann et al. 2007) and hypertension patients (Li, Stotts, and 
Froelicher 2007) also provided supporting evidence for the relationship between patients’ 
disease severity beliefs and higher medication regimen adherence.  
Evaluative beliefs about medications have also been found to be a consistently 
related to patient medication adherence. For example, a survey by Gatti and colleagues 
found that patients with generally negative beliefs about their medications were more 
likely to be medication non-adherers (Gatti, Jacobson, Gazamararian, Schmotzer, and 
Kripalani 2009).  
Evaluative beliefs about medication risks in particular have been found to be 
significantly associated with medication adherence in various disease contexts, including 
diabetes (Aikens and Piette 2009; Chao, Nau, and Aikens 2007; Mann et al. 2009) and 
depression (Brown et al. 2005). The results from the previous studies showed negative 
associations between beliefs regarding drug risks and medication adherence. Particularly, 
previous studies demonstrated that patients’ concerns about medication risks were one of 
the main barriers to medication adherence in the context of cardiovascular medication 
regimens (Kronish, Leventhal and Horowitz 2012; Marshall, Wolfe, and McKevitt 2012), 
high cholesterol patients (Mann et al. 2007), and type 2 diabetes patients (Mann et al. 
2009). Additionally, a survey with patients taking medications after coronary artery 
bypass graft (CABG) surgery found that medication non-adherent patients had higher 
beliefs about medication risks (Khanderia et al. 2008). 
Regarding the impact of patients’ evaluative beliefs about medication benefits, 
previous studies suggest that positive beliefs about medications, particularly positive 
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beliefs about the health outcomes from following the medication regimen (drug benefits 
and effectiveness), facilitate better medication adherence (Aiken and Piette 2009; Apter 
et al. 2003; McHorney et al. 2007). A study of asthma patients showed that patients with 
more positive views of their medications’ benefits were more likely to adhere to their 
medication regimen (De Smet et al. 2006). A survey of glaucoma patients also 
demonstrated that patients with positive beliefs about their medications’ benefits (i.e., 
their medications help improve their glaucoma condition) were more likely to adhere to 
their eye drop regimen (Friedman et al. 2009). 
Environmental factors 
 Previous studies on influencing factors of various health behaviors, including 
patient medication adherence, tended to focus on healthcare system factors and patient 
factors. However, some public health researchers have started paying attention to the 
importance of environmental factors. Conceptually, environmental factors are various 
micro and macro level physical, social, political, economic and sociocultural variables 
that surround individuals’ daily lives (Kremers 2010). Mass media content is regarded as 
one of such environmental factors. Recently, the importance of environmental factors on 
patient medication adherence has been addressed by one study. Kronish and Ye (2013) 
proposed that patient surroundings, such as workplaces, community, and media as 
environmental factors, indirectly influence patient medication adherence.  
 Environmental factors can influence individuals’ behavior in two ways: 1) 
through an indirect route by influencing individuals’ cognition, such as attitudes and 
intentions; and 2) through a direct route by functioning as a behavioral cue (Kremers 
2010). Previous theories on health behavior have primarily focused on the direct effect of 
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environmental factors. For example, health belief model (HBM) assumed that 
environmental factors, such mass media content, function as a cue-to-action, without 
influencing any cognitive variables (Janz and Becker, 1984). However, environmental 
factors can also indirectly influence patient behaviors. For example, frequent exposure to 
media messages, particularly medication-related messages, can influence patient beliefs 
and perceptions about their medications, which can lead them to adhere or not to their 
medication regimens. Through constant exposure to certain types of health messages in 
the mass media, patients would implicitly form related beliefs and use them in their 
decision-making.  
Although the potentially important role played by environmental factors in 
patients’ medication adherence has been proposed in the research literature, very few 
studies to date have empirically tested the effects of environmental factors on medication 
adherence. Studies examining DTCA effects on patients’ medication adherence are those 
few studies.  
2.1.4. DTCA as an environmental factor influencing medication adherence 
As one of the primary media content elements that patients are frequently exposed 
to in their daily lives, DTCA has the potential to influence patient medication regimen 
adherence, and this has been recently tested in certain limited ways. Previous studies 
examining DTCA effects on medication adherence focused exclusively on societal-level 
and aggregate effects using an economic modeling approach. Specifically, four studies 
investigated the relationship between DTCA exposure and patient medication adherence. 
These studies used patients’ pharmacy claim records from health insurance companies or 
patients’ medical records as a measure of medication adherence, and correlated the data 
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with DTCA expenditure data. Two of the studies (Donohue et al. 2004; Hansen, Chen, 
Gaynes, and Maciejewski 2010) compared the effects of various pharmaceutical 
marketing methods, including DTCA, on patient medication regimen adherence. The 
other two economic modeling studies (Bowman et al. 2004; Wosinska 2005) regarded 
DTCA as one of various predictors of patient medication adherence.  
One of the earliest studies testing on the relationship between DTCA and patient 
medication adherence was conducted by Donohue and colleagues (2004). The primary 
purpose of this study was to compare the effects of DTCA and other common 
pharmaceutical marketing methods—physician detailing and providing samples to 
physicians—on patients’ initiation of and adherence to antidepressant regimens. The 
researchers analyzed monthly advertising spending data of six antidepressant brands 
promoted by DTCA for the time period of 1997 to 2000, physician detailing data, and 
health insurance medical and prescription claims data. The results showed that high 
DTCA spending at the time of the illness diagnosis was positively related to both 
patients’ initiation of the advertised medications and the duration of antidepressant use 
(Donohue et al. 2004), but the positive association was weak and not brand-specific. 
DTCA spending of a specific brand was not only positively related to the advertised 
brand use, but also related to increased use of other brands in the same drug category. 
The authors interpreted these results as suggesting that there is a spill-over effect of 
DTCA and suggested that the positive association between patients’ increased medication 
adherence and DTCA expenditure was observed for antidepressants in general, not only 
for the advertised medications.  
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The primary purpose of Bowman et al. (2004) was to estimate an economic model 
predicting consumers’ product compliance in the context of prescription medication. 
DTCA expenditures for prescription drugs of four chronic diseases (arthritis, diabetes, 
high cholesterol, and hypertension) were included as one of the predictors of patient 
medication adherence. By analyzing patients’ drug purchase diary data, the study found 
non-significant and mixed results about the relationship between the amount of DTCA 
expenditure and patient medication adherence. The researchers suggested that DTCA 
could have both positive and negative effects; it could enhance patient medication 
adherence by putting to ideas about the drug regimen on top of patients’ mind, while they 
could also give false sense that patients’ were already cured by presenting healthy 
images. Overall, compared to other predictors, such as the salience of the condition (i.e. 
how much the condition severity was salient in patients’ mind) and the medications’ 
perceived costs, the effects of DTCA expenditure on patient medication adherence 
seemed to be small and inconsistent.  
Wosinska (2005) also estimated and tested a model of patient medication 
adherence by using DTCA of three statin brands expenditure data from Ad$pender and 
prescription claim data from Blue Shield of California from 1996 to 1999. Patients’ 
medication non-adherence was operationalized by counting the number of skipping days 
within 60 days (i.e., between the two 30-day prescription refill cycles), and DTCA 
expenditures were weighted to represent the differential effects of current and previous 
advertising on patients. Similar to Donohue et al. (2004), this study demonstrated that an 
overall increase in DTCA spending for the statins was positively related to patient statin 
adherence, but its economic impact was very small. Again, a small but positive 
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relationship was found for the drug category, rather than at the brand-level. The 
researcher suggested that DTCA could remind patients of their illness. 
A particularly interesting finding from Wosinska was a negative relationship 
between Lipitor ad spending and patient medication adherence – the negative effect was 
significant for new patients (who initiated the drug regimen when Lipitor started its TV 
commercials). The researcher interpreted that Lipitor TV ads, whose formats were 
different from other brand ads and included more drug risk information, might have 
possibly become a source of drug risk information for patients.  
Another study that demonstrated a category-level effects of DTCA was conducted 
by Hansen et al. (2010). As with the study of Donohue et al. (2004), the primary purpose 
of Hansen et al. was to examine the effects of DTCA and physician detailing on patients’ 
medication switching and adherence in the context of antidepressants. They divided 
patient medication adherence into two phases: 1) acute phase, in which patients had been 
taking prescription antidepressants for no more than 90 days, and 2) continuation phase, 
in which patients had been taking the medication for more than 90 days but less than 270 
days. The researchers investigated whether the effects of DTCA and physician detailing 
differed by the patients’ medication adherence phase. By analyzing antidepressant DTCA 
expenditure and insurance claim data for the time period of 2000 to 2004, the study 
showed that a category-level increase in DTCA expenditure was positively associated 
with patients’ medication adherence only for the continuation-phase patients, but not for 
the acute-phase patients. The results suggested that DTCA was more influential on 
patients who had been on the medication regimen for a longer period than on those who 
had recently initiated the regimen. Although this study did not formally apply the stage of 
    
 
29 
health behavior model, the results can be interpreted as showing that DTCA can be more 
influential on maintenance stage patients. 
 Overall, findings from the previous four studies examining DTCA effects on 
patients’ medication adherence can be summarized as follows: 1) there is a weak but 
positive association between DTCA spending and patient medication regimen adherence; 
2) the positive association between DTCA spending and patient medication adherence 
seems to be more pronounced for patients who have been on the medication for a longer 
period of time; and 3) the positive association between DTCA spending and medication 
adherence is more likely to be a category-level effect than a brand-specific effect.  
Research on DTCA effects on patient medication adherence is only recently 
emerging and remains very scarce. The previous studies on the relationship did not 
directly measure patients’ individual medication adherence behaviors, and did not 
provide any theoretical explanations for the underlying mechanism behind the positive 
association between DTCA and patient medication adherence. Some studies suggested 
the possibility that DTCA can be regarded as an environmental factor that influences 
patient medication regimen adherence by influencing their beliefs about their illnesses 
and drugs (e.g., Bowman et al. 2004; Wosinska 2005), but the suggested idea has not 
been empirically tested. As a media environmental factor providing information about 
illnesses and medications, DTCA has the potential to influence patients’ beliefs about 
their illnesses and medications, and such beliefs are known to be one of the most 
important predictors of patient medication adherence. Potential effects of DTCA on 
patients’ medication adherence via influencing beliefs can be understood as a media 
priming effect. 
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2.2. Theoretical Framework: Media Priming Effect 
2.2.1. Media priming effect theory and research 
Media priming effect is defined as the effect of short-term media exposure on the 
audience’s thoughts, beliefs, judgments, and behaviors (Roskos-Ewoldsen et al. 2007). 
Broadly, media priming effect has been studied in three areas—media violence priming, 
political priming, and stereotype priming. Media violence priming research has theorized 
and investigated how exposure to violent media content primes aggression-related affects 
and behaviors in various media contexts from movies to video games (e.g., Carnagey and 
Anderson 2005; Josephson 1987). Political priming studies have examined how exposure 
to political news and entertainment shows affects individuals’ views on politicians and 
political issues (e.g., Iyengar and Kinder 2010; Moy, Xenos, and Hess 2005). Stereotype 
priming research has investigated how exposure to media content portraying racial or 
gender stereotypes influence individuals’ evaluation of an event which is related to the 
racial and gender group (e.g., Monahan, Shtruilis and Brown Givens 2005; Power, 
Murphy and Coover 1996).  
Characteristics of media priming effect 
 The original concept of priming effect was developed in the social psychology 
field and thus, media priming effects and the original priming effects from social 
psychology share some similarities. First, media priming effects become stronger when 
the priming happened more recently or frequently. Roskos-Ewoldsen et al.’s review of 
media priming effects showed that recency and frequency of exposure were two main 
characteristics of media priming effects. Second, compared to other types of media 
effects, priming effects only last for a short time period  (Roskos-Ewoldsen, Klinger et al. 
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2007; Roskos-Ewoldsen, Roskos-Ewoldsen et al. 2009). Roskos-Ewoldsen, Klinger et al. 
(2007) conducted a meta-analysis of media priming effect research and found that media 
priming effects tended to dissipate over time. Although media priming effect studies have 
shown longer lasting effects than those found in the traditional social psychological 
priming studies, even the longest media priming effect lasted only for two months 
(Roskos-Ewoldsen, Roskos-Ewoldsen et al. 2009). 
There are also some unique aspects of media priming effects compared to 
traditional priming effects in social psychology. First, the nature of priming from media 
content exposure is incidental. Unlike an experimental setting in which individuals are 
forced to be exposed to the priming condition, in a real media viewing environment, 
individuals are typically unaware of the potential priming intent from media messages 
such as news and advertising, when they are exposed to them. Therefore, priming effects 
from media messages are usually caused by incidental exposure. 
Second, media exposure happens ubiquitously and for a long period of time. 
Roskos-Ewoldsen et al. (2009) pointed out that media’s ubiquitous nature could prime 
individuals’ thoughts or behaviors more strongly than the manipulation done in the lab 
setting (Roskos-Ewoldsen et al. 2009). Similar types of media messages are disseminated 
via multiple media channels surrounding our everyday lives. For example, in the context 
of advertising, Faber, Duff, and Nan (2012) argued that, as advertising messages are 
disseminated through multiple media channels simultaneously, individuals are exposed to 
the same advertising messages repeatedly. This ubiquitous nature of media increases the 
chance of being exposed to the same message repeatedly and frequently, which is closely 
related to stronger priming effects.  
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 Theoretical assumptions of media priming 
 Media priming effects are conceptualized based on the assumption that concepts 
are stored as a network in an individual’s long-term memory. Among the various 
networks of memory models (e.g., Anderson 1996; Higgins, Bargh and Lombardi 1985; 
Wyer and Srull 1980), Anderson’s ACT* model (1996) has been widely used as the basis 
for media priming effect models. According to Anderson (1996), an individual’s memory 
system called ACT productive system consists of the working memory (i.e., short-term 
memory) and the declarative memory (i.e., long-term memory). In this model, declarative 
representations, which are cognitive units such as constructs, knowledge, beliefs, and 
attitudes, are stored in the declarative memory in the form of a hierarchical network. 
When a cognitive unit in the declarative memory is activated, the unit becomes ready to 
move into the working memory, where it becomes accessible for making judgments.  
Because cognitive units are located in the associative network, which is an inter-
connected, hierarchical network in the declarative memory, the activation of one unit can 
spread to other connected units, known as the spread of activation. Priming happens 
when activation of one cognitive unit (e.g., belief regarding effectiveness of one’s current 
prescription medication) affects the activation of another connected cognitive unit (e.g., 
beliefs about other benefits of one’s current prescription medication), which in turn 
becomes readily accessible in the working memory (Anderson 1996). The accessible 
cognitive units in the working memory influence individuals’ subsequent decision-
making process (e.g., my current medication is good for my health) and behavior (e.g., 
staying on the current medication regimen). 
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Accessibility effects and relevant media priming research 
 Based on the concept of associative network of long-term memories, media 
priming effect studies view accessibility effects as the underlying mechanism of media 
priming effects. Accessibility effects refer to “the activation potential of available” 
knowledge, beliefs, and attitudes stored in one’s memory (Higgins 1996, p.134), which 
means that among knowledge, beliefs, and attitudes that already exist in one’s memory, 
certain types of knowledge, beliefs, and attitudes can become more readily accessible for 
making subsequent judgments. Accessibility effects can happen only among already 
available constructs of knowledge, beliefs, and attitudes. Belief salience is sometimes 
interchangeably used when referring to accessibility effects. However, Higgins (1996) 
points out that salience is the outcome of selective exposure, which is a different concept 
from accessibility. Thus, the current study uses the term, accessibility, to refer to 
increased possibility of memory activation.  
 Media priming effect research has studied how temporarily or chronically 
accessible cognitive units or affects influence individual audiences’ subsequent behaviors 
or judgments of an object. Since many previous priming effect studies employed lab 
experimental methods, their findings have primarily demonstrated temporary 
accessibility effects, which only exist for a couple of minutes to a couple of days 
(Higgins 1996). However, to better reflect the true nature of media exposure in the real 
world, some of the more recent media priming effect studies, particularly political news 
priming studies, have focused on how media exposure enhance chronic accessibility to 
certain cognitive units.  
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Chronically accessible cognitive units are more ready to be activated (Bargh and 
Pratto 1986) and relatively stable to guide the subsequent information processing (Lau 
1989). Chronic accessibility is associated with automatic processing (Bargh and Thien 
1985) and its effects are longer lasting, ranging from a couple of weeks (Higgins, King, 
and Mavin 1982) to over a year (Lau 1989). One example of media priming effects on 
chronic accessibility is found in Lau (1989), which examined enduring effects of 
individuals’ chronic accessibility of certain political constructs over time, influencing 
their attitudes toward politicians. Chronic accessibility of four political constructs—
politician, issue, group, and party—was measured by coding respondents’ answers to 
eight open-ended questions in a survey. Structural equation modeling results using data 
collected from 1956 to 1960 showed that heightened accessibility of the four 
hypothesized political constructs lasted for over four years. In follow-up studies, Lau also 
demonstrated that these four chronically accessible political constructs influenced 
respondents’ attitudes toward presidential candidates (Lau 1989). 
In a political news context, Price and Tewksbury (1997) developed a news 
priming model to explicate how exposure to political news primes individuals’ political 
decision-making, especially when evaluating political leaders and issues. Their model is 
based on Anderson’s ACT* model, which consists of knowledge store (i.e., long-term 
memory) and active thought (i.e., short-term memory). They also assumed that the 
associative network of cognitive units in long-term memory and salient attributes in 
media messages, such as political news, activate cognitive units in the long-term memory 
and move them to the short-term memory, where the activated cognitive units are readily 
used for political issue evaluation. Price and Tewksbury (1997) argued that social objects 
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and attributes, goals, values, motivation, and affects are stored as a form of associative 
network in the long-term memory.  
Political news priming studies have mainly focused on how news coverage of 
political affairs influences the kind of information that individuals use for overall 
evaluation of politicians. In particular, political news coverage has been found to enhance 
chronic accessibility of news-covered information in individuals’ minds (Roskos-
Ewoldsen et al. 2009). Chronically accessible information persists over time and is used 
for subsequent judgments and behaviors more than temporarily accessible information 
(Roskos-Ewoldsen et al. 2009). 
One of the earliest studies on political priming effect is Iyengar and Kinder’s 
experimental work (2009). In a series of experiments conducted from 1980, they showed 
various edited evening news segments (e.g., segments about American defense 
preparedness in experiment 1) to participants in the treatment conditions. They found that 
participants placed more weight on the political issues covered in the news they saw, 
which affected their overall evaluation of President Carter’s performance (Iyengar and 
Kinder 2009). Political priming effect has been studied in various contexts aside from 
traditional news media, on which Price and Tewksbury’s model was based, including 
entertainment media. For example, Moy, Xenos, and Hess (2005) found that the public’s 
evaluation of President George W. Bush’ character traits was primed by his appearance 
on The Late Show with David Letterman. 
The current study’s hypothesis model, which will be presented in the next chapter, 
is built based on Price and Tewksbury’s (1997) news priming model to investigate DTCA 
effects on individuals’ medication regimen adherence, for the following reasons: 1) the 
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nature of DTCA exposure is incidental, repetitive and gradual, which is similar to the 
nature of news exposure; and 2) patients use the information from advertisements, but 
usually do so a while after their exposure to the ads, which is also similar to the news 
priming situation.  
2.2.2. Media priming effect as the mechanism underlying the relationship 
between DTCA exposure and patient medication adherence 
Applying media priming effect theory and findings from relevant studies to 
DTCA context, it is expected that patients who are frequently exposed to DTC ads are 
more likely to have accessible beliefs about their illnesses and medications that are 
consistent with the DTCA content. Due to the rather standardized nature of DTCA 
content, patients are likely to be exposed to similar types of health information repeatedly 
through cumulative and constant exposure to DTCA, which, in turn, can make certain 
beliefs about the illnesses and the drugs chronically more accessible in patients’ minds.  
 
 The standardized nature of DTCA content 
 One of the unique characteristics of DTCA is that its content is regulated by the 
U.S. Food and Drug Administration (FDA), which requires every DTC ad to include both 
risk and benefit information about the advertised drug in a fair-balanced manner. Drug 
benefit information includes information on how the advertised drug treats certain 
medical symptoms, medication effectiveness, convenience, and innovation. Drug risk 
information includes common side effects, serious side effects, and the groups who may 
experience more harm than good (U.S. Food and Drug Administration 2015). 
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According to the FDA, three types of DTC are approved to be shown in the 
media: 1) product claim advertisements, 2) reminder advertisements, and 3) help-seeking 
advertisements. Product claim advertisements include the name of the brand, at least one 
benefit of the drug approved by the FDA, and risks of the drug. Reminder advertisements 
assume that patients already know about the use of the drug; thus, the purpose of these 
types of advertisements is to remind them of the drug name, but not explicitly mention its 
benefits or risks. Finally, help-seeking advertisements describe related illnesses, but do 
not mention a specific drug name or its risks and benefits (U.S. Food and Drug 
Administration 2012).  
Previous content analysis studies of DTCA (e.g., Frosch, Krueger, Hornik, 
Gonbolm, and Barg 2007; Macias, Pashupati, and Lewis 2007) have revealed that all 
DTC ads include information about the advertised medication’s benefits and risks, and 
the medical symptoms treated by the drug. A content analysis of TV DTC ads appearing 
during prime time TV shows in 2004 demonstrated that most ads were making factual 
(82%) claims about the drug’s benefits and risks, and provided information about related 
medical conditions such as causes, prevalence, and risk factors (Frosch et al. 2007).  
In terms of medication benefits, DTC ads emphasize the benefits of the advertised 
drugs for facilitating control of medical symptoms, the effectiveness and the safety of the 
advertised medications, and social benefits from the use of the advertised drugs. Folsom 
and colleagues conducted a content analysis of print DTC ads of urological drugs, and 
found that symptom control, effectiveness, and lifestyle enhancement were frequently 
presented as drug benefits (Folsom, Fesperman, Tojoula, Sultan, and Dahm 2010). 
Another content analysis of magazine DTC ads also showed that most DTC ads 
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emphasized the effectiveness and safety of the advertised drugs, as well as social benefits 
such as enhancement of the patient’s lifestyle (Bell, Kravitz, and Wilkes 2000). A more 
recent study on TV DTC ads also demonstrated that social appeals such as regaining 
control of one’s life by using the advertised drugs were frequently depicted, as well as the 
effectiveness and safety of drugs (Frosch et al. 2007). A content analysis of the visual 
cues from DTC ads showed similar results as well (Welch Cline and Young 2009).  
 As previous content analyses have demonstrated, information about illnesses and 
medications presented in DTCA tends to be standardized. Due to the standardized nature 
of DTCA content, patients are likely to be exposed to similar types of information about 
their illnesses and medications repeatedly through cumulative and constant exposure to 
DTCA. Thus, it is predicted that higher exposure to DTCA would likely lead to priming 
of certain health beliefs related to common DTCA content elements (e.g., drug benefits 
and risks), which, in turn, would influence subsequent medication adherence behavior. 
This predicted effect is explained in further detail in the following section. 
 Potential priming effects of standardized DTCA content 
The standardized information presented in DTCA would likely influence patients’ 
accessibility to two specific types of beliefs about their illnesses and medications: 
descriptive beliefs and evaluative beliefs. First, frequent exposure to DTCA can enhance 
the chronic accessibility to the descriptive beliefs about illnesses and medications 
because factual information about illnesses and medications are commonly presented in 
DTCA. Macias et al. (2007) showed that 74.5% of DTC ads provide general information 
about the advertised medications and the illnesses they treat, and Frosch et al. (2007) 
showed that 82% of TV DTC ads present factual information about the drug benefits and 
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risks. As the majority of DTC ads provide factual information about illnesses and 
medications, frequent exposure to DTC ads would likely make descriptive beliefs about 
illnesses and medications more chronically accessible in patients’ minds. Specifically, 
patients are likely to have more accurate descriptive beliefs about their condition and its 
potential impact on their life, as well as more accurate descriptive beliefs about the 
medication benefits and risks.  
Second, frequent exposure to DTCA can enhance patients’ chronic accessibility to 
evaluative beliefs about their illness severity and medications. Frosch et al. (2007) found 
that the advertised medications were commonly portrayed as a method to regain control 
of one’s health, which was lost because of an illness. This type of portrayal commonly 
emphasizes the negative aspects of illnesses (i.e., loss of control, severity of illness) and 
suggests taking the advertised medications as a solution (Frosch et al. 2007). Through 
frequent exposure to this type of portrayal of both illnesses and medications in DTCA, in 
patients’ minds, negative evaluative beliefs about illnesses and positive evaluative beliefs 
about medications could become more chronically accessible, eventually influencing 
patients’ decision to take their medications. 
 
2.3. Summary 
Medication adherence is patients’ health behavior to control their health conditions by 
taking medications as their healthcare providers prescribed. It is a continuous decision-
making process in which patients evaluate their health condition and the benefits and 
risks of their drugs, until it becomes a habit. On the continuum of medication adherence, 
where full adherence and non-adherence are placed at each end, three types of non-
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adherence behaviors are identified. Nonfulfilment is the primary medication non-
adherence, which happens when patients do not initiate their first prescription. 
Nonpersistent adherence is the most common type of non-adherence and happens when 
patients drop out of their medication regimen after the initiation. Nonconfoming 
adherence is failure to correctly follow given medication regimens, which is usually 
measured by the percentage of pills taken and the duration of medication taking. 
Because medication adherence behavior changes over time, it should be 
considered a multi-stage concept. Applying the stage of health behavior change model to 
the context of medication adherence, this study defines medication adherence as a 
process consisting of three stages: (1) the initiation stage, (2) the maintenance stage, and 
(3) the habit stage. The first stage of medication adherence—the initiation stage—starts 
when a patient obtains a prescription from his/her doctor and begins to take the 
medication. If the patient fills the first prescription and starts his/her medication regimen, 
the patient is said to have moved on to the second stage, called the maintenance stage. In 
this stage, a patient consciously re-assesses the value of continuing the newly adopted 
medication regimen behavior. At the final stage—the habit stage—patients take their 
medication as a habit, which is an automatic behavior that does not require any conscious 
re-evaluation of the value of their medication regimen. 
 Among the different stages of patients’ medication adherence, this study focuses 
on the maintenance stage for the following reasons: 1) the healthcare providers’ role is 
more influential than patients’ own cognitive efforts in the initiation stage and thus, the 
DTCA’s influence would likely be minimal at this stage; 2) although both maintenance 
and habit stages can be characterized as a continuation of the medication regimen, the 
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habit stage requires less or no cognitive efforts compared to the maintenance stage, and 
thus the influence of DTCAs would likely be minimal; 3) the maintenance stage still 
requires making a relatively conscious decision to stay or not to stay on the medication 
regimen, and DTCAs can have a considerably greater influence.  
 Previous studies on the influencing factors of patients’ medication adherence have 
examined various factors that can be broadly categorized to the healthcare system factors, 
the medication regimen factors, the patient factors, and the environmental factors. DTCA 
can be regarded as an environmental factor that indirectly influences patient medication 
adherence by increasing awareness of illnesses and affecting patients’ beliefs about their 
illnesses and medications. However, very few studies have examined DTCA effects or 
any other media factor effects on medication adherence. Only a handful of studies exist 
about DTCA effects on patient medication adherence, and they have demonstrated a 
weak, positive association between DTCA spending and patient medication regimen 
adherence. The positive association between DTCA spending and patient medication 
adherence is more likely to be a category-level effect than brand-specific effect, and more 
applicable to patients who are already following their medication regimens (i.e., in the 
maintenance stage).   
DTCA effects on patient medication adherence can be understood as a media 
priming effect. Media priming effect is a type of short-term media effects when media 
exposure influences audiences’ subsequent thoughts and behaviors. Based on the concept 
of associative network of memory, priming happens when the activation of a certain 
concept spreads to another connected concept in the memory network. The activation is 
readily accessible to be used for individuals’ subsequent decision-making and behavior, 
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which is called accessibility effects. Media priming effect research has investigated how 
temporarily or chronically accessible cognitive units influence the subsequent behavior or 
judgments of an object in the context of violent media exposure, news media, and 
stereotyping. Media priming effect becomes stronger when media exposure happens 
more frequently and recently, and lasts a relatively short period of time compared to other 
types of media effects.  
Price and Tewksbury (1997) developed a news priming model to explicate how 
exposure to political news primes individuals’ political decision-making, especially when 
evaluating political leaders and issues. They propose that salient attributes in political 
news activate cognitive units in individuals’ long-term memory. Because the nature of 
DTCA exposure is similar to the nature of news exposure, which is incidental, repetitive, 
gradual, and, just like news priming, there is a time gap between DTCA exposure and 
patients’ actual decision-making, this study builds its model based on Price and 
Tewksbury’s (1997) news priming model to investigate the DTCA effects on individuals’ 
medication regimen adherence. 
Because of the FDA regulation, DTCA is required to include information about 
both drug benefits and risks, as well as the information about the illness treated by the 
advertised drug. Previous content analyses of DTCA have shown that the content of 
DTCA is standardized. Most DTCA includes factual claims about the illness, medication 
benefits, and risks. The balance between the benefits and risks of the advertised drug is 
fair in regard to quantity. The most commonly used message appeal in DTCA is 
describing the illness as a serious condition hindering one’s healthy life, and suggesting 
the advertised medication as a method of re-gaining health.  
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Frequent exposure to DTCA’s standardized content can increase patients’ 
accessibility to certain types of descriptive beliefs and evaluative beliefs about their 
illnesses and medications. Specifically, frequent exposure to the DTCA’s factual claims 
about illness and medication benefits and risks can increase the accuracy and accessibility 
of descriptive beliefs, and frequent exposure to the portrayal advertised medication as a 
method of re-gaining one’s health can increase the accessibility to negative evaluative 
beliefs about illnesses severity. Overall, increased accessibility to descriptive and 
evaluative beliefs about illness and medication benefits and risks can affect patient 
medication adherence. 
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Chapter 3 
HYPOTHESES AND RESEARCH QUESTIONS 
3.1 Influencing Factors at Different Stages of Medication Adherence 
Previous studies on influencing factors of medication adherence have been conducted 
without considering the multi-stage nature of medication regimen adherence. However, 
the health behavior change stage models and the medication adherence literature suggest 
that different influencing factors might play different roles at different stages (e.g., Gellad 
et al. 2009; Rothman et al. 2011).  
 One of the main arguments of Rothman et al.’s stage of health behavior change 
model is that the psychological factors influencing new health behavior initiation and 
those influencing the maintenance of the newly adopted behavioral pattern differ. 
Specifically, they argued that self-efficacy and expectation about the outcome from 
performing a health behavior are important determinants of health behavior adoption for 
individuals in the initial phase, while satisfaction with the outcome from the behavior is a 
more important influencing factor for individuals in the maintenance phase. For the habit 
phase patients, who perform the behavior automatically, previous behavior is the main 
predictor of health behavior (Rothman et al. 2011).  
Empirical evidence supporting the notion of different influencing factors at 
different health behavior stages has been offered. In the context of a weight loss 
intervention program, one study found that self-efficacy was a strong predictor of 
individuals’ weight loss behaviors, such as dieting and exercising, during the weight loss 
intervention period; however, it did not predict individuals’ weight loss behavior after 
completing the intervention program (Linde, Rothman, Baldwin, and Jeffery 2006). In 
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the context of a smoking cessation intervention, another study also revealed self-efficacy 
as the main predictor of individuals’ initiation of smoking cessation (Baldwin et al. 
2006). But, after completing the program, satisfaction with the results of the smoking 
cessation program was the main predictor of continuation of smoking cessation.  
 In the patients’ medication adherence context, Gellad et al. (2009) proposed that 
some influencing factors of medication adherence could be more effective for patients at 
certain medication adherence stages. Based on a review of literature on influencing 
factors of medication adherence, they argued that healthcare system factors, such as 
healthcare costs, would be the main influencing factor that motivate or inhibit patients’ 
filling of the first prescription, which is the initial stage. However, for patients at the 
maintenance stage, medication-related factors, such as regimen complexity, and patients’ 
psychological factors, such as beliefs about their illnesses and medications, would play a 
more important role.  
Inferring from the research literature on health behavior stage models and the 
research on patient medication adherence reviewed in the previous section, the current 
study posits that DTCA’s effect on patient medication adherence is likely to be more 
prominent in the maintenance stage. In the initiation stage, the healthcare provider factor 
or the healthcare system factor, such as health insurance coverage of the medication cost, 
would likely be more influential in motivating patients’ medication-taking (Gellad et al. 
2009). Thus, DTCA would likely be minimally influential in this stage. In the habit stage 
as well, DTCA influence would likely be minimal, because patients’ cognitive processing 
and decision-making to or not to continue their medication regimen does not happen at 
this stage.  
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On the other hand, in the maintenance stage, medication adherence requires 
continuous and conscious decision-making by individual patients until it becomes a habit. 
Constant exposure to DTCA could enhance the accessibility of certain beliefs about 
medications, which would affect patients’ decision to or not to stay on their medication 
regimen. Therefore, frequent exposure to DTC ads is likely to have more substantial 
influence on patients in the maintenance stage than on those in other stages. . As 
discussed earlier, DTCA effects on the maintenance-stage patients’ medication adherence 
can be understood as a media priming effect. 
Focusing on medication adherence behaviors among patients at the maintenance 
stage of medication use, this study hypothesizes that the level of DTCA exposure will be 
positively associated with patients’ adherence to their medication regimen. Based on the 
theory of media priming effects and relevant empirical findings, DTCA is predicted to 
influence maintenance-stage patient medication adherence behaviors by increasing 
chronic accessibility of descriptive and evaluative beliefs about their illnesses and the 
medications they are taking. The following sections present specific hypotheses with 
justifications. 
 
3.2. Priming Effects of DTCA Exposure on Patients’ Beliefs about Their Illnesses 
and Medications 
The FDA requires, and the previous research of DTCA content demonstrates, that factual 
information about the advertised drugs’ benefits and risks and related illnesses is 
universally present in all branded (product-claim) DTC ads (Frosch et al. 2007; Marcias 
et al. 2007). Therefore, based on the media priming theory, repeated and cumulative 
    
 
47 
exposure to DTC ads would likely make the specific descriptive beliefs about the drugs 
and illnesses featured in DTC ads more accessible in patients’ long-term memory 
(Roskos-Ewoldsen et al. 2009).  
As suggested by Donohue et al. (2004) and Hansen et al. (2010), such priming 
effects on chronic accessibility of certain descriptive beliefs are likely to occur through 
overall DTCA exposure, not necessarily through exposure to ads promoting specific 
drugs taken by exposed patients. In other words, the hypothesized DTCA priming effects 
are not likely brand-specific effects. Thus, all of this study’s hypotheses are posed about 
the effects of general DTCA exposure, not brand-specific ad exposure. 
 Therefore, the following hypotheses are posed: 
H1. The level of patients’ DTCA exposure and the accessibility of descriptive 
beliefs about their illness in the patients’ memory will be positively related. 
 
H2. The level of patients’ DTCA exposure and the accessibility of descriptive 
beliefs about their drug benefits will be positively related. 
 
H3. The level of patients’ DTCA exposure and the accessibility of descriptive 
beliefs about their drug risks will be positively related. 
 
 
In addition, previous content analysis studies have shown that many DTC ads 
have the tendency to present information about illnesses and medication benefits by 
highlighting the severity of the illness as the obstacle to living a normal and healthy life, 
and by showing that the medication can help remove that obstacle. Repetitive exposure to 
such prevalent depiction of illnesses and medications in DTC ads can influence patients’ 
evaluative beliefs about their illnesses and medications. Repetitive exposure to an illness 
as a severe problem to their health and life can increase the chronic accessibility of 
    
 
48 
patients’ evaluative beliefs about their illnesses being a severe problem. Therefore, the 
following hypothesis is posed: 
H4. The level of patients’ DTCA exposure and the accessibility of evaluative 
beliefs about the severity of their illnesses in the patients’ memory will be 
positively related. 
 
 
 While a significant effect of DTCA exposure on patients’ evaluative beliefs about 
their medications is also predicted, the direction of the relationship is unclear. DTCA is 
required by the FDA to present both benefits and risks of the advertised drugs in a 
balanced manner, and previous content analysis studies have shown that both benefit and 
risk information types are presented equally in DTC ads, at least in terms of the quantity 
of information (Abel et al. 2007). Thus, frequent exposure to DTCA could lead to 
heightened accessibility of positive evaluative beliefs of drugs or negative evaluative 
beliefs, depending on which type of information had stronger impact on individual 
patients. Therefore, this study will pose a research question regarding the DTCA effects 
on patients’ evaluative beliefs about their medications: 
RQ1. How will the level of patients’ DTCA exposure and the accessibility of 
evaluative beliefs about their drugs be related? 
 
3.3. Belief Accessibility Effects on Patients’ Medication Adherence 
The next set of hypotheses test relationships between the descriptive and 
evaluative beliefs about illnesses and medications primed by DTCA exposure and patient 
medication regimen adherence behavior. Previous studies on psychological influencing 
factors of medication adherence have shown that patients with more accurate descriptive 
beliefs about their illnesses and drugs tend to adhere better to their medication regimen 
(e.g., Aperter et al. 2003; Friedman et al. 2008; Kim et al. 2007; Wells et al. 2008). Based 
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on these empirical findings and the media priming literature (e.g., Roskos-Ewoldsen et al. 
2009), it is predicted that increased accessibility of descriptive beliefs about illnesses and 
drug benefits caused by frequent DTCA exposure will be positively associated with 
medication adherence. The relationship between the descriptive beliefs about medication 
risks and patient medication adherence has not been directly tested. However, there are 
some experimental studies demonstrating negative relationships between exposure to 
DTCA risk information and patients’ attitude toward the advertised medication and 
choice of the advertised medication (e.g., Lu 2007; Nikam 2003).  
As discussed in the previous section, frequent exposures to factual claims about 
drug risks in DTCA is predicted to increase the accessibility of descriptive beliefs about 
the drug risks. Since attitude has been conceptualized and tested as a predictor of one’s 
behavior (Ajzen and Fishbein 1980), it is expected that the heightened accessibility of 
descriptive beliefs about medication risks is likely to be negatively associated with 
patient medication adherence. Thus, the following hypotheses are posed: 
H5. The level of accessibility of descriptive beliefs about the illness and patients’ 
medication adherence will be positively related. 
 
H6. The level of accessibility of descriptive beliefs about the medication benefits 
and patients’ medication adherence will be positively related. 
 
H7. The level of accessibility of descriptive beliefs about the medication risk and 
patients’ medication adherence will be negatively related.  
 
Previous studies on influencing factors of medication adherence have 
demonstrated that patients’ perceived severity of illness, which is a type of evaluative 
belief about illness severity, tends to be positively related to their medication adherence. 
Based on the empirical findings and the media priming literature (e.g., Roskos-Ewoldsen 
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et al. 2009), it is predicted that increased accessibility of evaluative beliefs about the 
illness severity will be positively associated with medication adherence. In addition, 
previous studies on influencing factors of medication adherence have shown that patients 
who perceive more benefits than risks from their medications tend to adhere better to 
their medication regimen (De Smet et al. 2006; Gatti et al. 2009). Therefore, the 
following hypotheses are posed:  
H8. The level of accessibility of evaluative beliefs about the illness severity and 
patients’ medication adherence will be positively related. 
 
H9. The level of accessibility of evaluative beliefs about the drugs and patients’ 
medication adherence will be related, and the direction of the relationship will 
depend on the nature of the evaluative beliefs (positive or negative).  
 
In addition, a research question will be posed to test the overall link between 
DTCA exposure and medication adherence behavior. Because some accessible beliefs are 
likely to be positively related to medication adherence while other types of beliefs are 
likely to be negatively related to the dependent variable, the following question is posed: 
RQ2:  Through the hypothesized priming effects, would the level of DTCA 
exposure positively or negatively influence patients’ medication adherence 
behavior? 
 
 The hypothesized associations between DTCA exposure, patients’ beliefs about 
their illnesses and medications, and patient medication adherence are illustrated in Figure 
2.  
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Figure 2. Hypothesized Effects of DTCA Exposure on Patients’ Belief Accessibility 
and Medication Adherence 
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Chapter 4 
PRELIMINARY QUALITATIVE STUDY 
4.1. Purpose of the Preliminary Study 
In order to obtain information necessary for developing the survey measurements for the 
main study, preliminary qualitative study was conducted using a series of in-depth 
interviews. Since this study focuses on medication regimen adherence at the maintenance 
stage, it is crucial to screen potential participants based on their medication use stage. For 
prescription medication users to reach the maintenance stage, it is required that they have 
spent a certain amount of time under the current medication regimen and made the 
transition from the initiation stage to the maintenance stage but not reached the habit 
stage yet. However, determining how to construct the screening measures is a challenging 
task due to a lack of clear guidelines in the existing research literature. 
Previous studies on the stage of health behavior model assumed a specific time 
period between one stage and the next (e.g., Prochaska and DiClemente 1983; Rothman 
et al. 2011). For example, Prochaska and DiClemente (1983) proposed a time period of 
six months between each stage transition in the context of smoking cessation. Similarly, 
Rothman et al. (2011) used seven consecutive days as the time frame for determining 
transition between stages.  
However, in the context of patient medication adherence, no previous research 
has proposed or empirically tested the amount of time needed for patients to move from 
the initiation to maintenance stage, and from the maintenance to habit stage. Some 
studies provide suggestive information that can be applied to conceptualizing a possible 
time frame for transition between the maintenance stage and the habit stage. For example, 
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Yeaw et al. (2009) studied the medication adherence pattern of six chronic disease 
patients using the pharmacy claims database, and reported that the number of drug claims 
by patients taking cholesterol-lowering medications showed drastic drops at the 30-day, 
60-day, and 90-day mark after starting their medications. This finding suggests that a 
maintenance pattern would likely be formed within the first 30 days of taking the 
medication and that after 90 days most patients would likely enter the habit stage. 
However, this notion has not been empirically tested and there is no solid empirical data 
based on which medication use stages can be determined. Therefore, one of the primary 
purposes of the preliminary qualitative study was to develop feasible screening measures 
for determining maintenance-stage patients.  
Another important purpose of the preliminary qualitative study was to learn 
patient characteristics in the maintenance and habit stages, in terms of their medication 
adherence behavior and their perceptions and beliefs of the medications. Specifically, 
interview questions were aimed at obtaining comments about patients’ perceptions and 
beliefs about their illnesses and their drug benefits and risks, to use them for developing 
statements for the accessibility to the beliefs accessibility measurements about the illness 
and medication measurements. The in-depth interviews were approved by the University 
of Minnesota Institutional Review Board (IRB). 
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4.2. Method: In-depth Interviews 
4.2.1. Study context: high cholesterol patients’ medication adherence 
As discussed earlier, the media priming effect of increasing chronic accessibility 
of certain beliefs tends to be a very short-term effect. Therefore, for testing DTC ad 
effects on patients’ medication regimen adherence through priming, it is important to 
select the specific type of prescription medications that was heavily advertised within a 
reasonable time period surrounding the data collection period. Two months is the longest 
effect period that has been observed in news priming research (Roskos-Ewoldsen et al. 
2009) and the longest effect period detected in psychology research is only a couple of 
weeks (Higgins et al. 1982). Based on these previous study findings, DTCA expenditures 
by medication types were checked for two months before the beginning of the 
preliminary qualitative study.  
The cholesterol-lowering medication regimen (e.g., Lipitor and Crestor) for 
patients with hyperlipidemia (high cholesterol) was selected as the research context for 
three reasons. First, cholesterol-lowering medications were one of the most heavily 
advertised drugs on the market within the two-month time window before the in-depth 
interviews started (Kantar Media 2013). Second, high cholesterol is a chronic condition 
treated by prescription drugs requiring the patients’ long-term commitment to the 
medication regimen, sometimes taken for the patients’ entire lifetime. Third, non-
adherence to the cholesterol-lowering medication regimen (e.g., skipping doses) does not 
lead to immediate negative consequences the patients can feel physically. Thus, it is 
relatively easier for patients to forget to take their medications and to become non-
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adherent to their medication regimen in various ways, compared to other types of 
medications for chronic conditions.  
4.2.2. In-depth interview procedure 
Sixteen semi-structured interviews were conducted with cholesterol patients currently on 
the cholesterol medication regimen, from February 10 to April 25, 2014. Interviewees 
were recruited in various ways. Online recruitment advertisements were posted on 
Craigslist and emailed to potential interviewees through the university staff listserv. 
Snowball sampling was also used relying on the cooperation of participants. Fifteen 
interviews were conducted in-person and one interview was conducted via Skype. The 
time and location of in-person interviews were selected by interviewees for their 
convenience, which varied from the university lab to coffee shops near their homes. The 
online interview was scheduled by the interviewee for the interviewee’s convenience. 
The interviews were conducted in English and each took about 30 minutes to 1 hour. All 
the interviews were digitally recorded with the permission of interviewees. Interviewees 
received a $20 gift card as a compensation for their participation. 
 The interview recordings were transcribed, resulting in a total of 141 pages of 
transcript, and analyzed by the author. The interpretative analysis approach (Lindlof and 
Taylor 2010) was taken for analyzing the data. The data were read carefully several times 
and examined line-by-line using analytic induction procedures and comparative analysis 
(Strauss and Corbin 1990). NVivo 10 for Mac was used for coding and investigating the 
emerging patterns. 
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4.3. Key Findings from the In-depth Interviews 
4.3.1. Interviewee characteristics  
In total, ten males and six females who were currently taking prescription 
cholesterol medications were interviewed. Fifteen interviewees were currently taking a 
prescription cholesterol medication, and one interviewee was taking niacin, a dietary 
supplement that helps control one’s cholesterol level. Although niacin is not a 
prescription medication, the interviewee was not excluded from the analysis because the 
niacin was prescribed by a doctor and she had been on the medication regimen for a 
while; thus, it was determined that she could provide valid information about regular 
medication regimen adherence behavior. Her medication use behavior and perception 
about her illness and medication, and DTCA were not very different from others taking 
prescription cholesterol medications. Age of the interviewees ranged from 40 to 84. In 
terms of race, most of interviewees were white; only one African American and one 
Asian were interviewed. All interviewees were at least high school graduates. Two had 
some college-level education, ten interviewees received a bachelor’s degree, two received 
a master’s degree, and one received a doctoral degree. They all resided in Minnesota.  
The time of initial diagnosis of their cholesterol condition ranged from 5 months 
to 26 years ago. The duration of their current cholesterol medication use ranged from 5 
months to 10 years, which means some started taking their medications immediately 
following their cholesterol condition diagnosis. Nine of the interviewees started taking 
cholesterol medications at the time of their diagnosis, whereas others tried other 
alternative options such as increasing physical exercises or eating healthy before 
beginning their prescription drug regimens. However, eventually, all were put on the 
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prescription medication, because their initial attempts to manage cholesterol with 
physical exercises and healthy eating were not enough to reach the healthy level of 
cholesterol.  
 More than half of the interviewees had been taking the same cholesterol 
medications that were first prescribed to them, whereas seven reported changing their 
medications. The most common reasons for change in medication were cost and 
insurance coverage. Specifically, they had to change their medications when their health 
insurance stopped or changed the coverage of the previous medication costs or when the 
generic version of the drug was introduced to the market. In addition, some changed their 
medications because of side effects experiences or because their condition deteriorated. 
The decision to change medication regimens was made by doctors, whom seemed to have 
considered the patients’ report of their condition changes or the patients’ insurance 
coverage. 
Most interviewees reported fully adhering to their current cholesterol-lowering 
medication. They never or rarely forgot to take their medications. Five interviewees 
reported that they sometime forgot to take their medications and the frequency of such 
non-adherence behaviors ranged from one to two times a week to twice a month. One 
interviewee reported that he once forgot to refill his medication. The demographic 
characteristics of interviewees and characteristics of their cholesterol medication use are 
summarized in Table 1. 
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Table 1. Characteristics of Interviewees 
 
Interviewee 
number Gender Age Race Education 
Duration on 
the current 
cholesterol 
medication 
#1 Male 40s White BA (MA 
student) 
2 years 
#2 Female 57 White Some college 2 years 
#3 Female 56 White High school 
(some AP 
courses) 
2 years 
#4 Male 84 White BA 26 years 
#5 Female 55 White BA 
(completing 
2nd degree at 
community 
college) 
5 years 
#6 Female 64 White BA 7~8 years 
#7 Male 70s Black Ph.D. 10 years 
#8 Male 66 White BA (MA 
student) 
8 years 
#9 Male 46 Asian BA 6 months 
#10 Male 62 White MS 10 years 
#11 Female 54 White BA (some 
MA) 
3 years 6 
months 
#12 Male 66 White BA 6 years 
#13 Male 58 White BA (2 BA) 6 years 
#14 Male 46 White GED (BA 
student) 
21 months 
#15 Male 59 White BA 2 years 
#16 Female 54 White MA 5 month 
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4.3.2. Feelings and thoughts about their cholesterol condition 
Many interviewees were well aware (“I’m cognizant of it” [#10]) of the fact that 
they had a health issue that they “need to address,” and “pay attention to (#1),” and that 
the high cholesterol issue was linked to other complications such as heart disease or 
stroke. However, most interviewees did not feel the seriousness of their cholesterol 
condition in their daily lives nor have any strong feeling about it: “No. I feel that I don’t 
think about it that much (#1)”; “Not serious…I am not anxious about it (#7).” In fact, 
they did not seem to think much about their cholesterol condition, did not “worry about 
it” (#1, #6, #9, and #12), were not “anxious” (#7) about it, and it did not “bother” them 
(#16).  
I don’t worry about it…I guess I don’t worry much about it, because of the drugs 
I am taking (#6). 
 
 It wasn’t bothering me before I went to the doctors, and doesn’t bother me after 
 now. I know it’s a big deal but I don't feel (so serious). I just take my medicine. 
 Until the next check-up, I will be better, in the range whatever the doctor said it 
 should be (#16). 
 
 Some interviewees even expressed positive feelings about their condition, because 
their cholesterol medication or other activities to manage their cholesterol level have been 
working successfully. 
 I feel good about it because the medication’s working, and so I feel like I’m 
 gonna be healthier because of the medication (#3). 
 
 My cholesterol? Oh I think it’s OK. I’m OK with it. I think it’s fine. (#4). 
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 Although they did not worry about their cholesterol condition in their daily lives, 
they reported that they were “motivated” (#10), “determined” (#11), and “disciplined” 
(#2 and #16) to continue health behaviors that help control their cholesterol condition, 
including taking a cholesterol medication. For example, #10 reported “I think in parts, it 
keeps me motivated to that (diet change and exercise),” and #8 said, “I don’t really think 
about it very much. At the same time, I would not stop taking statin.” 
 Five interviewees reported that they considered their cholesterol condition to be 
serious and expressed concern or worry about their condition. They tended to have family 
history of cholesterol issues or heart diseases; this may have made them feel more serious 
or anxious about the condition.  
 I think it's quite serious. In that, when I first discovered that it was high, I started 
 looking into my family history. And I found out that I've got a lot of family 
 history on both sides, both my parents and their siblings, and that they have heart 
 conditions, and, you know, either died early or had heart attacks or, you know, the 
 various heart-related ailments. So, umm, because of that, I took it fairly seriously 
 that I need to (#2). 
 
 I take it really seriously because cholesterol runs in my family, both sides.  And so 
 it’s something that I work diligently on and takes the medicine regularly, and 
 would like to be off in another year as completely as possible (#11). 
 
 I am very serious about it… My father died of heart condition. (There’s a) family 
 history. And he died very young, of heart condition. It’s many many years ago. 
 But I am very determined to take care of it, not let it cause any problems from the 
 rest of my family. When people do not have a personal connection, it’s very, sort 
 of, theoretical, philosophical, but it’s not real to them. When you have a personal 
 connection it takes on a whole new meaning as you probably know (#13).  
 
 In addition, female interviewees tended to express more concerns about their 
cholesterol issues, because they thought they should be healthy enough to take care of 
their family or to see their grandchildren grow.  
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 (I am) disciplined because if I'm going to be around to see my grandson grow up, 
 I'd better be doing everything I can to make that happen (#2). 
 
 But, you know, I was younger, I had a whole life, so I didn’t think about it that 
 much. Now, since I am sitting at 55, it’s like, you know, I want it for long because 
 my grandkids are little so I want to watch them, stay with them little longer. My 
 parents both died very young (#5). 
 
 Overall, interviewees tended to be well aware of their cholesterol condition’s 
seriousness, including its complication with other more serious illnesses such as heart 
disease. The awareness of the seriousness of the condition seems to be stronger among 
female interviewees and interviewees who had a family history of cholesterol condition 
or heart diseases. It seems that their awareness of the seriousness of the condition made 
them more motivated to manage their health condition. In addition, for some 
interviewees, they even used positive description about their condition, because their 
cholesterol condition was successfully managed by taking current cholesterol medication. 
Based on the interviewee comments, a series of descriptions about seriousness of the 
cholesterol condition were developed to form adjective pairs for the evaluative illness 
belief accessibility measurement in the main study (e.g., serious - not serious). The words 
or phrases frequently used by the participants to describe their cholesterol condition are 
summarized in Table 2. 
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Table 2. Frequently Used Descriptions for Their Cholesterol Condition 
 
Common  
themes 
Words or phrases 
Awareness Aware, cognizant 
Seriousness Serious, seriously, seriousness 
 Worry, concerned, anxious, bother, bothering 
 Not good, bad 
Complications Heart diseases (heart attack), and stroke 
Family history Hereditary, family history 
Motivation Motivated, determined, disciplined (to keep health behaviors) 
Positive feeling I will be better, feel good (because of the medication) 
 
4.3.3. Feelings and thoughts about their cholesterol medication regimen 
When it comes to overall thoughts about the medication, the most commonly 
used word to describe the cholesterol medication regimen was necessity. Interviewees 
tended to emphasize that taking their cholesterol medications was a requirement for them 
to control their cholesterol condition and ultimately to keep them healthy.  
 It’s “ I have to” “ must.” It’s needed and regimented, so taking it on time, same 
 time everyday. And I’m ….it’s important (#5). 
 
 It’s something you have to do or should do (#9). 
 
 No, it’s a necessity. It is at least a habit. To me, it’s somewhere between essential 
 and critical (#10). 
 
 I have to take it. I need to take it (#14). 
 
 Interviewees also mentioned their feelings about the ease of their medication 
regimen. Many of them thought their medication regimen was easy (#2, #9,#11,#12, and 
#15), simple (#16), convenient (#2 and #11),and not difficult, hard, or troublesome (#9 
and #11) because it just required taking one pill a day. In addition, words or phrases 
about the cholesterol medication cost were also frequently mentioned. Mostly, 
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interviewees who took generics thought it was cheap (#12), or less or not expensive (#4, 
#15) compared to more expensive branded medications such as Zocor or Lipitor.  
 Overall, interviewees reported that their cholesterol medication regimen is 
necessary for managing their health condition. Most of them thought their medications 
were an easy and cheap method to keep them healthy. The descriptions about necessity 
and the ease of regimen were used for developing the adjective pairs measuring the 
evaluative medication belief accessibility measurement in the main study. The most 
frequently used words or phrases to describe the cholesterol medication regimen are 
summarized in Table 3.  
 
Table 3. Frequently Used Descriptions for the Cholesterol Medication Regimen 
 
Common 
themes 
Words or phrases 
Necessity Necessarily, necessity, essential, critical, have to, must, need, 
needed 
 Option, options 
Ease of 
regimen 
Not burdened, troublesome, easy, not difficult, simple, 
comfortable, convenient 
 Hard, such a pain to take it 
Cost Cheap, inexpensive, not expensive 
 
 Benefits of the medication 
 Many of interviewees reported that their cholesterol medication was “working” 
(#1–#3, #6, #11, and #16). They stated they knew the medication was working because 
their cholesterol numbers were in the healthy range, although there was no physical 
condition improvement they could feel.  
 It is working, because those numbers, umm, became lower once I start taking the 
 medication. So therefore, I believe in the medication because of the numbers (#1). 
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 I certainly don’t feel anything. So the only proof comes empirically through the 
 follow-up with my doctor…So based on that it seems like it’s working (#9). 
 
 The belief that their medication was working seemed to convince them it helped, 
or will help, them be alive and remain healthy. Also, they believed it enabled them to 
complete everyday tasks. Such a belief also seemed to make them feel good about the 
medication and be satisfied with it (#1 and #12). 
 We have, mmm, when there is a clear weather, we walk everyday General Mills 
 research center park. Without fail, we leave in the morning,… Walking. And we 
 do that  every morning. Without fail. And in Winter, some exercises we do in the 
 house… I do some exercises… a stationary bicycle, and I ride that for 20 minutes 
 to half hours. Not everyday, but most days. And other than that, I mow the lawn 
 a lot (#4). 
 
 It’s something keep you alive and get you healthier, once you have. And I always 
 keep them in my bedside (#6). 
 I feel good about it because the medication’s working, and so I feel like I’m 
 gonna be healthier because of the medication (#3). 
 
 
 Although physical condition improvements were hardly felt, many interviewees 
reported that they experienced some psychological benefits. The most commonly 
addressed psychological benefit was comforting. Interviewees reported that taking their 
cholesterol medications comforted them to think that their condition would be better 
because of the medication. 
 I think it gives me a peace of mind. … my general concern about my health is 
 decrease because of the fact that I take the medication that ultimately is very 
 effective regulating cholesterol level (#10). 
 
 Reassuring… It’s just a kind of comforting. Just knowing what I’m doing, 
 probably better for me (#15). 
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 Feelings of pride and accomplishment were other reported psychological benefits 
mentioned by one interviewee. His feeling of pride and accomplishment seemed to stem 
from the fact that he was successful in taking care of his health issues.  
 In terms of successfully addressing something in that is a problem…I feel it’s 
 benefit to me because I feel like I am doing something about this issue…  It gets 
 me a sense of pride and accomplishment (#1) 
 
 Overall, experiencing the positive benefits of their medications seemed to 
influence interviewees to have positive views about their cholesterol medications. Some 
interviewees even reported that they were fortunate, lucky, and/or blessed to have their 
medications and living in an era where such medications are available. 
 So in terms of how I feel about taking it, I think I’m little bit lucky that such a 
 thing exist. I can’t imagine 50 year ago, even 20 years ago, people didn’t have the 
 choice (#9). 
 
 I would say what comes to my mind first is that it’s amazing that or able to take 
 something that has effects. I feel lucky that I’m able to do that. I’m able to get that 
 kind of medication, I’m able to potentially prolong my life (#10). 
 
 I personally feel very fortunate to live in that era that we’re living. Because 50 
 years ago, if I had this thyroid problem, my doctor (would) said, “There’s nothing 
 I can do for you.” Now they do surgery and  I take medication for it. It was gonna 
 create all kinds of fix. My cholesterol, 50 years ago, nobody knows about it. A lot 
 of people died of heart attacks (#12). 
 
 In sum, many of the interviewees reported that their medications were effective in 
keeping them living a healthy life. They also expressed various psychological benefits 
they felt from taking their medications, such as feelings of comfort and accomplishment 
of successfully dealing with one’s health issue. Some of the descriptions about 
medication benefits were used for developing adjective pairs measuring the evaluative 
belief accessibility about the medication in the main study (e.g., effective – ineffective; 
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important – unimportant; successful – unsuccessful). The most frequently used words or 
phrases to describe the cholesterol medication benefits are summarized in Table 4.  
 
Table 4. Frequently Used Descriptions for the Cholesterol Medication Benefits 
 
Common 
themes 
Words or phrases 
It's working 
 Working, works, effective, successful, successfully 
 Helping, helps, improve, progress; decreases, lowers (cholesterol level) 
Keep me 
healthy 
Keep (their) health, keep healthy, life, lifestyle, not falling 
over floor, walking, normal 
  Psychological 
benefits Well, good, best, satisfied/satisfying 
 Comforting, reassuring, giving a peace of mind, validation (number) 
 Fortunately, happy, lucky, marvelous, praise, important 
 Accomplishment, pride 
 
 
 Risks of the medication 
 Many of the interviewees were well aware of that side effects are risks linked to 
their medications and they can happen to them. Among interviewees, 10 reported that 
they had never experienced any side effects with their cholesterol medications. Among 
the six interviewees who had experienced side effects from their previous or current 
cholesterol medications, four interviewees answered they had experienced various side 
effect symptoms from their current cholesterol medications, such as flushing (#2 and #9), 
cramping (#14), and muscle pains (#14). Among the 10 interviewees who did not 
experience any side effects from their cholesterol medication, three interviewees reported 
they experienced side effects from other prescription medications. Since not many 
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interviewees experienced side effects from their current cholesterol medications, the 
interview question extended its focus to cover interviewees’ overall experience with any 
of their previous and current prescription medications, including cholesterol medications.  
  When describing their experience with the risks of prescription medications in 
general, the interviewees used various negative adjectives. Experiencing side effects were 
complicated and frustrating (#1), troublesome (#10), and made them a little 
uncomfortable (#6). Two interviewees reported that they were always very careful about 
any kind of risks when they had to start a medication (#4 and #7). One interviewee, who 
thought that the risk of a medication would not happen to him, described his side effect 
experience from a cholesterol medication as an awakening experience (#14). 
 When interviewees felt they had, or might have had, side effects, most tended to 
talk to their doctors about them first. The interviewees who did not report having any side 
effect stated that their doctors already explained the potential side effects to them when 
prescribing their medications. In addition, some interviewees reported they turned to the 
medication information in the container to seek more information and to learn more about 
their conditions before meeting with their doctors. 
 I saw my doctor and complained about the side effects, and I worked with  her to 
 find, different dosage to adjust, or sometimes to change it to the different drugs 
 would address to the same issues (#1). 
 
 Maybe it could’ve been in my head, but I would say that within the 3 months I 
 had some pain in my arm and I look back at the information from the companies. 
 Muscle soreness is the potential symptom, so I went back, and because I was 
 experiencing some muscle soreness in one of my arms and went back to talk to 
 my physician (#11). 
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 Among the interviewees who experienced side effects from their cholesterol 
medications, three did not consider cholesterol medication side effects seriously and 
experiencing the side effects did not influence them to stop their medications. They 
tended to describe their side effect experiences as a little uncomfortable (#6) but not a big 
issue, considering their age or comparing it to the benefits of the medication. Therefore, 
experiencing side effects did not seem to make them hesitant to take their medications. 
Many of them were already informed about the common side effects of their medications 
from their doctors or from their own research.  
 No, you know, if I were younger, it might. You know, if I’m younger, I 
 wouldn’t want the hassle. But I know I have to so it doesn’t change my view 
 now (#5). 
 
 The biggest thing is Advicor is a combination of niacin and statin. So the biggest 
 and most common side effect is a flushing, because of the niacin and combination 
 with statin…And I think I have noticed the touch of flushing. I am used to it in a 
 week (#9). 
 
 I was told, can cause deep muscle ache. I can't remember it was the blood 
 pressure medication or the cholesterol medication. I would say if I experience any 
 of that it was minimal. I move stuff around and I bump into stuff. I have aches 
 now and then. I can't even recall quite how I acquire if I drop something on my 
 leg or something. But in any of them, that’s minimal (#15). 
 
 One interviewee reported that he was currently suffering from cholesterol 
medication side effects. He felt his doctor did not warn him much about the side effects 
of the medication when it was prescribed to him, and he did not think that it would 
happen to him. He stated his side effect experience made him take more prescription 
medications to relieve the symptoms. Although he believed he was suffering from serious 
cholesterol medication side effects, it did not make him quit the original prescription 
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medication regimen. However, it made him hesitant to add another prescription 
medication to his regimen. 
 I wish he would’ve talked more about side effects…Because I always thought 
 when I read about side effects, in my mind, “That’s not gonna happen to me.” … 
 So this has been an awakening for me, an eye opener, thinking especially for 
 statin, it’s very common that people have this problem…In fact I even started 
 taking Celebrex because of the pain. I may not need the Celebrex (#14). 
 
 Q: So does the side effect experience make you hesitate more to add another 
 prescription medication in your regimen? 
 #14: Yes. I recently gain weight after I take Celebrex. And  I take Celebrex 
 because of the side effects from Prevastatin. Anyhow I need to talk to my doctor 
 (#14, about the influence of the side effects).  
 
 Overall, six interviewees reported that they had experienced or were experiencing 
side effects from prescription medications, and four cases were experiences related to 
previous or current cholesterol medications. Although it was uncomfortable and 
troublesome experience to them, their experiences of the medication side effects were not 
severe enough to affect their medication use. Only one interviewee, who was undergoing 
serious side effects from his cholesterol medication, reported that he was very hesitant to 
keep on taking the medication. The descriptions that interviewees used for their various 
prescription medication risk experiences were adopted for developing the measurement 
of the accessibility of evaluative beliefs about medication (e.g., makes me feel better – 
does not make me feel better). The most frequently used words or phrases for describing 
cholesterol medication side effects are summarized in Table 5.  
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Table 5. Frequently Used Descriptions for Risks of Prescription Medications 
(Including Cholesterol Medication Experiences) 
 
Common 
themes 
Words or phrases 
Pains, 
symptoms 
Example of symptoms: Muscular, back, joint, arm, leg, spine, 
bowel pains; cramping, diarrhea, flushing 
 Could be happening/not happening to me 
 Caused, causes, come/coming from (medication) 
 Symptom(s), problem(s) 
 Not feeling very good, bad, not good 
Actions 
taken 
Talk, tell or report to their doctor 
 Look back to information/ learn more about side effects/read about 
side effects 
 Switch, change (medication) 
 Hesitate to take/quit (the regimen) 
 Be/get used to it 
Positive 
descriptions 
Minimal, normal, common, feel any difference, and not affected 
 
Negative 
descriptions 
Worried, complicated, frustrated, awakening, careful, troublesome, 
and uncomfortable 
 
4.3.4. Transition from the maintenance to habit Stage  
According to Rothman et al. (2011), maintenance-stage patients consciously make 
a decision to continue engaging in their current health behavior, while habit-stage 
patients are automatically repeating their behavior. Habit is usually defined as an 
automatic behavioral sequence that consists of cues, rewards, and responses (Duhigg 
2012). It is formed and performed to achieve certain goals (Verplanken and Aarts 1999). 
For example, patients’ habit of taking a cholesterol medication is to achieve a goal of 
healthy living. Verplanken and Orbell (2003) pointed out three characteristics of habits: 
(1) habitual behaviors are performed frequently; (2) habit is formulated by specific 
frequent and successfully linked cues and behaviors; and (3) habit has an automatic 
nature. Based on the conceptualization by Rothman et al. (2011) and Verplanken and 
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Orbell (2003), three interviewees belonged to the maintenance stage and 13 belonged to 
the habit stage. Table 6 summarizes each interviewee’s medication adherence stage. 
  
Table 6. Interviewees’ Medication Adherence Stage 
 
Interviewee number Medication adherence stage 
#1 Habit 
#2 Habit 
#3 Maintenance 
#4 Habit 
#5 Habit/still forget sometimes 
#6 Habit 
#7 Habit/ but still conscious 
#8 Habit/demands some efforts 
#9 Maintenance 
#10 Habit 
#11 Habit 
#12 Habit 
#13 Habit 
#14 Maintenance 
#15 Habit/still needs to remember 
#16 Habit 
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Characteristics of the maintenance-stage patients 
  Consistent with Rothman et al.’s (2011) conceptualization of maintenance 
behavior, the maintenance-stage interviewees were more conscious about the overall 
procedure of taking their medications and weighed the benefits and risks of their 
medication over other options (#3 and #14). Particularly, they tended to view that they 
were responsible for their health and their family’s health decision-making (#3, #9, & 
#14), and actively sought health information from various sources (#9 & #14), or paid 
close attention to prescription drug advertisements (#3) to learn more about their 
medications.  
 Also, the maintenance-stage interviewees tended to show less strong habit 
characteristics than the habit-stage interviewees. First, the maintenance-stage 
interviewees reported that their cholesterol medication regimen still required conscious 
effort to remember. #9 regarded his medication regimen as burdensome, and something 
easy not to do. Second, they tended not to take their medications regularly as instructed 
by their doctors. For example, #14 said, “I didn’t follow that advice because I forget to 
take my medication sometimes. So I take some medication twice a day and some of it one 
time a day.”   
 Characteristics of habit-stage patients 
 Compared to the maintenance-stage interviewees, the habit-stage interviewees 
tended to show stronger habit characteristics. Particularly, they described their cholesterol 
medication regimen as a daily/nightly routine, which took place at the same time and 
place regularly. Also, they reported that their cholesterol medication use as an automatic 
behavior that did not require any conscious effort. 
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 When the habit-stage interviewees were asked to describe their cholesterol 
medication intake behavior, the most frequently mentioned characteristic was 
“regularity.”  “Habit” (#2, #8, #10, and #12) and “routine” (#1, #7, #8, #12, #13,and #15) 
were the most commonly used nouns to describe their medication intake behavior. Some 
interviewees were very reluctant to use the term habit to describe their medication intake, 
because they felt that habit has some compulsive (#1), addictive (#15), and/or reflexive 
(#7) aspects. Some interviewees who chose the term “habit” emphasized it was a 
“routine” that did not have addictive aspects (#13). Some interviewees even regarded 
their medication regimen as a “ritual” (#1) or described that they were very religious 
about it (#12). “Consistent” (#10) was another word that interviewees chose to describe 
their cholesterol medication intake.  
 In addition, the habit-stage patients reported that they usually took the medication 
at the same time and the same place, which is the key characteristic of strong 
habit.(Duhigg, 2012; Versplanken and Orbell 2003). Doing so enabled them to connect 
their cholesterol medication intake behavior to certain contextual cues, such as a specific 
time or place or other routine behavior patterns.  
 I take it every morning, at the same time approximately when I go to work, it’s 
 usually 6 in the morning. On weekends, it usually 8 or 9. It kept in the medicine 
 cabinet. I take one tablet every morning, usually at the same time (#11) 
 
 I take it everyday. I take at the same time everyday. I have to be honest with you, 
 I take two medications, one fore blood pressure and one for cholesterol…It’s the 
 same routine I get up, and go through sort of early morning  routine, shave, make 
 my coffee, and take my medication same time, pretty much  every morning (#13). 
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 Because the habitual cholesterol medication intake was linked to other contextual 
cues and some patterns of behavior linked to the habit, when there was a situation in 
which their regular routine pattern was broken (e.g., traveling), some interviewees 
mentioned, they had hard time continuously taking their medication. 
 I’ve not missed to take it for a long time. The times when I was most susceptible 
 to forgetting to take it are when I was traveling, if I go on vacation. You have to 
 almost create a new routine when you’re on vacation. And since most people         
 don’t travel regularly, it’s harder to form a travel routine as like a home routine 
 (#13). 
 
 Third characteristic of habit is that it is performed automatically. As Versplanken 
and Orbell (2003) indicated, most habit-stage interviewees tended to think that they took 
their cholesterol medications without much conscious effort; they regarded it as an 
automatic behavior. The most common analogy they used to describe their medication 
intake was “tooth brushing” (#2 and #9), because it is an automatic, routine behavior.  
 Although their cholesterol medication intake showed all three characteristics of 
habits, some habit-stage interviewees still had some of the characteristics from the 
maintenance stage, For instance, #10 took his cholesterol medication religiously and 
automatically, but he still weighed the benefits and risks of taking his medication and 
actively sought information about the medication from various sources. 
 Transition between the maintenance and habit stages 
 When it comes to the exact time frame for transitioning from the maintenance to 
habit stage, substantial individual differences were found. The time to form a medication 
intake habit ranged from immediately after starting the regimen to 6 years. The 
interviewees could be divided into three groups in terms of how long it took for them to 
form a habit with their cholesterol medication regimen.  
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The first group formed the habit of taking their medications immediately after 
starting their medication regimen. They tended to use a pillbox or smartphone app as an 
aid and had been on other medication regimens previously. The mentioned aid devices 
helped them form a habit right away. Pillboxes (#4, #11, #15, and #16) helped plan 
medication intake and see the achievement of following the regimen. Smartphone apps 
(#9 and #15) helped them by sending a reminder when it was time for medication intake 
and showing the trend of their cholesterol number as a record of improvement. In 
addition, individuals who were already on a regular medication regimen tended to move 
immediately to the habit stage.  
 I think it was immediate. And the reason it was immediate because I was already 
 in the process of taking other drugs in the morning, so I just added it to the 
 cocktails, so to speaking. It was another ingredient of the cocktail. That’s all 
 (#1). 
 
 The second group took longer to move to the habit stage. Typically, the 
cholesterol medication was their first prescription drug regimen. For example, #9 (still in 
the maintenance stage after taking the medication for six months), #11 (took 3 to 4 weeks 
to move to the habit stage), #12 (took 2 to 3 years), #13 (took a few months), and #15 
(took few refill cycles) reported that the cholesterol medication was their first regular 
prescription medication regimen.  
 It took a while, early on, to just get into the routine of when to take it (#15). 
 
 A few months going through all of the cycles of getting to take it and taking it 
 every morning, reordering it and so on. And then keep going through all of the 
 different cycles of getting and taking the medications, and then it becomes a 
 routine, and it’s just a second habit for me (#13) 
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 Some interviewees in this group reported that the transition to the habit stage took 
a while because it was very difficult for them to change their pre-existing lifestyle. In 
addition, some of them were in a situation that made forming a regular routine difficult. 
For example, #5 (took 5 to 6 years to move to the habit stage) was attending community 
college and her schedule was constantly changing. Side effect experience was another 
barrier for the maintenance stage patients’ transition to the habit stage. #14 (still in the 
maintenance stage after taking the medication for 21 months) believed he was suffering 
from serious side effects from his cholesterol medication, which made him hesitant to 
stay on the regimen. 
 I am having side effects. I didn’t know that it was side effect. My doctor didn’t 
 really warn me or he did warn me but I didn’t hear about statins that can cause 
 muscle pains or joint pain. And because of the five broken vertebrates, I have 
 pinch  nerves, and I have a arthritis in my spine. I am in pain a lot to be…I’ve 
 always have muscle pains, but I believe there was a noticeable difference  (after 
 start taking statins). I am thinking of doing an experiment of not taking it for 1 or 
 2 weeks. And then I would see during the 1 or 2 weeks if my pain gets better, then 
 I will know for sure it’s a statin (#14). 
 
 The final group was intentionally reluctant to move to the habit stage, even 
though they acknowledged that taking their medications was a part of their routine. 
Typically, they seemed to have a negative attitude toward any type of medications, 
particularly about the potential risks involving side effects. They were very cautious 
about any side effects, which was the main reason they did not want to make their 
medication regimen a habit.  
 I just hate taking drug. So if I can get away, without taking drug, even it’s 
 Tylenol…if I had a choice between Lipitor and not doing anything, I would not 
 do anything. Where this drug has less side effect, so I am more willing to take it. 
 So depends on side effects… Like I said, sometimes I feel that side effects are 
 worse than taking… not taking the drug (#3). 
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 Worried about it? When first taking any medication, I am careful to be aware of 
 any side effects (#7). 
 
  Overall, the interview results reveal some distinctive characteristics that separate 
maintenance-stage and habit-stage patients. Compared to the maintenance-stage 
interviewees, the habit-stage interviewees tended to show stronger habit characteristics, 
such as performing their medication intake regularly at a specific time and place, without 
conscious efforts. Although they clearly showed all the habit characteristics, some habit-
stage interviewees still consciously weighed the benefits and risks of taking their 
medication. Moreover, substantial individual differences were found in the between-stage 
transitions and some individuals showed both maintenance and habit stage 
characteristics.  
Although this qualitative study was aimed at obtaining information to determine 
the specific time frame for maintenance and habit stages, the findings suggest that trying 
to determine patients’ medication adherence stages using some kind of time frame 
measurements would be not only difficult but also inappropriate. Therefore, survey 
respondents for the main study will not be screened based on their medication regimen 
time period.  
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4.4. Summary 
In-depth interviews with 16 patients who were taking a cholesterol medication were 
conducted to develop the measurement of the main study and to determine the ways to 
systematically determine different stages of medication adherence. Cholesterol 
medication was chosen for the study context because its characteristics were well suited 
for testing the media priming effects of DTC ads. Ten men and six women who were 
currently taking a prescription cholesterol medication were interviewed. 
The results showed that interviewees were aware of that their cholesterol 
condition was a health problem, but most did not feel serious about the condition in their 
everyday lives. They only knew about their cholesterol problem when their doctors 
notified them of their cholesterol numbers from the lab test. Some female interviewees or 
interviewees with family history tended to feel more serious about the cholesterol 
condition in their daily life, while some had positive views about their health condition 
because they believed that their current cholesterol medications helped them to be 
healthy. The findings from the interviewees’ feelings and thoughts about their cholesterol 
condition were used for developing the evaluative belief about the illness severity 
measurement in the main study.  
When it came to their cholesterol medication regimen, many interviewees 
reported that it was something necessary and important to control their cholesterol 
condition. Many of them felt that taking their cholesterol medications was a simple and 
inexpensive way to keep them healthy. Most interviewees reported that their medication 
was working, although they could not physically feel the benefits. They knew it was 
working through the numbers received from their doctors, and some reported to believe 
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that the medication helped them to make it possible to live a healthy life. Most benefits of 
the cholesterol medication mentioned by the interviewees were psychological. 
Interviewees felt reassured and had a peace of mind after taking their medications and felt 
pride and accomplishment in that they were successfully handling their health problem. 
Some of the interviewees who were satisfied with their medications, said that they were 
lucky and fortunate to have such a treatment option. The descriptions about their 
medications were used for developing the evaluative belief about the drug measurement. 
Only six interviewees experienced side effects from their previous or current 
prescription medications, including their cholesterol medications. They described their 
side effect experience as uncomfortable and troublesome, and most of them reported this 
type of experience to their doctors. Even though it was not a good experience, many of 
them reported that experiencing the medication side effects did not affect their 
medication intake; their side effect experiences were just a little discomfort and they had 
already been informed about the side effects from their doctors. The descriptions about 
the prescription medication risk experiences were used for developing the measurement 
of the evaluative belief about the drug measurement.  
 Finally, the results from the in-depth interviews identified key characteristics of 
maintenance- and habit-stage patients, which were in line with those identified in relevant 
research literature. Among 16 interviewees, three showed strong maintenance-stage 
characteristics and 13 demonstrated habit-stage characteristics. The most distinctive 
differences between the maintenance-stage and habit-stage interviewees were the 
different levels of habit characteristics that their medication intake behavior showed. The 
maintenance-stage interviewees reported that they carefully contemplated the benefits 
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and risks of their medication intake. On the other hand, the habit-stage interviewees 
tended to show all three habit characteristics suggested by Versplanken and Orbell 
(2003); they took their medications regularly at a specific time and place, without 
conscious thought or efforts. However, some habit-stage interviewees still consciously 
evaluated their medications, which suggests that some habit-stage patients might still 
have some maintenance stage characteristics.  
 In addition, individual differences were found in the between-stage transitions. 
Broadly, three types of maintenance-to-habit transition were identified from the in-depth 
interview results. The first type of interviewees formed the habit of taking the medication 
immediately. They tended to use a pillbox or smartphone app as an aid and had a pre-
existing regimen. The second type of interviewees took longer to move to the habit stage. 
Typically, the cholesterol medication was their first prescription drug regimen. Some of 
them were in the situation that prevented them from taking their medications, such as 
having an irregular schedule or suffering from cholesterol medication side effects. The 
final type of interviewees was intentionally avoiding the transition to the habit stage, even 
though they described that taking the medication was a part of their routine. They were 
very aware of the negative aspects of a medication, such as its potentially addictive 
aspects and the risk of side effects.  
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Chapter 5  
MAIN STUDY METHOD: ONLINE SURVEY 
Based on the literature review and the preliminary in-depth interview results, an online 
survey was conducted to test the hypotheses and to investigate research questions. The 
sample was patients who were currently taking oral prescription blood thinners. The 
online survey was approved by the University of Minnesota Institutional Review Board 
(IRB). 
 
5.1. Study Context, Target Population, and Sampling 
The target population for the online survey was changed to patients who were taking 
blood thinners due to the DTCA expenditure trend change at the time the main study was 
conducted.  According to Ad$pender data for May 2014, Eliquis, a prescription blood 
thinner, was the second most heavily advertised drug, following Cialis (Kantar Media, 
2014). The total expenditure for the top three prescription blood thinners (i.e., Eliquis, 
Pradaxa, and Xarelto) was over $85 million between June and August 2014 while the 
total expenditure for all cholesterol-lowering medications was about $15 million.  
Blood thinners are medications used to reduce blood clot formation. They are 
prescribed to treat various blood clot problems, including atrial fibrillation (AFib or AF), 
heart attack, stroke, heart valve diseases, pulmonary embolism (PE; blood clots in the 
lungs), and deep vein thrombosis (DVT; blood clots in the legs). They are also prescribed 
to maintain health after heart valve surgeries, hip replacement surgery, and knee 
replacement surgery. In general, blood clot problems have characteristics that are similar 
to cholesterol problems, which make the drug type equivalently suitable for this study. 
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Skipping doses of a blood thinner medication does not have immediate consequences that 
patients can physically feel. Blood thinners are mainly used to prevent blood clots, which 
are unobservable from outside the body and do not involve immediate pain or other 
symptoms. However, in the long run, skipping doses can cause a patient’s condition to 
become fatal. Generally, non-adherence to a blood thinner regimen can increase a 
person’s chance of suffering from heart diseases or stroke.  
There are two types of blood thinners: oral medications and injections. Injectable 
forms of blood thinners, such as heparin, are usually prescribed to patients for a shorter 
period of time than oral medications and healthcare providers administer the injection. 
On the other hand, oral blood thinners, such as warfarin and Eliquis, are prescribed for 
patients who need to manage their condition for a longer period of time, and the 
medications are taken by patients without healthcare providers’ assistance. Therefore, 
oral blood thinners were selected as this study’s context. Aspirin, one of the most popular 
types of blood thinners prescribed to prevent heart diseases, was excluded from this study 
because consumers do not need a prescription to buy most aspirin products. 
The target population for this study is American patients ranging in age from 45 
to 80 and who are currently taking oral prescription blood thinners. The target population 
was selected based on the following reasons. First, the blood thinner use rate increases 
with age. The Centers for Disease Control and Prevention (CDC) and the National Center 
for Health Statistics’ report on prescription drugs showed that, from 2010 to 2012, 1.8% 
of Americans 18 or older were taking blood thinners; that rate dramatically increased to 
18.1% for Americans 60 years of age or older (National Center for Health Statistics, 
2014). In 2012, a report from the American Heart Association also showed that the 
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incident rate for AFib, one of the medical conditions for which blood thinners are 
prescribed, increased with age (Roger et al. 2011). In addition, many previous DTCA 
studies have focused on patients that are 45 years of age or older because of the 
prevalence of various chronic diseases among this demographic group. Therefore, the 
lower age limit for this study’s sample is set at 45.  
One of the issues to consider when studying the aging population is the potential 
memory issue that older people might have. Generally, aging is related to a decrease in 
both encoding and retrieval (Zacks, Hasher, and Li 2000) and to having false memories 
(Roediger and McDermott 2000). One study demonstrated that media exposure 
recognition error increased with age. In particular, after being exposed to TV news 
stories, adults who were 70 or older had more recognition test errors than adults under 70 
(Southwell and Langteau 2008). Considering the potential memory issues associated with 
aging, this study set the upper limit of the participants’ age to 80. 
A volunteer sample of 240 participants meeting the sample inclusion criteria was 
purchased from the Qualtrics Panel Management service. The Qualtrics online survey 
panels consist of individuals who volunteer to participate in Qualtrics surveys, and they 
were recruited from 62 partnered sampling service companies (e.g., Survey Sampling 
International [SSI]). Potential participants are recruited from the Internet and respondents 
are compensated by Qualtrics Panel Management. 
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5.2. Survey Procedure  
The online survey was designed using Qualtrics, available through the University of 
Minnesota’s institutional subscription. The link for the online survey was sent to the 
individuals in the study sample via the Qualtrics Panel Management service. An informed 
consent form was presented on the first page of the questionnaire and the survey began 
with three screening questions based on the participant eligibility criteria and the study’s 
quota requirement. The eligibility criteria included: (1) age between 45 and 80 years old; 
and (2) currently taking a prescription oral blood thinner. The quota requirement was 
equal number of men and women, so the study sample would represent the actual gender 
ratio of American patients with blood clot problems (Center for Disease Control and 
Prevention 2014). 
After the screening and quota questions were answered, the respondents answered 
questions about the medication adherence measures and belief accessibility measures. 
The belief accessibility measures were presented before the DTCA exposure frequency 
measures in order to prevent a potential priming effect during the survey process. 
Questions measuring the control variables were presented at the end. 
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5.3. Measurements 
5.3.1. Medication adherence  
 Adherence to the blood thinner refers to a patient’s compliance with the 
prescribed medication regimen to control his/her blood clot problem. As discussed 
earlier, three types of medication non-adherence behaviors have been identified and 
investigated in previous research: (1) nonfulfillment, (2) nonpersistent, and (3) 
nonconforming (Gellad et al. 2009). Because the present study focuses on the patients’ 
nonpersistent and nonconforming medication adherence, respondents who at least started 
their medication by filling their first prescription were recruited. Therefore, there is no 
case of nonfulfillment in this study’s sample.  
To measure the level of medication regimen adherence, this study modified 
Morisky, Ang, Krousel-Wood, and Ward’s (2008) 8-item measurement for medication 
adherence. Morisky et al.’s original 8-item measurement consists of seven yes/no 
questions and one 5-point scale. This measurement was validated through several steps 
(Morisky et al. 2008) and has been used in a number of previous studies (Ingles et al. 
2015; Newman-Casey et al. 2015; Krousel-Wood, Munter, Islam, Morisky, and Webber 
2012; Gatti, Jacobson, Gazmararian, Schmotzer, and Kripalani 2009). The eight original 
measurements consist of various types of medication non-adherence and the reasons for 
non-adherence. Among them, only the measurement items about the degree of 
medication adherence were selected and modified for the present study, because the 
current study mainly focus on the degree of patient medication adherence behavior. 
Respondents reported yes or no to the first five statements assessing whether or not 
respondents  had taken various types of medication non-adherence behaviors (e.g., Do 
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you sometimes forget to take your blood thinner pills?; Have you ever forgot to refill the 
prescription for your blood thinner?). The 5-point scale item measured how often the 
respondents had difficulty remembering to take their blood thinner medication based on a 
scale of 0 = Never to 4 = Very Often. The measurement items are listed in Appendix A.  
5.3.2. Belief accessibility  
 According to previous priming effect studies, belief accessibility can be 
operationalized in two ways: 1) correlation approach and 2) response time approach. The 
correlation approach has been widely used in studies on both temporary and chronic 
belief accessibility effects and measures accessibility to cognitive units in terms of the 
degree to which the primed beliefs are used in the subsequent decision-making, such as 
an evaluation of the primed topic (Higgins 1996). More recently, many priming effect 
studies have used the response time approach to measure belief accessibility. This 
approach is based on the assumption that more cognitively accessible units move more 
quickly into a person’s short-term memory, which becomes more readily available for the 
subsequent evaluation process (Bassili 1995). The present study uses both approaches to 
measure descriptive and evaluative belief accessibility.  
First, applying the correlation approach, survey respondents’ descriptive beliefs 
about the illness and the drug were measured by a series of yes/no questions; 12 
statements regarding the blood clot problem and the blood thinner benefits and risks (e.g., 
Blood clots could cause a stroke; blood thinners could cause severe bleeding; blood 
thinners reduce the risk of stroke) were given to respondents one at a time and they were 
asked to choose yes or no to each given statement. Each type of descriptive beliefs (about 
the illness, about the drug benefits, and about the drug risks) was measured using four 
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statements. The statements were developed based on the existing prescription blood 
thinner ads and the preliminary interview results. Descriptive belief statements about the 
illness and the drug benefits consisted of two correct and two incorrect statements and the 
statements about the drug risks consisted of three correct statements and one incorrect 
statement.  
The statements for the descriptive beliefs about the illness included: 1) blood clots 
could cause a stroke; 2) blood clots could cause indigestion; 3) blood clots could cause 
damages to the lungs and other organs; and 4) blood clots can be treated with dietary 
changes. The statements for the descriptive beliefs about the drug benefits included: 1) 
blood thinners lower the chance of blood clot formation; 2) blood thinners could improve 
lung functions; 3) blood thinners reduce the risk of stroke; and 4) blood thinners could 
improve digestion. The statements for the descriptive beliefs about the drug risks 
included: 1) blood thinners could cause severe bleeding; 2) blood thinners could cause a 
person to bruise easily; 3) blood thinners could cause blindness; and 4) stopping blood 
thinners could increase the risk of stroke. 
Applying the same correlation approach, evaluative beliefs about the illness 
severity and the drug were measured using a series of adjective pairs. For the evaluative 
beliefs about the illness severity, the respondents were instructed to choose one of the 
adjectives from each presented pair that best described their blood clot problem. Every 
adjective pair was presented using the statement, “My blood clot problem is….” The 
adjective pairs were displayed one pair at a time and a total of seven pairs were 
presented, including: 1) treatable – untreatable; 2) manageable – unmanageable; 3) severe 
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– not severe; 4) serious – not serious; 5) important – unimportant; 6) significant – 
insignificant; and 7) not frightening – frightening.  
Evaluative beliefs about the drug were measured using the same measurement 
approach. The adjective pairs were presented one at a time, with the statement, “My 
blood thinner (is)…” The pairs included: 1) beneficial – harmful; 2) safe – unsafe; 3) 
effective – ineffective; 4) successful – unsuccessful; 5) important – unimportant; 6) 
essential – optional; and 7) makes me feel better – makes me feel worse.  
Second, following the response time approach, the response time for each of the 
descriptive and evaluative belief accessibility questions was measured using the response 
latency technique. The response latency technique has been widely used to measure 
attitude accessibility (Mulligan, Grant, and Mockabee 2003). The assumption underlying 
this technique is that attitude accessibility reflects how strongly an object and its 
evaluation are linked in a person’s memory (Fazio 1995, as cited in Mulligan et al. 2003), 
and the response time to the attitude object indicates the strength of the linkage. 
Specifically, this measurement technique is designed based on the assumption that the 
respondents’ response time will be shorter when they encounter more accessible attitude 
items than when they encounter less accessible attitude items. Belief accessibility can be 
measured in the same way because beliefs are a component of attitude, and many 
response time attitude measurements consist of belief statements. Therefore, this study 
uses the same response latency technique used in previous attitude accessibility studies 
(e.g., Elliot et al. 2015; Grant, Mockabee, and Monson 2010; Mulligan et al. 2003).  
The response time of each of the descriptive and evaluative belief questions was 
measured using a response time checking function in Qualtrics. First, the baseline 
    
 
89 
response time for each respondent was assessed using a baseline statement, “Both men 
and women could have blood clot problems.” Then, response time to each of the 12 
descriptive belief statements and 14 evaluative belief adjective pairs, by measuring the 
time (in millisecond) each respondent took to answer each question. The example of the 
response time measurement is shown in Appendix B. 
5.3.3. DTCA exposure frequency 
To measure the individual-level exposure to DTC ads for prescription blood 
thinners, two types of advertising exposure frequency measures were administered: 1) the 
category-level DTCA exposure frequency, and 2) the brand-level DTCA exposure 
frequency.  The category-level DTCA exposure frequency refers to the number of 
respondents’ exposure to overall prescription blood thinner ads from Newspaper, TV, 
magazine, radio and the Internet. Respondents’ exposure to the blood thinner ads from 
the five media were measured by asking “ How often have you seen ads for blood 
thinners in the past 3 months?” The questions provided six frequency options, ranging 
from 1 = Never to 6 = Almost every day. If a respondent answered “1 = Never” to all five 
of the media, the survey system let the respondent skip the subsequent questions 
measuring the brand-level DTCA exposure frequency.  
The brand-level DTCA exposure frequency was measured using the same 6-point 
scales (1 = Never, 6 = Almost every day) for three blood thinner brands that were 
currently advertised during the data collection period or had been advertised within three-
month time window before the data collection. The brand list included three oral 
prescription blood thinners, Eliquis, Pradaxa, and Xarelto that were currently advertised 
at the time of the data collection.  The measurement items are listed in Appendix A.  
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5.3.4. Control variables 
 In addition to the key variables, various control variables were measured. Based 
on the in-depth interview results and a review of previous research on media priming 
effect and the medication adherence literature, the control variables were selected 
because they are likely to significantly influence media priming effects or patients’ 
beliefs about their illnesses and medications, and their medication regimen adherence. 
For example, patients’ relationship with their doctors has been found to be related to 
patient medication adherence in the previous medication adherence literature (Gellad et 
al., 2009; Nguyen et al., 2009; Wu et al., 2008) and the in-depth interview results. 
Previous medication adherence literature has shown a positive relationship between the 
level of patients’ satisfaction and trust with their healthcare providers and their 
medication adherence (Gellad et al., 2009). In the in-depth interviews as well, it was 
found that patients tended to adhere to their medication regimen better when they trusted 
and were satisfied with their current doctors and they had a tendency to conform to their 
doctor’s medical decisions.  
 The included control variables were demographics (age, sex, household income, 
education, and race), medication-related variables (health insurance status, out-of-pocket 
cost, duration of blood thinner intake, number of prescription medication taken, side 
effect experience, and the level of satisfaction with and trust in the current doctor), and 
media use variables (general media use, health media use, and health media attention). 
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 Demographic variables 
Age, sex, household income, education, and race were measured as demographic 
variables. The screening question asking, “What is your age as of today?” was used as the 
age measurement and the quota question asking, “What is your sex?” was used for 
measuring respondents’ sex.  Income, education, and race were measured using questions 
adopted from the 2010 US Census (U.S. Census Bureau, 2010). Annual household 
income was measured with a 9-point scale, ranged from $ 0 to $ 9,999 to $200,000 or 
more. Education was measure with a 10-point scale, ranged from “No schooling 
complete, or less than 1 year” to “Doctoral degree (PhD, EdD, etc).” Race was measured 
with two measurements. Respondents were first asked whether they are of Hispanic, 
Latino, or Spanish origin, then asked, respondents’ race was by asking “ What is your 
race?” with six categories. 
Medication-related variables 
Health insurance status, out-of-pocket cost, the duration of blood thinner intake, 
the number of prescription drugs taken, side effect experience, and the level of 
satisfaction with and trust in the current doctor were measured as the medication-related 
variables that can affect respondents’ descriptive and evaluative beliefs and their 
medication adherence behavior.  
Health insurance status was measured by a yes/no question asking whether they 
had health insurance including private health insurance plans. Out-of-pocket cost for 
purchasing the current blood thinner was measured by two questions. The first question 
asked “How many days of supply do you get for your current blood thinner?” Then, the 
second question asked “How much do you co-pay (the cost you pay in addition to the 
    
 
92 
insurance coverage) for your current blood thinner?” The respondents were asked to write 
down the cost per their typical days of supply answered in the previous question.  
Duration of blood thinner use was measured by a single open-ended question 
asking “Approximately how long have you been taking your current blood thinner?”   
The number of prescription drugs taken was measured by first asking respondents were 
asked whether they were taking prescription medications other than a blood thinner. If 
they reported “yes,” they were instructed to record how many prescription medications 
(including blood thinner) they were currently taking. 
In addition, side effect experience was measured. Side effect experience was 
measured by a single yes/no question asking whether the respondents had experienced 
any side effects with their current blood thinners. . For trust in and satisfaction with the 
current healthcare provider, the respondents were asked to rate their level of satisfaction 
with and trust in the current doctor who checks their blood clot problems using a 5-point 
scale (Satisfaction: 1 = Very dissatisfied to 5 = Very satisfied; Trust: 1 = Highly distrust 
the doctor to 5 = Highly trust). 
Media use variables 
Media use variables were also included as control variables, because individuals 
who more frequently use media that are heavily used for the prescription blood thinner 
DTCA have a higher possibility of being exposed to more DTC ads than those who use 
such media less frequently, which could affect this study’s dependent variables.  The 
level of media use was measured in 3 ways: general media usage, health media usage, 
and health media attention.  
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General media use was measured by asking the respondents about their use of five 
types of media. The hours and minutes that each respondent spent on reading newspapers 
and magazines, watching TV, listening to the radio, and using the Internet were 
measured. Because media use patterns tend to be different on weekdays and weekends, 
the media usage time were asked separately for typical weekdays and weekends.  
Second, health media use was measured by asking “About how often have you 
read or heard such health content from the following media in the past 3 months?” in 
each of the five media. Health-related media usage was included because prescription 
medication DTC ads are more likely to appear in health-related content. For example, 
Xarelto, a prescription blood thinner, is more frequently appeared in the heart health 
section of WebMD. The level of health-related media usage was measured with 6-point 
scales, ranging from 1 = Never to 6 = Almost every day. 
Finally, health media attention, which was about the level of attention paid to 
each of the five health-related media, was measured by asking how much attention 
respondents paid to health or medical topics in five media (newspapers, TV, magazines, 
radio, and the Internet). A 5-point scale (from 1 = None to 5 = A lot) was used for 
measuring the attention level. 
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Chapter 6 
DATA ANALYSIS & RESULTS 
6.1 Sample Characteristic 
6.1.1. Demographic characteristic 
The average age of the study sample was 63.10 and half of the sample was male 
(50%, n = 120). The respondents’ median household income fell between $35,000 and 
$49,999, and the median education attainment level, some college education or 
Bachelor’s degree (BA). In terms of race, a majority of the respondents were Non-
Hispanic whites (90%, n = 216). The descriptive statistics of sample’s demographic 
characteristics are presented in Table 7. 
 
Table 7. Demographic Characteristics of the Study Sample 
 
Demographic 
variables Descriptive statistics 
Age Mean = 63.10 (SD = 8.30) 
Sex Male = 120 (50%) 
Female = 120 (50%) 
Household income Median: 5 ($35,000–$49,999) 
Education 
Median: 5 (some college education or BA)  
Race Non-Hispanic white = 216 (90%) 
Hispanic white = 9 (3.8%)  
Black = 9 (3.8%) 
Asian = 1 (.4%)  
Native Hawaiian or Pacific Islander = 1 (.4%)  
Mixed = 4 (1.7%)  
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 6.1.2. Medication-related characteristics 
 The survey respondents’ medication-related characteristics were also examined.  
Most of the respondents showed at least some form of medication non-adherence 
behavior with their current blood thinners (63.3%, n  = 151). The average duration of 
blood thinner intake was 63.56 months. The average out-of-pocket cost for purchasing 
the current blood thinner was $12.24 per month, and most of the respondents had a health 
insurance (95%, n = 228). Most the respondents did not experience side effects from 
taking their current blood thinners (82.1%, n = 197), and they tended to show a high level 
of satisfaction with and trust in their current doctor (satisfaction: M = 4.43, SD = .99; 
trust: M = 4.57, SD = .84). The descriptive statistics of the respondents’ medication-
related characteristics are summarized in Table 8. 
 
Table 8. Descriptive Statistics of the Respondents’ Medication-related 
Characteristics 
 
Medication-related variables Descriptive statistics Range 
Medication adherence Mean = 7.46 (SD = 1.77) 0 = full non-adherence ~ 9 = full adherence 
Duration of prescription 
blood thinner use Mean = 63.56 (SD = 63.06) 0 ~ 342 months 
Prescription blood thinner 
cost per month 
Mean = $ 12.24 (SD = 
29.40) $ 0 ~$ 290 
Health insurance status 
Had a health insurance = 
228 (95%)   
Number of prescription 
medications used  Mean = 5.88 (SD = 3.94) 1 ~ 29 
Side effect experience 
Yes = 43 (17.9%)  
Satisfaction with doctor Mean = 4.43 (SD = .99) 1 = very dissatisfied ~ 5 = very satisfied 
Trust in doctor Mean = 4.57 (SD = .84) 1 = highly distrust the doctor ~ 5 = highly trust 
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6.2. Characteristics and Computation of Key Variables 
This study tests the relationships among three key variables: Medication adherence, 
DTCA exposure frequency, and belief accessibility. This section explains how each of 
the key variables was operationalized and computed. 
6.2.1. Operationalization and computation of medication adherence 
As explained in Chapter 5, patient medication adherence was operationalized as 
the extent to which respondents adhere to their prescription blood thinner regimen, and 
measured by five yes/no questions about the various types of medication non-adherence 
behavior, and one, 5-point scale measuring the difficulty of remembering the medication 
regimen. A medication adherence score was created by counting the number of “no” 
answers to the five yes/no questions asking about medication non-adherence behavior, 
and summating the score with the answer from the one 5-point scale question (reverse-
coded).  
6.2.2. Operationalization and computation of belief accessibility 
Previous priming studies have applied the correlation approach (i.e. measuring the 
correlation between the primed cognitive constructs and the cognitive outcomes such as 
evaluations and attitudes toward an object) and the response time approach (i.e., 
measuring the response time to the given choices to the question). Based on the previous 
study approaches, the current study adopted both approaches to measure patients’ belief 
accessibility, and operationalized the content and the response time to each descriptive 
and evaluative beliefs about the illness and the drug. Particularly, four different types of 
belief accessibility variables were computed for each of the beliefs about the illness and 
beliefs about the drug: (1) content of descriptive beliefs; (2) response time of descriptive 
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beliefs; (3) content of evaluative beliefs; and (4) response time of evaluative beliefs. 
Detailed information on the operationalization and computation of belief accessibility 
variables is presented in Table 9 and 10.  
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Table 9. Operationalization and Computation of Descriptive belief accessibility 
 
Descriptive beliefs Conceptual definition Operationalization 
About the illness How easily an individual can access to 
accurate beliefs about their illnesses  
Content: The accuracy of a respondent’s beliefs 
about the blood clot problem (the higher, the 
more accurate) 
Response time: How quickly a respondent 
responded to each of the statements about the 
descriptive beliefs about the blood clot problem 
(the quicker, the more accessible) 
About the drug benefits How easily an individual can access to 
accurate beliefs about their drug benefits 
Content: The accuracy of a respondent’s beliefs 
about the blood thinner benefits (the higher, the 
more accurate) 
Response time: How quickly a respondent 
responded to each of the statements about the 
descriptive beliefs about the blood thinner 
benefits (the quicker, the more accessible) 
About the drug risks How easily an individual can access to 
accurate beliefs about their drug risks, such 
as side effects 
Content: The accuracy of a respondent’s beliefs 
about the blood thinner risks (the higher, the 
more accurate) 
Response time: How quickly a respondent 
responded to each of the statements about the 
descriptive beliefs about the blood thinner risks 
(the quicker, the more accessible) 
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Table 10. Operationalization and Computation of Evaluative Belief Accessibility 
 
Evaluative beliefs Conceptual definition Operationalization 
About the illness severity How easily an individual can access to 
positive or negative beliefs about their 
illness severity 
Content: The valence of a respondent’s beliefs 
about his/her blood clot problem (the higher, the 
more severe) 
Response time: How quickly a respondent 
responded to each of the adjective pairs about the 
evaluative beliefs about his/her blood clot 
problem severity (the quicker, the more 
accessible) 
About the drug How easily an individual can access to 
positive or negative beliefs about their 
drugs 
Content: The valence of a respondent’s beliefs 
about his/her blood thinner (the higher, the more 
positive)  
Response time: How quickly a respondent 
responded to each of the adjective pairs about the 
evaluative beliefs about his/her blood thinner 
(the quicker, the more accessible) 
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Descriptive belief accessibility in terms of the belief content accuracy was 
computed by counting the number of correct answers for each belief category (0 = all 
incorrect, 4 = all correct). Response time of each of the descriptive belief accessibility 
categories was calculated as follows: First, the raw score of the response time to each 
descriptive belief statement was converted to seconds. The raw score of the baseline 
response time measure was subtracted from each converted raw score for adjustments. 
After the subtraction, the adjusted response time scores within each belief category were 
summated. As a result, response time scores were generated for descriptive beliefs about 
the illness, about the drug benefits, and about the drug risks. 
Evaluative belief accessibility variables in terms of the belief content were 
computed in the following ways. For evaluative beliefs about the illness severity, each 
positive adjective selection was coded to -1, while each negative adjective selection was 
coded to 1. Then, the scores were summated to create an evaluative belief about the 
illness severity score in which higher numbers indicate more severe illness beliefs. The 
summated scores for the evaluative beliefs content about blood clot problem severity 
ranged from -7 = not at all severe) to 7 = very severe.  
For the content of evaluative beliefs about the drug, each positive adjective 
selection was coded to 1 and each negative adjective selection was coded to -1; and then 
the scores were summated to create an evaluative beliefs about the drug score in which 
higher numbers indicate more positive beliefs. Among the seven adjective pairs used for 
measuring evaluative beliefs about the drug, one pair (makes me feel better vs. doesn’t 
make me feel better) was dropped from the computation, because the answer to that 
question showed different patterns than those for the other six items. As a result, the 
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summated scores for the evaluative beliefs about the drug ranged from -6 = all negative 
to 6 = all positive.  
To compute the response time variables for evaluative belief accessibility, the 
same method used for the response time of descriptive beliefs was applied: The baseline 
response time score were subtracted from each raw response time score of the evaluative 
adjective pairs; then, the adjusted response time scores within each belief category were 
summated to create response time variables of evaluative beliefs about the illness and the 
drug. 
6.2.3. Operationalization and computation of DTCA exposure frequency  
As described in Chapter 5, DTCA exposure frequency was measured by two sets 
of 6-point scales: (1) category-level DTCA exposure frequency (DTCA exposure 
frequency for newspapers, magazines, TV, radio, and the Internet) and (2) brand-level 
DTCA exposure frequency (DTCA exposure frequency by brands for three advertised 
blood thinner brands). Since prescription blood thinner ads appeared on TV, magazine, 
and the Internet at the time of the data collection, respondents’ exposure to the blood 
thinner ads from TV, magazine, and the Internet were used for the data analysis.  Each 
DTCA exposure frequency were ranged from 1 = Never to 6 = Almost everyday. Because 
of the weak correlation among the individual DTCA exposure frequency variable scores, 
they were not combined but used as individual variables for data analysis. 
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6.2.3. Operationalization and computation of media-related variables as 
control variable 
General media use and health media use were measured in the average hours and 
minutes of using five media (newspapers, magazines, TV, radio, and the Internet) on 
weekdays and on weekends. All measured media usage time data were converted to 
minutes. Then, the general media use variable was created by averaging the minutes of all 
five media use on weekdays and weekends. The health media use variable was created by 
averaging the health media use minutes on weekdays and weekends. In addition, the 
health media attention variable was created by averaging the individual data indicating 
attention paid to health-related content in five different media. 
 
6.3. Descriptive Statistics of Key Variables 
Key variables’ descriptive statistics were examined and basic statistical assumptions for 
later analyses were checked, including normality.  
6.3.1. Medication adherence 
The medication adherence scores ranged from 0 = full non-adherence to 9 = full 
adherence. Many of the respondents showed at least some types of medication non-
adherence behavior with their current blood thinners (62.9%, n  = 151). The mean 
medication adherence score was 7.46 (SD = 1.77; skewness = -1.55; kurtosis = 2.65). 
Overall, most respondents tended to be highly adherent to their blood thinner regimen. 
The histogram of medication adherence score distribution is presented in Figure 3. 
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Figure 3. Histogram of Medication Adherence Scores 
 
6.3.2. Belief accessibility 
Content of descriptive beliefs. Scores of the three types of descriptive belief 
content variables ranged from 0 = completely inaccurate to 4 = completely accurate. The 
mean score for descriptive beliefs about the illness was 3.23 (SD = .82; skewness = -.63; 
kurtosis = -.74), 3.15 (SD = .81; skewness = -.29; kurtosis = -1.42) for descriptive beliefs 
about the drug benefits, and 3.66 (SD = .54; skewness = -1.32; kurtosis = .79) for 
descriptive beliefs about the drug risks. Overall, descriptive statistics showed that most 
respondents tended to have accurate beliefs about their blood clot problems and blood 
thinners. The histogram of the score distribution for each type of descriptive beliefs is 
presented in Figures 4 through 6. 
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Figure 4. Histogram of Content of Descriptive Beliefs about the Illness 
 
Figure 5. Histogram of Content of Descriptive Beliefs about the Drug Benefits 
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Figure 6. Histogram of Content of Descriptive Beliefs about the Drug Risks 
 
 
Response time of descriptive beliefs. The scores of the response time for the three 
types of descriptive beliefs ranged from -35.00 to 21.43. The scores include negative 
numbers because of the response time adjustment based on the baseline response time, as 
described in the earlier section. The mean score for the descriptive beliefs about the 
illness was .34 (SD = 6.61; skewness = -.83, kurtosis = 4.46), for the descriptive beliefs 
about the drug benefits it was -1.07 (SD = 6.16; skewness = -. 61; kurtosis = 2.47), and 
for the drug risks -2.44 (SD = 6.15; skewness = -.80, kurtosis = 5.89). The histograms of 
the response time scores (presented in Figures 7 through 9) suggested that each 
distribution of response time scores was concentrated around 0, which means that the 
average response time scores were not very different from the baseline response time. 
Compared to the baseline response time, the average response time scores for both 
descriptive beliefs about the drug benefits and drug risks were smaller, which means that 
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the two types of descriptive beliefs were relatively more accessible than the baseline. The 
average response time for descriptive belief about the illness was slightly larger than the 
baseline response time.  
 
Figure 7. Histogram of Response Time of Descriptive Beliefs about the Illness 
 
 
Figure 8. Histogram of Response Time of Descriptive Beliefs about the Drug 
Benefits 
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Figure 9. Histogram of Response Time of Descriptive Beliefs about the Drug Risks 
 
Content of evaluative beliefs. The computed scores of evaluative beliefs about the 
illness severity ranged from – 7 = not severe at all to 7 = strongly severe, and the average 
score was -3.42 (SD = 2.11, skewness = .02 kurtosis = -.60). The scores of evaluative 
beliefs about the drug ranged from -6 = very negative  to 6 = very positive, and the mean 
score was 5.78 (SD = .77, skewness = -4.20, kurtosis = 20.54). Overall, the distribution of 
the content of evaluative beliefs scores showed that respondents generally believed their 
blood clot problems were not severe and that respondents seemed to have a very positive 
view about their blood thinners. The distribution of scores for the content of evaluative 
beliefs regarding the illness severity and the drug is presented in Figures 10 and 11. 
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Figure 10. Histogram of Content of Evaluative Beliefs about the Illness Severity 
 
 
Figure 11. Histogram of Content of Evaluative Beliefs about the Drug 
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 Response time of evaluative beliefs. The mean response time score for the 
evaluative beliefs about the illness severity was -4.79 (SD = 10.46, skewness = -1.03, 
kurtosis = 5.29), and the mean score for the evaluative beliefs about the drug was -9.87 
(SD = 9.46, skewness = -.94, kurtosis = 3.25). The negative average scores for both types 
of evaluative beliefs indicate that evaluative beliefs about the illness severity and about 
the drug were relatively more accessible than the baseline. The distribution of the 
response time scores for each type of evaluative beliefs is presented in Figures 12 and 13. 
The descriptive statistics of all belief accessibility variables are summarized in Table 11. 
 
Figure 12. Histogram of Response Time of Evaluative Beliefs about the Illness 
Severity 
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Figure 13. Histogram of Response Time of Evaluative Beliefs about the Drug 
Table 11. Descriptive Statistics of Belief Accessibility Variables 
 
  N Mean (SD) Range 
Content of 
descriptive 
beliefs 
   
About the 
illness 
240 3.23 (.82) 0 ~ 4 
About the drug 
benefits 
240 3.15 (.81) 0 ~ 4 
About the drug 
risks 
240 3.66 (.54) 0 ~ 4 
Response time of 
descriptive 
beliefs 
About the 
illness 
195 .27 (6.28) -33.25 ~ 16.77 
About the drug 
benefits 
195 -1.07 (6.16) -27.18 ~ 15.51 
About the drug 
risks 
195 -1.57 (6.15) -35.00 ~ 21.43 
Content of 
evaluative beliefs 
About the 
illness severity 
240 -3.42 (2.11) -7 ~ 7 
About the drug 240 5.78 (.77) -6 ~ 6 
Response time of 
evaluative beliefs 
About the 
illness severity 
195 -4.79 (10.46) -62.67 ~ 29.96 
About the drug 195 -9.87 (9.46) -55.43 ~ 14.67 
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6.3.3. DTCA exposure frequency 
Category-level DTCA exposure frequency. Although category-level DTCA 
exposure frequency was measured for five different media, given that only three media 
were used for prescription blood thinner DTCA around the data collection time period, all 
analyses for testing this study’s hypotheses and research questions included category-
level DTCA exposure frequency variables for only the applicable three media (TV, 
magazines, and the Internet). The mean score for the TV DTCA exposure frequency was 
3.9 on a 6-point scale (SD = 1.73, skewness = -1.03, kurtosis = 5.29), for magazine 
DTCA exposure frequency 2.13 (SD = 1.36, skewness = 1.12, kurtosis = .36), and for 
Internet DTCA exposure frequency 2.66 (SD = 1.64, skewness = .52, kurtosis = -1.02). 
The descriptive statistics suggested that respondents were more frequently exposed to 
DTCA in TV than in the other media. The score distribution for each of the category-
level DTCA exposure frequency variables is presented in Figures 14 through 16. 
 
Figure 14. Histogram of Category-level DTCA Exposure Frequency: TV 
    
 
112 
 
Figure 15. Histogram of Category-level DTCA Exposure Frequency: Magazine 
 
Figure 16. Histogram of Category-level DTCA Exposure Frequency: Internet 
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Brand-level DTCA exposure frequency. The mean score for Eliquis ad exposure 
frequency was 2.76 on a 6-point scale (SD = 1.71, skewness = .45, kurtosis = -1.18), for 
Pradaxa ad exposure frequency 2.98 (SD = 1.68, skewness = .22, kurtosis = -1.31), and 
for Xarelto ad exposure frequency 3.17 (SD = 1.77, skewness = .11, kurtosis = -1.35). 
The results showed that respondents were not very frequency exposed to the three blood 
thinner brands’ ads. In a relative sense, ad exposure frequency was slightly higher for 
Xarelto ads than the other two brands. The score distributions for the three brand ads are 
presented in Figures 17 through 19. The overall descriptive statistics of all DTCA 
exposure frequency variables are summarized in Table 12. 
 
Figure 17. Histogram of Brand-level DTCA Exposure Frequency: Eliquis 
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Figure 18. Histogram of Brand-level DTCA Exposure Frequency: Pradaxa 
 
 
Figure 19. Histogram of Brand-level DTCA Exposure Frequency: Xarelto 
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Table 12. Descriptive Statistics of DTCA Exposure Frequency Variables 
 
  Mean (SD) 
Category-level DTCA exposure 
frequency 
TV 3.90 (1.73) 
Magazine 2.13 (1.36) 
Internet 2.66 (1.64) 
Brand-level DTCA exposure 
frequency 
Eliquis 2.76 (1.71) 
Pradaxa 2.98 (1.68) 
Xarelto 3.17 (1.77) 
 
 The descriptive statistics of the key variables and their histograms showed that 
none of the key variables had a normal distribution. In preparation for the hypotheses 
testing analyses, several normalization processes were attempted, including log-
transformation and square root transformation, but the transformation process did not 
significantly improve the normality of the variables. Therefore, this study decided to use 
the original scores of the key variables for hypotheses testing. While necessary caution 
should be exercised in interpreting analysis results that might be affected by statistical 
testing assumption violations, this study’s analysis approaches (multiple regression) are 
considered acceptable given that multiple regression analysis is relatively more flexible 
and robust than other parametric tests (Cohen and Cohen 1983; Hair, Black, Babin, and 
Anderson 2009). 
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6.4. Testing Priming Effects of DTCA Exposure Frequency on Patients’ Belief 
Accessibility  
H1 through RQ1 test priming effects of DTCA exposure frequency on patients’ beliefs 
about their illnesses and the drugs. Specifically, H1 predicted a positive relationship 
between DTCA exposure frequency and patients’ descriptive beliefs about the illness, H2 
predicted a positive relationship between DTCA exposure frequency and the descriptive 
beliefs about the drug benefits, and H3 predicted a positive relationship between DTCA 
exposure frequency and the descriptive beliefs about the drug risks. H4 hypothesized a 
positive relationship between DTCA exposure frequency and patients’ evaluative beliefs 
about the illness severity, and RQ1 was posed about the relationship between DTCA 
exposure frequency and the evaluative beliefs about the drug.  
 Before testing each hypothesis and addressing the research question, bivariate 
correlation analyses were conducted to explore the relationships among key variables. 
After the correlation analyses, multivariate hierarchical regression analyses were 
conducted. 
6.4.1. Correlation analysis of the relationship between DTCA exposure 
frequency and belief accessibility 
 The first set of correlation analyses was performed to explore the relationship 
between DTCA exposure frequency and the content of descriptive and evaluative beliefs, 
and the second set of correlation analyses was conducted to explore the relationships 
between DTCA exposure frequency and the belief response time variables. Table 13 
presents the results from correlation between DTCA exposure frequency and content of 
descriptive and evaluative beliefs. 
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Table 13. Correlations between Category-level DTCA Exposure Frequency and 
Content of Descriptive and Evaluative Beliefs 
 
 TV Magazine Internet 
Descriptive beliefs about the 
illness .04  -.27 ** -.28 ** 
Descriptive beliefs about the 
drug benefits .04  -.30 ** -.25 ** 
Descriptive beliefs about the 
drug risks -.01  -.20 ** -.18 ** 
Evaluative beliefs about the 
illness severity .14  .13 * .18 ** 
Evaluative beliefs about the 
drug -.05  -.08 
 -.14 * 
     *p < .05; **p < .01 
 
 
 The correlation analyses between DTCA exposure frequency and the content of 
beliefs showed the generally negative relationship between DTCA exposure frequency 
and the accuracy of descriptive beliefs. All three descriptive beliefs (descriptive beliefs 
about the illness, the drug benefits, and the drug risks) were negatively related to DTCA 
exposure via magazine and the Internet. The results seem to suggest that respondents who 
were more frequently exposed to DTCA tended to have less accurate beliefs about their 
blood clot problems and blood thinners. However, for the most heavily used DTCA 
medium, TV, no significant correlation between the two was found.  
For evaluative beliefs about the illness and the drug, only very weak and limited 
correlations were found between DTCA exposure frequency and evaluative beliefs (see 
Table 13). Weak, positive relationships were found between DTCA exposure via 
magazines and the Internet, and patients’ evaluative beliefs about their illness severity. In 
other words, respondents who were more frequently exposed to DTCA tended to evaluate 
their blood clot problem more severely. However, the relationship was not significant for 
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TV DTCA. For evaluative beliefs about the drug, very weak, negative correlations were 
found only for the Internet DTCA exposure frequency.  
 The correlation analysis of the relationship between the brand-level DTCA 
exposure frequency and the content of beliefs showed no significant relationship. The 
results are summarized in Table 14. 
 
Table 14. Correlations between Brand-level DTCA Exposure Frequencies and 
Content of Descriptive and Evaluative Beliefs  
 
 Eliquis Pradaxa Xarelto 
Descriptive beliefs about the 
illness .00  -.08  -.03  
Descriptive beliefs about the 
drug benefits .08  .01  .03  
Descriptive beliefs about the 
drug risks -.01  .02  -.01  
Evaluative beliefs about the 
illness severity .11  .10  .11  
Evaluative beliefs about the 
drug .04  .04  .04  
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 Correlation analysis results for the relationships between DTCA exposure 
frequency and response time of descriptive and evaluative beliefs showed no significant 
correlation for any of the variable pairs. The correlation results are presented in Tables 15 
and 16. 
 
Table 15. Correlations between Category-level DTCA Exposure Frequencies and 
Response Time of Descriptive and Evaluative Beliefs  
 
 TV Magazine Internet 
Descriptive beliefs about the 
illness .01  -.02  .02 
Descriptive beliefs about the 
drug benefits -.03  .08  .00 
Descriptive beliefs about the 
drug risks -.12  -.00  -.02 
Evaluative beliefs about the 
illness severity -.04  -.03  -.02 
Evaluative beliefs about the 
drug -.04  .04  .03 
 
Table 16. Correlations between Brand-level DTCA Exposure Frequencies and  
Response Time of Descriptive and Evaluative Beliefs  
 
 Eliquis Pradaxa Xarelto 
Descriptive beliefs about the 
illness .00  .03  .01  
Descriptive beliefs about the 
drug benefits .07  .02  .04  
Descriptive beliefs about the 
drug risks .00  -.05  -.05  
Evaluative beliefs about the 
illness severity .10  .01  .05  
Evaluative beliefs about the 
drug .07  -.01  .03  
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6.4.2. Relationships between control variables and belief accessibility 
 Next, the relationships among various control variables and the belief 
accessibility were investigated. Demographic variables (age, sex, income, education, and 
race), media use (general media use, health media use, and health media attention), and 
medication-related variables (the duration of blood thinner intake, out-of-pocket cost, the 
number of prescription drug taken, side effect experience and  health insurance status) 
were examined for their potential effects on belief accessibility.  
 First, correlation analyses between continuous, control variables and the content 
of descriptive and evaluative beliefs were conducted and the results are presented in 
Table 17. The results showed that health media use and health media attention were 
significantly and negatively related to the accuracy of all three types of descriptive 
beliefs, out-of-pocket cost was negatively related to accuracy of descriptive beliefs about 
the illness, and the number of prescription drugs taken was positively related to accuracy 
of two descriptive beliefs. The results suggest that respondents with more frequent use of 
and paid more attention to health content in media  tended to have less accurate beliefs 
about their blood clot problems and blood thinners. For evaluative beliefs, only age and 
health media attention had weak correlation with evaluative beliefs about illness severity. 
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Table 17. Correlations between Control Variables and Content of Descriptive and 
Evaluative Beliefs  
 
 Descriptive 
beliefs about 
the illness  
Descriptive 
beliefs about 
the drug 
benefits 
Descriptive 
beliefs about 
the drug risks 
Evaluative 
beliefs about 
the illness 
severity 
Evaluative 
beliefs about 
the drug 
Age .11 .07 .13 -.19 ** -.02 
 
Income -.01 -.09 -.05 .04 .08 
 
Education -.08 -.05 -.12 -.04 .09 
 
General media use -.05 -.07 -.03 -.06 -.12 
 
Health media use -.26 ** -.24 ** -.24 ** .12 -.02 
 
Health media 
attention -.25 ** -.26 ** -.22 ** .18 ** -.09 
 
Duration of blood 
thinner intake .07 .04 .08 -.08 .07 
 
Out-of-pocket cost -.13 * -.12 -.05 -.01 -.10 
 
Number of 
prescription drug 
taken 
.17 * .14 * .11 .00 .07 
 
 
The relationships between categorical control variables and content of beliefs 
were investigated by conducting a series of t-tests. First, Table 18 presents t-test results 
comparing content of descriptive and evaluative beliefs between men and women. 
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Overall, no meaningful difference was found between men and women, with only one 
belief variable, descriptive beliefs about the drug benefits, showing a significant 
difference. 
 
Table 18. T-test Results for Content of Descriptive and Evaluative Beliefs by Sex 
 
Beliefs Sex N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Female 120  3.32  0.82   1.65(238)  
Male 120  3.14  0.82   
 
Descriptive 
beliefs about the 
drug benefits 
Female 120  3.74  0.48  2.29(228.13) * 
Male 120  3.58  0.59   
 
Descriptive 
beliefs about the 
drug risks 
Female 120  3.25  0.76  1.84(238) 
 
Male 120  3.06  0.85   
 
Evaluative 
beliefs about the 
illness severity 
Female 120  -3.38  2.03  .24(238) 
 
Male 120  -3.45  2.19   
 
Evaluative 
beliefs about the 
drug 
Female 120  5.80  0.71  .34(238) 
 
Male 120  5.77  0.83  1.65(238) 
 
  *p < .05 
 
The comparisons between non-Hispanic white respondents and others also 
showed no meaningful difference between the two racial groups in terms of their 
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descriptive and evaluative beliefs about their blood clot problems and blood thinners. As 
presented in Table 19, the only significant between-group difference was found for 
evaluative beliefs about the drug, indicating that non-Whites tended to have slightly more 
positive beliefs about their blood thinners. 
 
Table 19. T-test Results for Content of Descriptive and Evaluative Beliefs by Race 
 
Beliefs Race N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Non-
Hispanic 
White 
216  3.26  0.82   -1.97(238)  
Other 24  2.92  0.83    
Descriptive 
beliefs about the 
drug benefits 
Non-
Hispanic 
White 
216  3.68  0.53  -1.16(238)  
Other 24  3.54  0.59    
Descriptive 
beliefs about the 
drug risks 
Non-
Hispanic 
White 
216  3.18  0.80  -1.25(238)  
Other 24  2.96  0.86    
Evaluative  
beliefs about the 
illness severity 
Non-
Hispanic 
White 
216  -3.41  2.09  -.20(238)  
Other 24  -3.50  2.30    
Evaluative  
beliefs about the 
drug 
Non-
Hispanic 
White 
216  5.88  0.40  4.39(215.0) ** 
Other 24  6.00  0.00    
 **p < .01 
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No significant difference was found in descriptive and evaluative beliefs between 
those who had experienced side effects from their current blood thinners and those had 
not. The results are presented in Table 20. 
 
Table 20. T-test Results for Content of Descriptive and Evaluative Beliefs by Side 
Effect Experience 
 
Beliefs Side effect N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Experience 
43  3.21  0.83   .17(238)  
No 
experience 197  3.24  0.82   
 
Descriptive 
beliefs about the 
drug benefits 
Experience 
43  3.63  0.49  .46(238) 
 
No 
experience 197  3.67  0.55   
 
Descriptive 
beliefs about the 
drug risks 
Experience 
43  3.19  0.79  -.28(238) 
 
No 
experience 197  3.15  0.82   
 
Evaluative 
beliefs about the 
illness severity 
Experience 
43  -3.33  1.80  -.31(238) 
 
No 
experience 197  -3.44  2.17   
 
Evaluative 
beliefs about the 
drug 
Experience 
43  5.67  0.75  1.03(238) 
 
No 
experience 197  5.81  0.77   
 
 
The t-test results comparing those with health insurance and those without it 
showed some significant differences in their descriptive beliefs about their illness and 
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drugs (see Table 21). The mean scores of descriptive beliefs were significantly different 
between those who had health insurance and those who did not. Generally, respondents 
with health insurance tended to have more accurate beliefs about their blood clot 
problems and the blood thinners. No significant difference was found for the two 
evaluative belief variables. 
 
Table 21. T-test Results for Content of Descriptive and Evaluative Beliefs by Health 
Insurance Status 
 
Beliefs 
Health 
Insurance N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Insurance 228  3.26  0.82   2.83(238) ** 
No 
insurance 12  2.58  0.67    
Descriptive 
beliefs about the 
drug benefits 
Insurance 228  3.68  0.53  2.75(238) ** 
No 
insurance 12  3.25  0.62   
Descriptive 
beliefs about the 
drug risks 
Insurance 228  3.18  0.81  2.15(238) * 
No 
insurance 12  2.67  0.78    
Evaluative 
beliefs about the 
illness severity 
Insurance 228  -3.42  2.05  -.10(11.49) 
 
No 
insurance 12  -3.33  3.17    
Evaluative 
beliefs about the 
drug 
Insurance 228  5.80  0.74  .82(11.41) 
 
No 
insurance 12  5.50  1.24    
  **p < .01; *p < .05 
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 Next, relationships between various control variables and response time of 
descriptive and evaluative beliefs were investigated using a series of correlation analyses 
and t-tests. The results showed no significant relationships between the control variables 
and the belief response time variables. The correlation analyses results and the t-test 
results are summarized in Tables 22 through 26. 
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Table 22. Correlations between Control Variables and Response Time of 
Descriptive and Evaluative Beliefs  
 
 Descriptive 
beliefs 
about the 
illness  
Descriptive 
beliefs 
about the 
drug 
benefits 
Descriptive 
beliefs 
about the 
drug risks 
Evaluative 
beliefs 
about the 
illness 
severity 
Evaluative 
beliefs 
about the 
drug 
Age -.02  -.11  -.06  .01  -.07  
Income .05  .04  -.02  -.10  .08  
Education -.05  -.06  -.02  -.12  .02  
General media 
use .06  -.02  .03  .01  .06  
Health media 
use -.04  .04  -.01  -.07  .05  
Health media 
attention -.05  .07  -.03  -.07  .05  
Duration of 
blood thinner 
intake 
-.01  -.04  -.10  -.03  -.08  
Monthly cost of 
blood thinner -.01  .02  -.02  -.07  .05  
Number of 
prescription 
drug taken 
-.01  -.08  -.00  -.04  -.09  
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Table 23. T-test Results for Response Time of Descriptive and Evaluative Beliefs by 
Sex 
 
Beliefs Sex N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Female 118  0.86  6.40   1.23(227)  
Male 111  -0.21  6.82   
 
Descriptive 
beliefs about the 
drug benefits 
Female 114  -0.99  5.45  .37(220) 
 
Male 108  -1.32  7.47   
 
Descriptive 
beliefs about the 
drug risks 
Female 117  -0.82  6.98  .76(226) 
 
Male 111  -0.15  6.63   
 
Evaluative 
beliefs about the 
illness severity 
Female 115  -3.97  10.70  1.75(224) 
 
Male 111  -6.55  11.52   
 
Evaluative 
beliefs about the 
drug 
Female 113  -8.99  9.90  1.54(215) 
 
Male 104  -11.27  11.88  1.23(227) 
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Table 24. T-test Results for Response Time of Descriptive and Evaluative Beliefs by 
Race 
 
Beliefs Race N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Non-
Hispanic 
White 
207  0.25  6.61   .63(227)  
Other 22  1.19  6.75    
Descriptive 
beliefs about the 
drug benefits 
Non-
Hispanic 
White 
201  -1.06  6.38  -.65(220)  
Other 21  -2.02  7.68    
Descriptive 
beliefs about the 
drug risks 
Non-
Hispanic 
White 
208  -1.26  6.86  .73(226)  
Other 20  -0.09  6.32    
Evaluative 
beliefs about the 
illness severity 
Non-
Hispanic 
White 
204  -5.13  11.32  -.44(224)  
Other 22  -6.22  9.74    
Evaluative 
beliefs about the 
drug 
Non-
Hispanic 
White 
200  -10.10  10.63  .09(215)  
Other 17  -9.85  14.42    
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Table 25. T-test Results for Response Time of Descriptive and Evaluative Beliefs by 
Side Effect Experience 
 
Beliefs Side effect N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Experience 42  -0.14  7.30   .52(227)  
No 
experience 187  0.45  6.46    
Descriptive 
beliefs about the 
drug benefits 
Experience 43  -0.52  7.32  -.71(220) 
 
No 
experience 179  -1.30  6.30    
Descriptive 
beliefs about the 
drug risks 
Experience 43  -0.45  7.42  -.76(226) 
 
No 
experience 185  -1.32  6.67    
Evaluative 
beliefs about the 
illness severity 
Experience 42  -4.36  8.94  -.56(224) 
 
No 
experience 184  -5.43  11.62    
Evaluative 
beliefs about the 
drug 
Experience 38  -9.34  9.59  -.46(215) 
 
No 
experience 179  -10.24  11.21    
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Table 26. T-test Results for Response Time of Descriptive and Evaluative Beliefs by 
Health Insurance Status 
 
Beliefs 
Health 
Insurance N Mean SD t (df) 
Descriptive 
beliefs about the 
illness 
Insurance 218  0.29  6.58   -.57(227)  
No 
insurance 11  1.44  7.53    
Descriptive 
beliefs about the 
drug benefits 
Insurance 214  -1.19  6.37  -.43(220) 
 
No 
insurance 8  -0.18  9.95    
Descriptive 
beliefs about the 
drug risks 
Insurance 217  -1.21  6.75  -.55(226) 
 
No 
insurance 11  -0.06  8.20    
Evaluative 
beliefs about the 
illness severity 
Insurance 215  -5.12  11.14  .70(224) 
 
No 
insurance 11  -7.51  11.99    
Evaluative 
beliefs about the 
drug 
Insurance 206  -10.10  10.88  -.12(215) 
 
No 
insurance 11  -9.70  12.37    
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6.4.3. Regression analyses for testing H1 through RQ1: Relationship between 
DTCA exposure frequency and content of the beliefs  
 The results from the preliminary bivariate correlation analyses between DTCA 
exposure frequency and the belief accessibility variables indicated no significant 
relationship between DTCA exposure frequency (both category-level and brand level) 
and belief accessibility measured in response time. Also, no significant relationship was 
found between brand-level DTCA exposure frequency and content of beliefs. Therefore, 
multivariate regression analyses for testing H1 through RQ1 were performed only for the 
relationship between category-level DTCA exposure frequency and content of descriptive 
and evaluative beliefs about the illness and the drug.  
For each regression analysis, control variables were selected based on the 
preliminary bivariate analysis results. Since age, sex, health media use, health media 
attention, out-of-pocket cost, and the number of prescription drugs taken were found 
significantly related to some of the descriptive and evaluative belief content variables, 
they should be included as control variables. Between health media use and health media 
attention, a rather strong correlation was found (r = .67, p < .01), suggesting a potential 
multicollinearity issue. As health media attention was significantly correlated with belief 
accessibility variables more than health media use, it was decided to enter this variable. 
 A series of hierarchical regression analyses were conducted and control variables 
and independent variables were entered for all five hierarchical regression analyses in the 
following ways: In the first block, age, sex, health media attention, out-of-pocket cost, 
and the number of drugs taken were entered as control variables. Three category-level 
DTCA exposure frequency variables (TV, magazine, and the Internet) were entered in the 
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second block as independent variables predicting the content of descriptive and 
evaluative beliefs about the illness and the drug. 
 First, to test H1, the relationship between category-level DTCA exposure 
frequency and  content of descriptive beliefs about the illness was examined. As 
presented in Table 27, the results showed a significant positive relationship between TV 
DTCA exposure frequency and the accuracy of descriptive beliefs about the illness (β = 
.22, p < .01). It means that respondents who were exposed more frequently to DTCA via 
TV tended to have more accurate beliefs about their blood clot problems, which is in line 
with the hypothesis. Contrary to the expectation, however, a significant negative 
relationship was found between Internet DTCA exposure frequency and the accuracy of 
descriptive beliefs about the illness (β = -.23, p < .01), which suggested that respondents 
who were more frequently exposed to DTCA on the Internet tended to have less accurate 
beliefs about their blood clot problems. None of the control variables were significantly 
related to the dependent variable. Overall, the results provide rather mixed support for 
H1, with TV DTCA exposure frequency having effects consistent with the hypothesis but 
Internet DTCA exposure frequency showing an opposite direction effect on descriptive 
beliefs about the illness.  
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Table 27. Hierarchical Regression for Testing the Relationship between Category-
level DTCA Exposure Frequency and Content of Patients’ Descriptive Beliefs about 
the Illness (N = 234) 
 
 Predictors       Beta 
Block 1. Control variables Age -.03 
 Sex -.09 
 Health media attention -.11 
 Out-of-pocket cost -.09 
 Number of drugs taken .11 
Block 2. Category-level 
DTCA exposure frequency 
TV .22 ** 
Magazine -.14 
Internet -.23 ** 
 df = 8, MS = 3.54, F = 6.04, p < .01; adjusted R2 = .15 
 **p < .01 
 
 Next, another hierarchical regression analysis tested H2, which predicted a 
positive relationship between DTCA exposure frequency and the accuracy of descriptive 
beliefs about the drug benefits. The results showed a significant positive relationship 
between TV DTCA exposure frequency and the accuracy of descriptive beliefs about the 
drug benefits (β = .22, p < .01), but negative relationships between magazine and Internet 
DTCA exposure frequency variables and the accuracy of beliefs (magazine DTCA: β = -
.20, p < .05; Internet DTCA: β = -.20, p < .05). The results suggest that respondents who 
were exposed more frequently to TV DTCA tended to have more accurate beliefs about 
their blood thinner benefits, but those who were exposed to magazine and Internet DTCA 
more frequently tended to have less accurate beliefs. Overall, the findings offer mixed 
support for H2, with only TV DTCA exposure frequency showing the predicted effect on 
the accuracy of beliefs about the drug benefits. The results are summarized in Table 28. 
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Table 28. Hierarchical Regression for Testing the Relationship between Category-
level DTCA Exposure Frequency and Content of Patients’ Descriptive Beliefs about 
the Drug Benefits (N = 234) 
 
 Predictors        Beta 
Block 1. Control variables Age -.07 
 Sex -.10 
 Health media attention -.10 
 Out-of-pocket cost -.08 
 Number of drugs taken .06 
Block 2. Category-level 
DTCA exposure frequency 
TV .22 ** 
Magazine -.20 * 
Internet -.20 * 
 df = 8, MS = 3.35, F = 5.90, p < .01; adjusted R2 = .17 
 **p < .01; *p < .05 
 
 The third hierarchical regression analysis tested H3, which predicted a positive 
relationship between DTCA exposure frequency and the accuracy of descriptive beliefs 
about the drug risks. The results, presented in Table 29, demonstrated no significant 
relationships between them. Among the control variables, however, sex and health media 
attention were negatively related to the accuracy of descriptive beliefs about the drug 
risks (sex: β = -.14, p < .05; health media attention: β = -.16, p < .05). In other words, 
females and respondents who paid less attention to health content in various media 
tended to have more accurate beliefs about their blood thinner risks. Thus, H3 was not 
supported.  
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Table 29. Hierarchical Regression for Testing the Relationship between Category-
level DTCA exposure frequency and Content of Patients’ Descriptive Beliefs about 
the Drug Risks (N = 234) 
 
 Predictors        Beta 
Block 1. Control variables Age .06 
 Sex -.14 * 
 Health media attention -.16 * 
 Out-of-pocket cost -.01 
 Number of drugs taken .04 
Block 2. Category-level 
DTCA exposure frequency 
TV .07 
Magazine -.10 
Internet -.05 
 df = 8, MS = .854, F = 3.12, p < .01; adjusted R2 = .07 
**p < .01; *p < .05 
 
 The fourth hierarchical regression analysis tested H4, which predicted a positive 
relationship between DTCA exposure frequency and the content of evaluative beliefs 
about the illness severity. The results, presented in Table 30, showed no significant 
relationship between DTCA exposure frequency and evaluative beliefs about the illness 
severity. Among the control variables, only sex was negatively related to the dependent 
variable (β = -.18, p < .05). In other words, females would likely evaluate their blood clot 
problems more severely. Thus, H4 was not supported. Another hierarchical regression 
analysis tested the relationship between DTCA exposure frequency and content of 
evaluative beliefs about the drug, addressing RQ1. As presented in Table 30, the results 
showed no significant relationship between DTCA exposure frequency and evaluative 
beliefs about the blood thinners.  
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Table 30. Hierarchical Regression for Testing the Relationship between Category-
level DTCA Exposure Frequency and Content of Patients’ Evaluative Beliefs (N = 
234) 
 
  About the illness severity 
About the 
drug 
 Predictors Beta  Beta 
Block 1. Control 
variables 
Age -.18 * -.09 
Sex -.02 -.02 
Health media attention .13 -.01 
Blood thinner cost -.04 -.10 
Number of medications taken .03 .05 
Block 2. 
Category-level 
DTCA exposure 
frequency 
TV .10 .03 
Magazine .01 .03 
Internet -.01  -.18 
 
Adjusted R2  .04 .04 
  df = 8,  
MS = 9.70, 
F = 2.31,  
p < .05 
df = 8,  
MS = .68, F 
= 1.14,  
p = .34 
   **p < .01; *p < .05 
 
Overall, the five hierarchical regression analyses testing the relationship between 
DTCA exposure frequency and content of descriptive and evaluative beliefs 
demonstrated mixed results: TV DTCA exposure were positively related to three 
descriptive beliefs, but magazine and Internet DTCA exposure were generally negatively 
related to them. The result also indicate that DTCA exposure frequency seem to have no 
effects on the accessibility to evaluative beliefs. The results of H1 through H4 and RQ1 
testing are summarized in Table 31. 
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Table 31. Summary of H1 ~ H4 and RQ1 Test Results 
 
H/RQ Results Other significant 
predictors 
H1 
DV: Descriptive 
beliefs about the 
illness 
Supported for TV DTCA exposure 
frequency only 
Not supported for magazine DTCA 
exposure frequency 
Not supported for Internet DTCA 
exposure frequency (opposite 
direction) 
Not supported for brand-level DTCA 
exposure frequency 
 
H2 
DV: Descriptive 
beliefs about the 
drug benefits 
Supported for TV DTCA exposure 
frequency only 
Not supported for magazine DTCA 
exposure frequency (opposite 
direction) 
Not supported for Internet DTCA 
exposure frequency (opposite 
direction) 
Not supported for brand-level DTCA 
exposure frequency 
 
H3 
DV: Descriptive 
beliefs about the 
drug risks 
Not supported for category-level and 
brand-level exposure frequency 
Sex (female > male) and 
health media attention 
(negative) 
H4 
DV: Evaluative 
beliefs about the 
illness severity 
Not supported for category-level and 
brand-level exposure frequency 
Age (negative) 
RQ1 
DV: Evaluative 
beliefs about the 
drug 
No significant relationship between 
category- and brand-level exposure 
freuquency and evaluative beliefs 
abut the drug 
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6.5.  Testing Belief Accessibility Effects on Patient Medication Adherence 
H5 through H9 predicted the belief accessibility effects on patient medication adherence. 
Specifically, H5 expected a positive relationship between patients’ descriptive beliefs 
about their illness and their medication adherence, H6 expected a positive relationship 
between the descriptive beliefs about the drug benefits and patient medication adherence, 
and H7 predicted a negative relationship between the descriptive beliefs about the drug 
risks and patient medication adherence. H8 and H9 predicted  the positive relationships 
between patients’ evaluative beliefs about the illness severity and the drug with patient 
medication adherence. Before testing the hypotheses using multivariate analysis 
approaches, first, a series of correlation analyses was performed to explore the 
relationships among the key variables.  
6.5.1. Correlation analyses of the relationship between belief accessibility and 
patient medication adherence 
 The relationships between patients’ descriptive and evaluative belief accessibility 
and their medication adherence were explored with correlation analysis. First, the content 
of descriptive and evaluative beliefs were correlated with medication adherence, and the 
results are presented in Table 32. The results showed that only the three descriptive belief 
variables (descriptive beliefs about the illness, the drug benefits, and the drug risks) were 
positively correlated with patient medication adherence. Neither of the evaluative belief 
content variables was significantly correlated with medication adherence. The results 
suggest that respondents who had more accurate beliefs about their blood clot problems 
and blood thinner benefits and risks tended to adhere more to their blood thinner regimen.  
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 Another correlation analysis was performed exploring the relationships between 
response time of descriptive and evaluative beliefs and patient medication adherence. The 
analysis showed that response time of descriptive beliefs about the illness was positively 
related to patient medication adherence (see Table 32). It means that patients who were 
less accessible to the accurate beliefs about the illness tended to adhere more to their 
blood thinner regimen. 
 
Table 32. Correlations between Belief Accessibility and Medication Adherence 
 
  Content Response time 
Descriptive beliefs  
 
 
About the 
illness .27 * .13 * 
About the drug 
benefits .25 ** .00 
 
About the drug 
risks .13 * .01 
 
Evaluative beliefs  
 
About the 
illness severity -.01  .03 
 
About the drug .10 .00 
    **p < .01; *p < .05 
 
6.5.2. Correlation analyses of the relationship between control variables and 
patient medication adherence 
 The relationship between various control variables and patient medication 
adherence was investigated by performing a correlation analysis and several t-tests. 
Demographic variables (age, sex, income, education, and race) and medication-related 
variables (duration of blood thinner intake, out-of-pocket cost, the number of prescription 
drugs taken, side effect experience, health insurance status, and satisfaction with and trust 
    
 
141 
in current doctors) were selected as control variables for testing the belief accessibility 
effects on patient medication adherence.  
 First, correlation analysis between continuous control variables and patient 
medication adherence was conducted. The results, as presented in Table 33, showed that 
age, the number of prescription drugs taken, and satisfaction with and trust in the current 
doctor had significantly positive relationships with patient medication adherence. That is, 
older respondents who took greater numbers of prescription drugs were more adherent to 
their blood thinner medication regimen, and those who were more satisfied with and 
highly trust their doctors tended to adhere to the regimen better. The results also showed 
a negative relationship between monthly out-of-pocket cost for blood thinners and patient 
medication adherence, which means that respondents who paid more for their blood 
thinner purchase tended to adhere less to their medication regimen.  
 
Table 33. Correlations between Control Variables and Patient Medication 
Adherence 
 
Control variables Medication adherence  
Age .28 ** 
Income -.07 
Education -.03 
Duration of blood thinner 
intake .05 
Out-of-pocket cost -.27 ** 
Number of prescription drug 
taken .19 ** 
Satisfaction with Doctor .17 ** 
Trust in Doctor .17 ** 
                 **p < .01; *p < .05 
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 Relationships between categorical control variables and patient medication 
adherence were examined by conducting several t-tests. The results showed that the mean 
scores of patient medication adherence were significantly different between those with 
health insurance and those without (t (51.87) = 1.86, p < .05). That is, respondents with 
health insurance tended to adhere more to their blood thinner regimen. No other variables 
showed significant differences in medication adherence. The t-test results are 
summarized in Table 33. 
 
Table 33. T-test Results for Relationships between Patient Medication Adherence 
and Control Variables 
 
Control variables N Mean SD t (df) 
Sex 
Female 120  7.53  1.59   .62(238)  
Male 120  7.39  0.19   
 
Race Non-
Hispanic 
Whites 
216  7.56  1.68  -1.87(25.61) 
 
Others 24  6.63  2.37   
 
Side effect 
experience Experience 43  6.91  2.27  1.86(51.87) 
 
No 
experience 197  7.58  1.63    
Health insurance 
status Insurance 228  7.52  1.72  2.28(238) * 
No 
insurance 12  6.33  2.46    
  **p < .01; *p < .05 
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6.5.3. Regression analyses for testing the relationship between belief 
accessibility and patient medication adherence 
 The results from the preliminary correlation analyses showed that generally, there 
was no significant relationship between the belief response time variables and patient 
medication adherence, and between the content of evaluative beliefs and medication 
adherence. Response time of descriptive beliefs about the illness was positively related to 
patient medication adherence, but the correlation was not strong enough to test when 
including various control variables. Therefore, multivariate hierarchical regression 
analyses testing the hypotheses were performed only for the relationship between the 
content of descriptive beliefs and patient medication adherence, which are predicted by 
H5 through H7.  
 For each analysis, control variables were selected based on the preliminary 
bivariate analyses results. Since age, out-of-pocket cost, the number of prescription drugs 
taken, and satisfaction with and trust in doctors were significantly related to medication 
adherence, they were entered into regression as control variables. Between satisfaction 
with the doctor and trust in the doctor, a rather strong correlation was found (r = .67, p < 
.01), causing multicollinearity concerns. As relevant previous research focused more on 
the effects of patient satisfaction with their medications rather than with their doctors 
(e.g., Gellad et al., 2009), trust in the current doctor was selected for this study’s 
hypotheses testing. 
 To test H5 through H7, hierarchical regression analyses were conducted by 
entering age, out-of-pocket cost, number of drugs taken, and trust in the current doctor as 
control variables in the first block, and entering the three descriptive beliefs variables 
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(about the illness, about the drug benefits, and about the drug risks) in the second block. 
As presented in Table 34, the results demonstrated that the accuracy of descriptive beliefs 
about the illness and about the drug risks was positively related to patient medication 
adherence (descriptive beliefs about the illness: β = .19, p < .01; descriptive beliefs about 
the drug risks: β = .16, p < .05). In other words, respondents with more accurate beliefs 
about their blood clot problems and their blood thinner risks tended to adhere more to 
their medication regimen. Among the control variables, age was positively related to 
patient medication adherence (β = .20, p < .01), while out-of-pocket cost was negatively 
related to it (β = -.20, p < .01). The results suggested that older respondents with less 
burden of out-of-pocket cost tended to adhere more to their blood thinner regimen.  
Overall, the results provide support for H5, which predicted a positive 
relationship between descriptive beliefs about the illness and patient medication. On the 
other hand, H6 (positive relationship between descriptive beliefs about the drug benefits 
and medication adherence) and H7 (negative relationship between descriptive beliefs 
about the drug risks and medication adherence) were not supported. H8 and H9, which 
predicted positive relationships between evaluative beliefs and patient medication 
adherence, were also not supported (see the preliminary correlation analysis results). The 
results were summarized in table 34.  
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Table 34. Hierarchical Regression for Testing the Relationship between Patients’ 
Descriptive Beliefs and Medication Adherence (N = 234) 
 
 Predictors          Beta 
Block 1.  
Control variables 
Age .20 ** 
Out-of-pocket cost -.20  ** 
Number of drugs taken .07 
Trust in doctor .08 
Health insurance status -.01 
Block 2.  
Patients’ descriptive 
beliefs 
About the illness .19 ** 
About the drug benefits -.05 
About the drug risks .16 * 
 df = 8, MS = 20.33, F = 7.84, p < .01; adjusted R2 = .19 
* p < .05; **p < .01 
 
Taken together, the results indicate that being accessible to accurate beliefs about 
the illness and the drug risks were positively associated with patient medication 
adherence. The hypotheses test results are summarized in Table 35. 
 
Table 35. Summary of H5 ~ H9 Test Results 
 
Hypotheses Results Other significant predictors 
H5 Supported Age (positive) and out-of-pocket 
costs (negative)  H6 Not supported 
H7 Not supported  
(Opposite direction is 
significant) 
H8 Not supported 
H9 Not supported 
      DV: Patient medication adherence 
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6.6. RQ2: Mediation Effects of Belief Accessibility on the Relationship Between 
DTCA Exposure Frequency and Patient Medication Adherence 
RQ2 examined whether DTCA exposure effects on patient medication adherence was 
mediated by the belief accessibility effects. Before testing the potential mediation effect, 
a series of correlation analyses were first conducted to explore about the relationship 
between DTCA exposure frequency and patient medication adherence. 
6.6.1. Correlation analyses of the relationship between DTCA exposure 
frequency and patient medication adherence 
 As presented in Tables 36 and 37, the results of correlation analyses of the 
relationship between DTCA exposure frequency and patient medication adherence 
showed a negative relationship between DTCA exposure frequency and patient 
medication adherence. It means that patients who were more frequently exposed to DTC 
ads tended to be less adherent to their blood thinner regimen. The significantly negative 
relationship was found both at the category-level (except for TV DTCA exposure 
frequency) and the brand-level DTCA exposure frequency.  
 
Table 36. Correlations between Category-level DTCA Exposure Frequencies and 
Patient Medication Adherence  
 
 1 2 3 4 
1.TV  .33 ** .43 ** -.12 
2.Magazine    .57 ** -.30 ** 
3.Internet     -.21 ** 
4.Medication 
Adherence  
 
  
  
                **p < .01 
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Table 37. Correlations between Brand-level DTCA Exposure Frequencies and 
Patient Medication Adherence  
 
 1 2 3 4 
1.Eliquis   .65 ** .62 ** -.15 * 
2.Pradaxa    .65 ** -.20 ** 
3.Xarelto      -.15 * 
4.Medication 
Adherence 
  
 
 
 
  
*p < .05; **p < .01 
 
6.6.2. Mediation analyses for testing the mediation effect of descriptive beliefs 
on the relationship between category-level DTCA exposure frequency and patient 
medication adherence 
 Results from the earlier hypotheses testing results suggested that there could be a 
potential mediation effect of the content of descriptive beliefs on the relationship between 
the category-level DTCA exposure frequency and patient medication adherence. 
Hierarchical regression analyses for testing H1 through H2 showed significant 
relationships between the category-level DTCA exposure frequency and content of 
descriptive beliefs about the illness and the drug benefits, and the results from the 
hierarchical regression analyses for testing H5 through H7 demonstrated the positive 
relationship between the descriptive beliefs and medication adherence. Therefore, a series 
of mediation tests was conducted using a Sobel test for the effects of the content of 
descriptive beliefs on the relationship between category-level DTCA exposure frequency 
and patient medication adherence. 
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 A series of Sobel tests was conducted by using the mediation analysis macro for 
SPSS developed by Preacher and Hayes (2004). The macro was developed for a formal 
direct test of the significance of the indirect effect of a mediator, by comparing the 
indirect effect to the null hypothesis that assumes the indirect effect is 0 (Preacher and 
Hayes, 2004). The Sobel test was conducted as follows: First, unstandardized coefficient 
and standard error (S.E.) of the relationships among the independent variable (IV), the 
mediation variable (MV), and the dependent variable (DV) were calculated by using 
simple OLS regression. The significance of the indirect effect (i.e., the product of the 
effect of IV on MV and the effect of MV on DV) was tested by comparing it to the null 
hypothesis. 
 The predicted mediation effect of the content of the descriptive beliefs about the 
illness on the relationship between DTCA exposure frequency and patient medication 
adherence was tested. Sobel test results showed that there was a significant mediation 
effect of descriptive beliefs about the illness on the relationship between Internet DTCA 
exposure frequency and patient medication adherence. The negative total effect of 
Internet DTCA exposure frequency becomes significantly weaker when it was mediated 
by the content of descriptive beliefs, which suggest that being accessible to accurate 
beliefs about the illness may reduce the negative effect of Internet DTCA exposure on 
patient medication adherence. However, the indirect effect of Internet on patient 
medication adherence seemed not to happen through increasing belief accessibility; 
Internet DTCA exposure frequency was still negatively related to descriptive beliefs 
about the illness in the mediation relationships. The relationship was summarized in 
Figure 20.  
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 The mediation effect of descriptive belief accessibility was not found for the 
relationship between TV DTCA exposure frequency and medication adherence. Potential 
mediation effect of the content of descriptive beliefs about the drug benefits on the 
relationship between DTCA exposure frequency and patient medication adherence was 
also tested but no significant mediation effect was found. . Table 38 summarized the 
results of the Sobel tests. Overall, the mediation tests showed no evidence of DTCA’s 
positive indirect effect on patient medication adherence via increasing patients’ belief 
accessibility 
 
Table 38. Mediation Analysis for Testing the Relationship among Category-level 
DTCA Exposure Frequency, Content of Patients’ Descriptive Beliefs and 
Medication Adherence  
 
IV: 
Category-
level DTCA 
exposure 
frequency 
MV:  
Content of the descriptive 
beliefs 
Coefficie
nt for the 
total 
effect 
Coefficient for 
the direct effect 
Indirect effect 
of IV on DV 
(SE) 
  TV   About the illness  -.12 -.14 * .01(.02)   
  Internet   About the illness -.23 ** -.16 * -.07 (.02)  
** 
  TV   About the drug benefits -.12 -.13 .01(.01) 
  Magazine   About the drug benefits -.39 ** -.37 ** -.02(.03) 
  Internet   About the drug benefits -.23 ** -.21 ** -.02(.02) 
      DV = patient medication adherence; * p < .05; ** p < .01 
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Figure 20. Mediation Effect of Content of Descriptive Beliefs about the Illness on the 
Relationship Between Internet DTCA Exposure Frequency and Patient Medication 
Adherence 
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Chapter 7 
SUMMARY AND DISCUSSION 
DTCA of prescription drugs is one of the main pharmaceutical marketing methods, and 
heated debates about its potential positive and negative impacts on individuals and 
society have been continuing. DTCA supporters have argued for DTCA’s various 
positive effects, such as its potential role as a patient health information source, 
encouraging patients to visit their doctors and to obtain timely disease diagnosis and 
treatment, reminding patients of their medication regimens, and reducing overall health 
costs. However, opponents contend that DTCA has many negative effects, such as 
providing inaccurate information, encouraging unnecessary prescriptions, and increasing 
misuse of prescription drugs, which lead to healthcare cost increase.  
 Although the potential effects of DTCA on patient medication adherence have 
been one of the main questions of the DTCA debates and patient medication non-
adherence is an important issue in the pharmacy and public health fields, only a limited 
number of economic modeling studies exist on the potential effects of DTCA. By 
comparing the DTCA expenditure data and patient insurance claims data, the previous 
economic modeling studies have shown small but positive effects of DTCA on patient 
medication adherence. However, there is no empirical study on the relationship between 
individual-level DTCA exposure and patient medication adherence behaviors. 
 From a behavioral perspective, the current study examined the individual-level 
DTCA exposure effects on patients’ medication-related beliefs and behaviors. Applying 
media priming effect theory, this study hypothesized that frequent DTCA exposure would 
influence patient medication adherence by increasing the accessibility of certain beliefs 
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about the relevant illnesses and drugs. Preliminary in-depth interviews and an online 
survey were conducted to test nine hypotheses and to address two research questions. The 
following section summarizes the main study findings. 
 
7.1. Summary of Study Findings 
This study hypothesized that frequent individual-level DTCA exposure would be 
positively related to the accessibility of patients’ descriptive beliefs about their illnesses 
(H1) and their drugs’ benefits (H2) and risks (H3), as well as evaluative beliefs about 
their illness severity (H4). Also, DTCA exposure frequency was predicted to have some 
influence on patients’ evaluative beliefs about their drugs (RQ1). In turn, increased 
accessibility of descriptive and evaluative beliefs was expected to be related to patient 
medication adherence. Specifically, based on the previous research on medication 
adherence, patients’ descriptive beliefs about their illnesses (H5) and their drugs’ benefits 
(H6), and evaluative beliefs about the illness severity (H8) were predicted positively 
related to patient medication adherence. Descriptive beliefs about the drug risks were 
expected to be negatively related to patient medication adherence (H7). The relationship 
between evaluative beliefs about the drug and patient medication adherence would be 
dependent on the valence of the evaluative beliefs. Based on previous research, it was 
hypothesized that positive evaluative beliefs about their drugs would lead patients to 
better adhere to their medication regimen, while the opposite would occur if evaluative 
beliefs about their drugs were negative (H9). Lastly, this study tested the mediation effect 
of belief accessibility in between DTCA exposure and patient medication adherence 
(RQ2).  
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7.1.1. Priming effects of DTCA exposure on patients’ beliefs about their 
illnesses and medications 
The results of a series of hierarchical regression analyses provided only very 
limited support for priming effects of category-level DTCA exposure frequency on 
patients’ descriptive beliefs about their illnesses and drugs. The priming effect 
hypotheses were supported only for the relationships between TV DTCA exposure 
frequency and the accuracy of descriptive beliefs about the illness and the drug benefits. 
Patients who were more frequently exposed to DTC ads on TV were likely to have more 
accurate descriptive beliefs about their blood clot problems and the benefits of their blood 
thinners. However, TV DTCA exposure frequency was not significantly related to other 
types of beliefs. Contrary to the hypotheses, magazine and Internet DTCA exposure had 
significant but negative relationships with some types of patient beliefs. Specifically, 
Internet DTCA exposure frequency was negatively related to patients’ descriptive beliefs 
about their illnesses and the drug benefits, and magazine DTCA exposure frequency was 
negatively related to beliefs about the drug benefits.  
The study findings did not provide any evidence of the brand-level effects of 
DTCA exposure frequency on belief accessibility. Also, DTCA exposure frequency had 
no significant relationship with evaluative belief accessibility or any of the response time 
measures of belief accessibility.  
In addition to DTCA exposure frequency, sex and attention paid to health media 
were significantly associated with patients’ descriptive beliefs about drug risks, and age 
was negatively related to patients’ evaluative beliefs about the illness severity. In other 
words, female patients who paid less attention to health content in mass media were more 
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likely to have accurate beliefs about their drugs’ risks, and older patients tended to 
evaluate their illness as being less severe.  
7.1.2. Belief accessibility and patient medication adherence 
The hypothesized effects of descriptive and evaluative belief accessibility on 
patient medication adherence were also tested. Hierarchical regression results generally 
did not support this study’s hypotheses. The only result in line with the hypotheses was 
found for the relationship between the accuracy of descriptive beliefs about the illness 
and patient medication adherence. Patients who had more accessible beliefs about their 
blood clot problems tended to better adhere to their blood thinner regimen. Contrary to 
the hypothesis, the accessibility of descriptive beliefs about drug risks was positively 
related to patient medication adherence. The results suggested that patients who had more 
accessible beliefs about blood thinner risks tended to better adhere to their drug regimens. 
Response time measures of descriptive belief accessibility were not significantly related 
to medication adherence.  
No significant relationship was found between evaluative beliefs (both content 
and response time) and patient medication adherence. Among the control variables, 
patient age was positively related to medication adherence, while out-of-pocket cost was 
negatively related to medication adherence. This means that older patients seemed to 
better adhere to their medication regimens, while patients who had greater financial 
burden in terms of drug costs were less likely to adhere to their medication regimens. 
Finally, the mediating mechanism of DTCA priming effects on patient medication 
adherence through increasing certain types of belief accessibility was tested. Overall, 
correlation analysis results showed a generally negative relationship between DTCA 
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exposure frequency and patient medication adherence. However, a series of Sobel tests 
failed to provide support for the predicted mediation effect of DTCA exposure. Only one 
type of DTCA exposure frequency influenced patient medication adherence through one 
type of belief accessibility: The negative effect of Internet DTCA exposure frequency on 
patient medication adherence was mediated by increased accessibility of descriptive 
beliefs about the illness.  
7.2. Discussion of Findings 
7.2.1. Individual-level DTCA effects on patient medication adherence 
The findings from the current study provide valuable insights into individual-level 
DTCA exposure’s effects on patient medication adherence, an underexplored aspect of 
DTCA effects. Many of previous studies on the relationship between DTCA exposure 
and patient medication adherence tested the relationship by using DTCA expenditure data 
as a DTCA exposure indicator and patient insurance claims records as an indicator of 
medication adherence. These studies have focused on proposing and testing economic 
prediction models of patient medication adherence, considering DTCA as one of many 
predictors of medication adherence.  
The current study is the first attempt to examine the relationship between DTCA 
exposure and patient medication adherence by directly measuring individual patients’ 
DTCA exposure by media and by brands, and their medication-related beliefs and 
medication adherence behaviors. Furthermore, this study attempted to explain the 
potential relationship between DTCA exposure and patients’ medication adherence by 
applying the media priming effect framework.  
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In contrast to previous studies, this study did not find evidence of a positive 
relationship between patients’ individual-level DTCA exposure and their medication 
adherence. While previous econometric analysis studies showed a weak but positive 
relationship between DTCA expenditures and patients’ medication adherence (e.g., 
Bowman et al. 2004; Donohue et al. 2004; Hansen et al. 2010; Wosinska 2005), this 
study’s multivariate hierarchical regression results showed extremely limited support for 
the hypothesized relationships between individual-level DTCA exposure and medication 
adherence.  
Particularly, the findings from this study suggest that DTCA exposure may not be 
directly related to patient medication adherence, but more closely related to some types of 
beliefs about the illness and the medication that are accessible in patients’ mind.  
Multivariate hierarchical regression analyses results showed only limited support for the 
category-level DTCA exposure’s relationship with patients’ accessibility to specific types 
of descriptive beliefs about their illnesses and medications. Furthermore, the nature of the 
relationships between category-level DTCA exposure and descriptive belief accessibility 
seemed to differ by media; TV DTCA exposure showed the expected positive 
relationship with the accuracy of descriptive beliefs about illness and drug benefits, while 
magazine DTCA exposure was negatively related to descriptive beliefs about drug 
benefits, and Internet DTCA exposure was negatively related to descriptive beliefs about 
the illness and the drug. 
The differences found across media channels can be explained in a couple of 
ways. First, the different ways in which drug benefit and risk information is presented in 
different types of DTC ads may explain the between-media differences found in this 
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study. Specifically, FDA requires all product-claim ads to disclose drug risk information 
by inserting brief summary of detailed information about the risks of the advertised drug 
in the main part of the ad. However, for broadcast ads, such as TV DTCA, the risk 
information disclosure requirement is differently applied: They are only required to 
include major risks of the drug as long as they provide alternative sources of detailed risk 
information (U.S. Food and Drug Administration, 2015). Typical examples are the small 
prints reading, “see our ads in XXXX magazine” or “visit our website at XXXX,” 
presented in TV DTC ads. Therefore, compared to TV DTCA, magazine and Internet 
DTC ads tend to present more detailed drug risk information, and the detailed 
information could confuse or overwhelm patients, which in turn, could influence patients’ 
descriptive beliefs about drug benefits and risks negatively.  
Second, this study’s sample characteristics, especially age, might explain the 
between-media differences in the relationship between category-level DTCA exposure 
frequency and descriptive belief accessibility. The sample of this study consisted of older 
patients, age between 45 and 80. Although there is no known study that directly tested 
how younger and older patients might react differently to DTC ads in different media 
channels, the health information seeking literature provides some relevant insights. 
Pervious literature on health information seeking demonstrated that older patients tended 
to prefer traditional media sources, such as TV and radio (Hall, Bernhardt, and Dodd 
2015) and older patients were less likely to use Internet DTC ads as the prescription drug 
information source (DeLorme, Huh, and Reid 2011). Older patients’ particular media 
preference and different levels of exposure to DTCA across different media might have 
some links to this study’s findings.  
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Although some significant associations between category-level DTCA exposure 
and descriptive belief accessibility were found, the current study’s findings showed that, 
in general, DTCA exposure frequency did not have significant indirect effect on patient 
medication adherence via belief accessibility. Overall, findings from this study suggest 
that DTCA may not be directly or indirectly related to patient medication adherence in a 
short period of time, but it may have some limited effects on priming patients’ descriptive 
beliefs about their illnesses and the drugs.  
7.2.2. The importance of patients’ psychological characteristics as influencing 
factors on patient medication adherence 
Previous studies from the pharmacy and public health fields have conceptualized 
patient medication adherence as a complex public health issue with various influencing 
factors, such as healthcare system factors, medication regimen factors, patient factors, 
and environmental factors (e.g., Gellad et al. 2009; Kronish and Ye 2013). The results 
from the current study also showed that demographic factors (age), healthcare system 
factor (out-of-pocket costs), and patients’ psychological factors (descriptive beliefs about 
the illness and the drug benefits) were significantly associated with patient medication 
adherence.  
Especially, this study’s findings suggest the importance of patients’ psychological 
factors, such as descriptive beliefs about their illnesses and their drugs, as significant 
influence on patients’ medication adherence. Previous research and intervention 
campaigns to improve patient medication adherence tended to place more emphasis on 
healthcare system factors, based on the assumption that patients were mere followers of 
the guidance provided by healthcare providers (Sabatâe 2003). In terms of patient factors, 
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many previous studies based their conceptual frameworks and study designs on the 
biomedical perspective, which might have caused them to focus more on patient 
demographics than on psychological factors (Sabatâe 2003).  
The current study’s findings indicated that patients’ beliefs were significantly 
related to medication adherence even after controlling for patients’ demographics, 
healthcare provider factors, and medication-related factors. These findings suggest that a 
patient’s illness- and drug-related beliefs, which are psychological factors, are important 
factors influencing medication adherence. Specifically, descriptive beliefs about the 
illness were positively related to patient medication adherence, which is consistent with 
previous study results (e.g., Kim et al. 2007; Mann et al. 2009).  
In addition, this study separately tested potential effects of patients’ descriptive 
beliefs about drug benefits and risks on medication adherence and found some 
differences between drug benefit and risk beliefs. Previous studies tended to 
operationalize descriptive beliefs about drugs in general, without separating the concept 
into beliefs about drug benefits and risks (e.g., Apter et al. 2003; Friedman et al. 2008; 
Wells et al. 2008), and suggested a generally positive relationship between the accuracy 
of the beliefs about drugs and patient medication adherence. However, this study’s 
findings showed that, while descriptive beliefs about drug benefits were not significantly 
related to medication adherence, descriptive beliefs about drug risks were positively 
related to patient medication adherence. The current study findings might be explained by 
the nature of the main behavior goal of the maintenance- and habit- stage patients and its 
connection to their motivation system activation. The sample of this study included 
maintenance- and habit- stage patients, and the main behavioral goal for them tends to be 
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focused on maintaining their desirable healthy condition, which can be closely connected 
to the activation of behavioral inhibition motivation system (BIS). According to 
motivation system theory, BIS is connected to avoiding negative outcomes, such as 
punishments and pain (Carver and White 1994). Because the nature of the goal of 
maintenance- and habit-stage patients, their BIS system would likely be more activated 
than behavioral approach system (BAS). The activation of BIS system would, in turn, 
lead them to be more sensitive to drug risk information than benefit information, because 
drug risk information is more closely connected to the potential undesirable outcomes 
that they want to avoid to maintain their healthy condition.  
Contrary to previous research findings, this study did not find any supporting 
evidence of the positive role of evaluative beliefs about illness severity and the 
medication. Previous medication adherence literature demonstrated that patients’ 
evaluative beliefs about illness severity and the drug were positively related to 
medication adherence (e.g., Gellad et al. 2009; Park and Jones 1997), but such a 
relationship was not found in this study. The non-significant relationship might be due to 
the sample characteristics of this study. Most of the respondents of this study were highly 
adherent to their medication regimens, with high levels of habit strength. Prochaska and 
DiClemente’s health behavior stage model proposed that the evaluation of risks and 
benefits of a certain health behavior would likely be an important factor for patients who 
are considering to initiate a new health behavior, which suggest that evaluative beliefs 
could be more influential in motivating patients in the initiation stage than those who in 
the maintenance or habit stage (Prochaska and DiClemente 1992). 
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7.3. Implications 
7.3.1. Theoretical implications  
 Effects of media exposure on patient health behaviors  
 Previous research has paid limited attention to the effects of media exposure on 
individuals’ health behaviors. The health belief model (HBM) is one of the few 
theoretical models that include the role of media as a predictor of patients’ health 
behavior. However, the role of media messages in HBM is still very limited: The model 
proposes that individuals’ perceptions about their illnesses and drugs are only influenced 
by demographic and psychological characteristics, which are free from other influences, 
such as media messages. In such a model, media messages are conceptualized as a cue-
to-action that triggers individuals’ heath behaviors by increasing the level of threat that 
individuals feel regarding their illnesses (Janz and Becker 1984). 
 Some researchers paid attention to the potentially important role of media 
messages on individuals’ health behaviors. Particularly, Kremers (2010) proposed that 
mass media could work as an environmental factor that indirectly influence patients’ 
behavior via patients’ various psychological factors. In the context of patient medication 
adherence, Kronish and Ye (2009) proposed mass media as one of the environmental 
factors influencing patient medication adherence, and Wosinska (2005) suggested that 
DTCA exposure could increase the salience of certain types of beliefs about illness and 
drugs. However, the proposed role of media messages on patients’ health-related 
perceptions and behaviors have not been empirically tested.  
 The findings of this study suggest that media messages may not directly influence 
individuals’ health behavioral outcomes, but may play some indirect role through its 
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relationships with patients’ psychological factors, such as beliefs. This study found that 
frequent exposure to DTC ads did not seem to directly influence patient medication 
adherence behavior, which is different from the HBM’s assumption of media messages’ 
function as a cue-to-action. Instead, this study’s findings demonstrated that some types of 
DTC ads could increase the accessibility of patients’ descriptive beliefs about their 
illnesses and drugs. The findings suggest that media messages, such as DTCA, can play a 
more important role in influencing patients’ psychological factors than directly 
influencing their behaviors. The effects of mass media, including advertising, on various 
psychological factors related to patients’ health behaviors should be further investigated. 
 Weak and limited media priming effects of advertisements 
 This study is one of the very few studies that empirically tested the media priming 
effects of advertising. Previous media priming effect studies have focused on how 
repetitive exposure to information from news media content, such as political news, can 
increase audience’ accessibility to cognitive constructs related to the particular media 
content (Rokos-Ewoldsen et al. 2008).  However, media priming effect should not be 
confined to news exposure: Repetitive exposure to advertisements can also increase 
chronic accessibility of the information or beliefs contained in the advertisements. 
Specifically, due to the rather standardized nature of DTCA content across different 
brands and drugs, frequent DTCA exposure can increase accessibility of illness- and 
medication-related beliefs in patients’ minds.  
 Despite advertising’s potential to enhance consumers’ chronic accessibility to 
cognitive constructs from advertisements, there has been no known study about DTCA’s 
media priming effects on patient behavior. Although priming effect is not a new concept 
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to advertising researchers, previous advertising priming studies have focused on the very 
short-term priming effects of specific advertising content elements on subjects’ 
immediate temporary access to beliefs and attitudes regarding the advertised product or 
brand (e.g., Yi 1993; Yoo 2011). The weak and mixed results found from this study 
suggest that advertising’s media priming effect would likely be weak and limited, and 
call for further research.  
7.3.2. Practical implications 
Patient medication adherence is not only a public health issue but also closely 
linked to the long-term sales outcomes of pharmaceutical companies (MouKheiber 2012). 
The findings from this study offer some  practical implications for pharmaceutical 
marketers.  
First, the current study findings suggest that effective communication of 
information about seriousness of illnesses in DTC ads could have indirect impact on 
improving patients’ medication adherence. The results showed that TV DTCA exposure 
was positively related to patients’ accessibility to accurate beliefs about their illnesses, 
which was positively related to patients’ medication adherence. As discussed earlier, the 
medication adherence behavior of the maintenance- and the habit-stage patients might be 
more influenced by BIS motivation activation, which is linked to the sensitivity to 
avoiding undesirable outcomes. Therefore, targeting this group of patients, advertising 
messages focusing on the seriousness of illnesses and consequences of not treating them 
would likely be more effective than focusing on drug benefits. 
Second, this study’s findings offer important insight addressing the question of 
possible negative effects of drug risk information in DTCA on patients’ medication use 
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and adherence. The study results indicate no empirical evidence of the common concerns 
and speculations that drug risk information in DTCA might scare patients leading them to 
avoid taking their drugs that are necessary for treating their medical conditions. Based on 
the findings, pharmaceutical marketers should not be concerned about the possibility of 
DTCA’s risk information causing patients’ avoidance of drug treatment or diminished 
regimen adherence.  
 
7.4. Limitations and Suggestions for Future Research 
7.4.1. Limitations 
This study has several limitations. First, this study was designed as a cross-
sectional study. This study’s methodological decision to use a cross-sectional survey 
method was made because patients’ medication adherence behaviors are difficult to 
observe in an experimental setting (Park and Jones 1997), and in order to observe DTCA 
media priming effects in a natural setting. Due to the study method, while this study can 
suggest relations or associations between DTCA and presumed effects, it cannot offer a 
true causality test of DTCA effects. To address this limitation, future research should 
design a study that is more appropriate for testing the causal relationship. For example, 
longitudinal observational research in collaboration with the pharmacy department at 
healthcare facilities would be a good alternative method for testing the effects of DTCA 
on patients’ medication adherence behaviors over time. Particularly, patient records from 
the pharmacy department can be used to identify patients at different stages of medication 
use and to track patients’ medication use and refill over time. Also, qualitative methods 
could provide additional valuable insights on the relationship between DTCA exposure 
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and patient medication adherence.  For example, ethnography can provide researchers a 
chance to holistically understand patients’ experience with DTCA and their medications 
from patients’ point of view (Lindlof and Taylor 2010). 
Second, this study’s sample is a non-probability sample, and thus the 
representativeness and generalizability of the study findings cannot be claimed. Because 
of the low incidence rate of chronic blood thinner users and a lack of data on the 
population of patients with blood clot problems, it was not possible to perform 
representative sampling of American patients on the blood thinner regimen. In addition, 
the sample tended to be homogenous in terms of the level of medication adherence and 
habit strength. More than 50% of the respondents were very highly adherent to their 
blood thinner regimens (i.e., a score of 8 or 9) and the mean habit strength of the sample 
was 4.34 out of 5, which indicates that a majority of the study participants were in the 
habit stage. This may have made it difficult to detect the hypothesized DTCA effects. The 
current study intended to compare DTCA’s priming effects on patients in different 
medication adehrence stages, but due to the limitation of the sample, such comparisons 
could not be performed. Therefore, the findings from this study should be cautiously 
interpreted and future research needs to implement more careful sampling approaches to 
include more diverse respondents and to test the potential differences in medication 
adherence between maintenance-stage and habit-stage patients.  
One possible way to identify the maintenance- and habit-stage patients more 
accurately is using patient records. Patient records can help identify patients who recently 
initiated a drug regimen and made transition to the early period of the maintenance stage. 
By tracking the pattern of medication-related behaviors of patients who first obtained 
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their prescription, patients’ medication adherence stage can be more accurately identified. 
Another way to identify maintenance-stage patients is to include more relevant screening 
questions. For example, the results from the preliminary qualitative study suggested that 
habit-stage patients tended to show stronger habit characteristics than maintenance-stage 
patients. Therefore, the habit-strength scale developed in the prescription medication 
context can be used as a screening question for patients’ medication use stage 
determination.  
Third, this study relied on a self-reported medication adherence measurement. 
Self-reporting is one of the commonly used medication adherence measurements that can 
be effectively administered through a survey. However, self-reporting alone cannot 
accurately capture patient medication adherence. Previous studies compared other types 
of medication adherence measurements (e.g., biological markers and pill count) and 
respondents’ self-reports, and found that self-reports tended to inflate the medication 
adherence rate (e.g., Paulson, Krause, and Iber 1977; Rand et al. 1992). Future research 
should employ both self-reporting and other types of medication adherence 
measurements. 
Fourth, this study’s response-time measurements were susceptible to response 
time differences caused by individual respondents’ computer and Internet connection 
conditions. This study used the timing function provided by Qualtrics, which recorded the 
timing of respondents’ first click, last click, and the page submission made within a page. 
The timing function is a convenient way to measure belief accessibility in an online 
survey, but its reliability could be affected by each respondent’s Internet connection 
speed and device functions. Although a baseline response time measurement was 
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incorporated, this study could not control each respondent’s survey-taking environment, 
such as the computer or mobile device used for taking the survey, or the speed and 
reliability of the Internet service that each respondent used. The lack of control over 
respondents’ survey taking devices and the Internet service may have influenced 
respondents’ response timing: While some respondents’ Internet connections might be 
consistently reliable and fast, others might have experienced slow connection speeds. 
Also, the devices’ processing abilities could have affected the webpage loading speed, 
which might have affected the response time data. Future research should develop a more 
reliable way to control each respondent’s survey-taking environment and to measure 
response time more accurately. 
7.4.2. Future research directions 
 Building upon this study’s findings and considering its limitations, future research 
should continue investigating DTCA’s role on patients’ medication use and medication 
regimen adherence. First, the relationship between DTCA exposure and patient 
medication adherence should be examined beyond the category-level DTCA exposure 
effects. Previous studies tended to investigate category- or brand-level DTCA effects on 
patient medication adherence, because they usually tested the relationship in a specific 
prescription medication context. For example, Wosinska (2005) investigated the 
relationship in the context of statins and Hansen et al. (2010) examined the relationship in 
the anti-depressant context. The results from previous studies consistently showed weak 
but positive category-level DTCA effects on patients, which suggest that patients were 
influenced by overall exposure to DTC ads for drugs treating the same or similar illness, 
rather than influenced by ads for specific brands. Current study also suggests limited 
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category-level DTCA effects. Given that no research has investigated effects of general 
DTCA exposure across different drug categories on patients’ medication use behaviors, 
future research is encouraged to investigate the potential relationship between general 
exposure to all types of DTCA and patient medication-related perceptions and behaviors. 
Second, DTCA’s priming effects on other cognitive constructs in patients mind 
need to be examined. This study examined DTCA’s effects on patient medication 
adherence through enhancing chronic accessibility to illness- and medication-related 
beliefs, and showed limited priming effects of DTCA on specific types of beliefs. 
However, frequent exposure to DTCA could have other types of priming effects on 
patients by increasing the accessibility to other types of cognitive constructs. One 
potential cognitive construct that can be primed by DTC ads is a healthy living goal. 
DTCA constantly depicts healthy and active individuals involved in various healthy 
behaviors, such as having a physically active lifestyle, eating healthy foods, and spending 
quality time with friends and family. Through frequent exposure to healthy lifestyles 
depicted in DTCA, patients may be primed to set a goal of living a healthy life. As a 
cognitive construct, goals can be primed through media exposure (Price and Tewksbury 
1997), but the potential goal-priming effects of media exposure have not been studied in 
detail. Future research should investigate the potential goal-priming effects of frequent 
DTCA exposure. 
 Third area that future research should consider is the effect of general media 
coverage of prescription drugs and other competing advertisements, which may influence 
DTCA effects on patient medication adherence. Wosinska (2005) suggested that other 
than DTCA exposure, there might be effects caused by news media exposure on patients’ 
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medication adherence. During the data collection period of Wosinska’s study, there was a 
case of the withdrawal of Baycol, which was one of prescription cholesterol medications. 
Wosinska speculated that heavy media coverage of the Baycol case and its role in 
patients’ deaths might have influenced patients’ drug regimen adherence. Specifically, 
the heavily covered negative consequences of Baycol were likely to have enhanced 
cholesterol patients’ accessibility to beliefs about the drug risks.  
In addition to the potential priming effects of media news coverage of prescription 
drugs, some competing advertising messages regarding prescription medications can also 
affect patients. For example, various law firms run advertisements seeking for potential 
clients to participate in their class action lawsuits against the makers of prescription 
medications. Such class action lawsuit advertisements tend to emphasize most serious 
side effects of prescription medications, which can influence patients’ beliefs about 
medication benefits and risks. Future research should examine how competing media 
coverage and advertisement messages can influence DTCA effects on patients’ belief 
accessibility and medication adherence.  
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Appendix A. Online Survey Questionnaire 
INFORMATION ABOUT THE RESEARCH 
 
Consumer Perceptions of Blood Thinner Medication Advertisements 
 
You are invited to be in a research study about consumer perceptions of advertisements for 
prescription blood thinners. You were selected as a possible participant because you volunteered 
to participate in the study.  
This study is being conducted by Heewon Im (imxxx037@umn.edu), Ph.D. candidate at the 
University of Minnesota’s School of Journalism and Mass Communication.  
 
Procedures: 
If you agree to be in this study, I would ask you to do the following things: 
You will answer online survey questions about your experience and perceptions of prescription 
drug advertisements, beliefs about your blood clot problem and blood thinner taking behavior 
and the blood thinner medication you’re currently taking. The study will take about 15 to 20 
minutes of your time. 
 
Confidentiality: 
The records of this study will be kept private. In any sort of report I might publish, I will not 
include any information that will make it possible to identify a subject. Research records will be 
stored securely, and only the researcher will have access to the records.  
 
Voluntary Nature of the Study: 
Participation in this study is voluntary. Your decision whether or not to participate will not affect 
your current or future relation with the University of Minnesota or Qualtrics. If you decide to 
participate, you can choose not to answer any questions or can withdraw at any time without 
affecting those relationships. 
 
Contacts and Questions: 
The researcher conducting this study is Heewon Im. If you have questions, you are encouraged 
to contact the researcher at the School of Journalism and Mass Communication, University of 
Minnesota, 330 Murphy Hall, 206 Church St. Southeast, Minneapolis, MN 55455, (612) 626-
0221, imxxx037@umn.edu. You may also contact the researcher’s faculty advisor Professor Jisu 
Huh at the School of Journalism and Mass Communication, University of Minnesota, 338 
Murphy Hall, 206 Church St. Southeast, Minneapolis, MN 55455, (612) 626-5527, 
jhuh@umn.edu.  
If you have any questions or concerns regarding this study and would like to talk to someone 
other than the researcher(s), you are encouraged to contact the Research Subjects’ Advocate 
Line, D528 Mayo, 420 Delaware St. Southeast, Minneapolis, MN 55455, (612) 625-1650. 
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If you want, you can request the researcher (Heewon Im, imxxx037@umn.edu) an electronic 
copy of this information to keep for your record. 
 
 
I have read and understand the information above, and I agree to participate in this study. 
 
  Yes 
  No (If “No” is selected, skip to the end of survey) 
<Page Break> 
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Q1. What is your age as of today? Please enter your age in the space below. 
 _________________ years old  
(If Q1 is less than 45 or is greater than 80, skip to the end of survey)  
Q2. What is your sex? 
  Male            Female            
 
Q3. Are you currently taking any prescription oral blood thinner medications?  
Prescription blood thinners are medications prescribed to prevent blood clots from forming. 
Coumadin, Eliquis, Pradaxa, Xarelto and Wafarin are examples of oral prescription blood 
thinners. Please select “No,” if you are taking aspirin (because it is not a prescription blood 
thinner) or receiving Heparin or other injection form of blood thinners. 
   Yes  
   No  (If “No” is selected, skip to the end of Survey) 
<Page Break> 
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Q4. The following statements are about your current blood thinner regimen. Please indicate 
how much you agree or disagree with each statement. 
 Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
I take my blood 
thinner automatically.           
It makes me feel 
weird if I do not take 
my blood thinner. 
          
I take my blood 
thinner without much 
thought. 
          
Taking my blood 
thinner is part of my 
daily or nightly 
routine. 
          
<Page Break> 
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Q5. Please answer the following questions about your current blood thinner regimen by 
choosing either “yes” or “no” for each question. 
Questions Yes No 
Do you sometimes forget to take your blood thinner pills? 
     
Have you ever forgot to refill the prescription for your blood 
thinner? 
 
    
Over the past 2 weeks, were there any days when you did not take 
your blood thinner? 
 
    
Have you ever cut back or stopped taking your blood thinner 
without telling your doctor? 
 
    
Did you take your blood thinner yesterday?     
 
Q6. Below are some reasons people miss or stop taking their blood thinner. Choose any that 
have ever applied to you (Choose all that apply). 
   A change in routine  
   Cost of the medication 
   Simply forgetting  
   The medication made me feel worse  
   Traveling or being away from home 
   It felt like my blood clot problem was under control 
   It seems like a hassle to stick to the treatment plan 
   None of the above/ I have never missed or stopped taking my blood thinner. 
 
Q7. How often do you have difficulty remembering to take your blood thinner? 
     Never          Rarely         Sometimes      Often       Very Often 
 -------------- -------------- -------------- ---------------  
<Page Break> 
 
 
 
Instructions for Q8-1 through Q8-13: In this section, you will see a series of short statements 
about blood clot problems and blood thinners. If you believe the statement is true, click “yes” or 
if you believe it’s untrue, click “no.” 
 
 Please try to click your answer as quickly as possible without thinking too much.  
<Page Break> 
 
Q8-1. Both men and women could have blood clot problems.  
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  Yes            No 
<Page Break> 
Q8-2. Blood clots could cause a stroke. 
  Yes            No 
<Page Break> 
Q8-3. Blood clots could cause indigestion. 
  Yes            No 
<Page Break> 
Q8-4. Blood clots could cause damages to the lungs and other organs. 
  Yes            No 
<Page Break> 
Q8-5. Blood clots can be treated with dietary changes. 
  Yes            No 
<Page Break> 
Q8-6. Blood thinners could cause severe bleeding. 
  Yes            No 
<Page Break> 
Q8-7. Blood thinners could cause a person to bruise easily. 
  Yes            No 
<Page Break> 
Q8-8. Blood thinners could cause blindness. 
  Yes            No 
<Page Break> 
Q8-9. Stopping blood thinners could increase the risk of stroke. 
  Yes            No 
<Page Break> 
Q8-10. Blood thinners lower the chance of blood clot formation.  
  Yes            No 
<Page Break> 
 
Q8-11. Blood thinners could improve lung functions. 
  Yes            No 
<Page Break> 
Q8-12. Blood thinners reduce the risk of stroke. 
  Yes            No 
<Page Break> 
Q8-13. Blood thinners could improve digestion. 
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  Yes            No 
<Page Break> 
 
Instructions for Q9-1 through Q9-7: In this section, you will see several pairs of adjectives 
that might describe your thoughts and feelings regarding your blood clot problem. Please 
click the adjective that is consistent with your thoughts or feelings. 
 
 Please try to click your answer as quickly as possible without thinking too much.  
<Page Break> 
 
Q9-1. My blood clot problem is… 
  Treatable            Untreatable 
<Page Break> 
Q9-2. My blood clot problem is… 
  Manageable            Unmanageable 
<Page Break> 
Q9-3. My blood clot problem is… 
  Severe            Not severe 
<Page Break> 
Q9-4. My blood clot problem is… 
  Serious            Not serious 
<Page Break> 
Q9-5. My blood clot problem is… 
  Important            Unimportant 
<Page Break> 
Q9-6. My blood clot problem is… 
  Significant            Insignificant 
<Page Break> 
Q9-7. My blood clot problem is… 
  Not frightening            Frightening 
<Page Break> 
 
Instructions for Q10-1 through Q10-7: In this section, you will see several pairs of adjectives 
that might describe your thoughts and feelings regarding the blood thinner you’re currently 
taking. For each sentence, please click the adjective that is consistent with your thoughts or 
feelings. 
 
 Please try to click your answer as quickly as possible without thinking too much.  
<Page Break> 
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Q10-1. My blood thinner is... 
  Beneficial            Harmful 
<Page Break> 
Q10-2. My blood thinner is... 
  Safe            Unsafe 
<Page Break> 
Q10-3. My blood thinner is... 
  Effective            Ineffective 
<Page Break> 
Q10-4. My blood thinner is... 
  Successful            Unsuccessful 
<Page Break> 
 
Q10-5. My blood thinner is... 
  Important            Unimportant 
<Page Break> 
Q10-6. My blood thinner is... 
  Essential            Optional 
<Page Break> 
Q10-7. My blood thinner... 
  Makes me feel better            doesn’t make me feel better 
<Page Break> 
 
 
 
 
 
 
 
 
 
The following questions ask about your typical media use. 
 
Q11. On a typical weekday, about how many hours and minutes do you spend using 
the following media? Please type how many hours and minutes. 
 Example: 
 1) If you spend less than an hour, please type “0” in the hours column and type in the 
 minutes column. 
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 2) If you do not use the specific medium, please type “0” in both the hours and 
 minutes columns. 
 3) If you spend about 2 hours, type “2” in the hours column and type “0” in the 
 minutes column. 
 
 Hours Minutes 
Reading newspapers (excluding online 
reading) 
  
Watching television (excluding online 
viewing) 
  
Reading magazines (excluding online 
reading) 
  
Listening to the radio (excluding online 
listening or podcasts) 
  
Using the Internet for non-work purposes   
 
Q12. On a typical weekend, about how many hours and minutes do you spend using 
the following media? Please type how many hours and minutes.  
 Hours Minutes 
Reading newspapers (excluding online 
reading) 
  
Watching television (excluding online 
viewing) 
  
Reading magazines (excluding online 
reading) 
  
Listening to the radio (excluding online 
listening or podcasts) 
  
Using the Internet for non-work purposes   
<Page Break> 
 
Q13. Some media provide health content (e.g., articles about health in newspapers or 
magazines, health-related news on TV or the radio, health segments on TV or radio 
shows, and health information on the Internet). About how often have you read or heard 
such health content from the following media in the past 3 months? 
 
Never 
Less 
than 
once a 
month 
About  
once or 
twice a 
month 
About 
once a 
week 
Several 
times a 
week 
Almost 
every day 
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In newspapers 
             
On television 
             
In magazines  
            
On the radio  
            
On the Internet  
            
<Page Break> 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instruction for Q14-1 through Q14-5: Please indicate how much attention you pay to health or 
medical topics in each of the following media sources. 
 
Q14-1. In newspapers 
  None  ----------- ----------- ----------- -----------  A lot 
Q14-2. On television 
  None  ----------- ----------- ----------- -----------  A lot 
Q14-3. In magazines 
  None  ----------- ----------- ----------- -----------  A lot 
Q14-4. On the radio 
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  None  ----------- ----------- ----------- -----------  A lot 
Q14-5. On the Internet 
  None  ----------- ----------- ----------- -----------  A lot 
<Page Break> 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following questions ask about blood thinner advertisements (ads). 
Q15. How often have you seen ads for blood thinners in the past 3 months? 
 
Never 
Less 
than 
once a 
month 
About  
once or 
twice a 
month 
About 
once a 
week 
Several 
times a 
week 
Almost 
every day 
In newspapers 
             
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On television 
             
In magazines 
             
On the radio 
             
On the Internet 
             
 
(If you selected “Never” for all 5 types of media, skip to Q19.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q16. Please try to remember the most recent blood thinner ads you’ve seen or heard. 
Please type all things you can remember from the ads (e.g., drug brand name, what 
happens in the ad, etc.). If you remember nothing particular, type “None.” 
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<Page Break>  
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Q17. Have you seen or heard ads for the following drug brands within the past 3 
months? Place click the box next to the brand name (choose all that apply). 
  Aggrenox   Plavix  
  Brilinta   Pletal  
  Coumadin   Pradaxa  
  Effient   Ticlid  
  Eliquis   Warfarin  
  Jantoven   Xarelto  
  Persantine    None of the above  
<Page Break> 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instruction for Q18-1 through Q18-4: In this section, you will see a series of blood thinner ads. 
Please click and watch each ad before answering the question, and indicate whether or not you 
have seen the ad within the past 3 months. 
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Q18-1. Have you seen or heard this ad within the past 3 months?   
 
  
  Yes, I have seen it.           No, I have not seen it. 
 
Q18-2. Have you seen or heard this ad within the past 3 months?   
  
  
  Yes, I have seen it.           No, I have not seen it. 
 
 
 
 
 
Q18-3. Have you seen or heard this ad within the past 3 months? 
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  Yes, I have seen it.           No, I have not seen it. 
  
Q18-4. Have you seen or heard this ad within the past 3 months? 
  
  
   Yes, I have seen it.           No, I have not seen it. 
<Page Break> 
 
 
 
 
 
 
Q19. How often have you seen ads for the following blood thinner brands within the 
past 3 months? If you have not seen any particular blood thinner ad, please select 
“Never” for that particular brand ad. 
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Never 
Less than 
once a 
month  
About 
once or 
twice a 
month  
About 
once a 
week  
Several 
times a 
week 
Almost 
every day 
Coumadin             
Eliquis             
Pradaxa             
Xarelto             
Warfarin             
<Page Break> 
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Q20. What is the name of the blood thinner that you are currently taking? (Please check the 
label of your prescription medication container.) _________________________ 
 
Q21. Have you ever been prescribed other blood thinners before being put on your current 
blood thinner regimen? 
   Yes             No  
 
Q22. Approximately how long have you been taking your current blood thinner? Please type 
the duration in the boxes below. (You should fill out all the boxes to go on to the next page). 
 Example: 
 1) If you have taken the medication for about 6 months, type “6” in the month(s) 
 box and type “0” in the year(s) box. 
 2) If you have taken the medication for about 2 years, type “0” in the month(s) box 
 and type “2” in the year(s) box. 
 
 Months(s) Year(s) 
I have been taking my 
current blood thinner for  
  
<Page Break> 
 
Q23. Do you currently have health insurance?  
Health insurance include private healthcare purchased through your current or former 
employer or union or purchased by you or your family members, public insurance such as 
Medicare and Medicaid, TRICARE or other military healthcare and VA.  
 
   Yes           No (If “No” is selected, skip to Q29.) 
 
Q24. Does your health insurance provide prescription medication coverage? 
   Yes           No (If “No” is selected, skip to Q29.) 
 
Q25. Do you use your prescription medication coverage provided by your health insurance? 
   Yes           No (If “No” is selected, skip to Q29.) 
 
Q26. Do you use your prescription medication coverage provided by your health insurance to 
purchase your current blood thinner? 
   Yes           No (If “No” is selected, skip to Q29.) 
 
 
 
Q27. How many days of supply do you get for your current blood thinner? 
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   30 days             60 days             90 days             Other (Please type the number in  
         the box)_________ 
Q28. How much do you co-pay (the cost you pay in addition to the insurance coverage) for 
your current blood thinner? Please write down the cost per your typical days of supply 
answered in Q27. 
$ _______  
Q29. On average, how much do you pay out of pocket per month for your blood thinner? 
 $ _______ per month 
(If “Yes” is selected in Q26, do not show this question.) 
<Page Break> 
 
Q30. How often do you take your blood thinner on a typical day? 
  Once 
  Twice 
  More than twice: Please type how many times you take on a day. ____ 
 
Q31. Other than the blood thinner, do you take any other prescription medication(s) on a 
regular basis?  
   Yes             No (If “No” is selected, skip to Q33.) 
 
Q32. How many prescription medications are you currently taking? Please type the number of 
medications you take (including the blood thinner).  ____________  
Example: If you’re currently taking one blood thinner, two prescription 
medications for high blood pressure, and one prescription medication for diabetes, 
write “4.” 
Q33. Which of the following medical conditions do you take your blood thinner for? (Choose 
all that apply.) 
  Atrial fibrillation (AF or AFib) not caused by a heart valve problem 
  Coronary artery disease or coronary heart disease 
  Deep vein thrombosis (DVT) or blood clots in legs 
  Pulmonary Embolism (PE) or blood clots in the lung 
  Family history of blood clot formation 
  Heart valve disease 
  Stroke 
  Hip or knee replacement surgery 
☐ Heart valve surgery 
  Other: Please type your medical condition in the blank. _________ 
<Page Break> 
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Q34. Have you ever experienced any side effects while taking your current blood thinner? 
   Yes             No (If “No” is selected, skip to Q35.) 
 
Q35. Did you report the side effect(s) of your current blood thinner to your doctor?  
   Yes             No  
<Page Break> 
 
Q36. How many times did you visit your doctor for a regular blood monitoring (the 
international normalized ratio test or INR test) last month?  
  Never in the last month  
  Once 
  Twice 
  More than twice 
 
Q37. Overall, how satisfied are you with your current doctor who checks your blood clot 
problem? 
  Very dissatisfied      
  Somewhat dissatisfied     
  Neither satisfied nor dissatisfied      
  Somewhat satisfied      
  Very satisfied 
 
Q38. Overall, how much do you trust your current doctor who checks your blood clot 
problem? 
  Highly distrust the doctor 
  Somewhat distrust     
  Neither trust nor distrust      
  Somewhat trust    
  Highly trust 
<Page Break> 
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Q39. The following statements are about your typical reactions to your doctor’s advice or 
treatment recommendations or your healthcare decision-making. Please indicate how much 
you agree with each statement by selecting one of the five options for each. 
 Strongly 
disagree 
Somewhat  
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
I almost always rely 
on and act upon the 
advice of my doctor. 
          
When it comes to 
making decisions 
about my health, I am 
more independent 
than conforming. 
          
If my doctor is very 
persuasive, I tend to 
change my opinion. 
          
I do not give in to my 
doctor easily.           
I tend to rely on my 
doctor when I have to 
make an important 
decision about my 
health. 
          
<Page Break> 
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Q40. What is your combined annual household income, meaning the total pre-tax 
income from all sources earned in the past year?   
  $0 to $9,999  
  $10,000 to $14,999  
  $15,000 to $19,999  
  $20,000 to $34,999  
  $35,000 to $49,999  
  $50,000 to $74,999  
  $75,000 to $99,999  
  $100,000 to $199,999  
  $200,000 or more  
Q41. What is the highest grade of school you have completed or the highest degree you 
have received? 
  No schooling completed, or less than 1 year 
  Nursery, kindergarten, and elementary (Grade 1–8) 
  High school (Grade 9–12, no degree) 
  High school graduate (or equivalent) 
  Some college (1–4 years, no degree) 
  Associate degree (including occupational or academic degrees) 
  Bachelor’s degree (BA, BS, AB, etc.) 
  Master’s degree (MA, MS, MENG, MSW, etc.) 
  Professional school degree (MD, DDC, JD, etc.) 
  Doctoral degree (PhD, EdD, etc.) 
 
Q42. Which state do you currently reside in?  _______________________ 
 
Q43. Are you of Hispanic, Latino, or Spanish origin? 
  No, not of Hispanic, Latino, or Spanish origin 
  Yes, of Hispanic, Latino, or Spanish origin 
 
Q44. What is your race? 
 White  
 Black, African American 
 American Indian or Alaska Native  
 Asian  
 Native Hawaiian or other Pacific Islander 
 Other or mixed 
 
 
Thank you for your participation. Have a wonderful day! 
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Appendix B. Belief Accessibility Measurement Example 
 
 
 
